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Preface
Chapter 1 was, in part, written in collaboration with Kelly Metcalf Pate (Johns Hopkins
University, Baltimore, MD) and Allison Vitsky (Pfizer Global Research and Development, San
Diego, CA), and is adapted from a chapter entitled "Platelets and Hemostasis" contained in the
forthcoming third edition of Comprehensive Toxicology (Elsevier, Inc.). Experiments exploring
the megakaryocyte as an innate immune cell, as discussed in Chapters 2 and 3, are presently
being drafted as manuscripts for submission. The development of a microfluidic device for the
exploration of platelet-leukocyte interactions, as described in Chapter 4, has previously been
published in the Journal of Leukocyte Biology under the title "Technical Advance: Changes in
neutrophil migration patterns upon contact with platelets in a microfluidic assay." The
preliminary findings described in the Appendix regarding the changes in megakaryocyte
differentiation in the presence of lipopolysaccharide will continue to be explored, with future
experiments looking into related changes in resultant platelet phenotype utilizing new tools, such
as those developed and described in Chapter 4.
The work presented in this thesis is the product of the author, with contributions from other
laboratory members and collaborators across MIT and Harvard. I am particularly grateful to
James Fox, without whose encouragement, criticism, and unwavering support this project could
never have materialized. I would also like to thank Jacquin Niles, who served as my thesis
committee chair and provided valuable guidance and feedback throughout this process. Other
individuals from the Division of Comparative Medicine provided invaluable feedback on a
variety of topics. Especially noteworthy were the contributions of Sureshkumar Muthupalani,
who provided experimental guidance on experimental pathology and image analysis; Yan Feng,
who aided in special staining techniques for bacterial co-localization; Ellen Buckley and Carolyn
Madden, who provided bacterial cultures for experiments and clinical laboratory guidance; and
Joanna Richards and Caroline Atkinson of the pathology service team, who prepared
histopathology samples for analysis. Nicki Watson from the Whitehead Institute performed the
immune-gold labeling and some of the electron microscopy. Two undergraduate research
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students, David Olaleye and Skyler Kaufman, aided in cell toxicity assays and histopathology
image analysis.
The teams at the Center for Engineering in Medicine, the BioMEMs Resource Center, and the
Center for Surgery, Innovation & Bioengineering (Massachusetts General Hospital, Boston,
MA), under the leadership of Daniel Irimia, Mehmet Toner, and Ronald Tompkins, were also
integral to the success of this thesis. A debt of gratitude is further owed to Charles Vanderburg
(Harvard NeuroDiscovery Center, Boston, MA), whose ideas and assistance proved essential to
the development, maturation, and interpretation of this thesis material. Additionally, Lawrence
Zuckerbeg and Martin Selig (Dept. of Pathology, Massachusetts General Hospital) aided in
histopathology sample collection, analysis, and electron microscopy. Finally, a number of
laboratory members and researchers were especially helpful, or co-authored one or more of the
papers published during this thesis, and thus deserve special recognition. These include Felix
Ellett, Shannon Tessier, Keith Wong, Caroline Jones, Anna Lee, Julianne Jorgensen, and Anika
Marand. And, of course, patient sample collection would not have been possible without the
assistance of the clinical diagnostic laboratory team at MGH. To all these individuals-and to
others far too numerous to list here-I give my profound thanks for making this research
possible.
I would like to thank and acknowledge my thesis committee for their endless support,
mentorship, and guidance of this work.
This work was supported by the T32-0D019078-28 (JGF), the P30-ES002109 (JGF), the P50-
GM021700 (RGT), the GM092804 and All 13937 (to D.I.), and the Harvard NeuroDiscovery
Center. All microfabrication procedures were performed at the BioMEMS Resource Center
(EB002503).
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Abstract
Megakaryocytes (MKs), one of the largest and rarest hematopoietic stem cells in the bone
marrow, have traditionally played a primary role in hemostasis as precursors to platelets, which
are importantly, one of the most abundant cell types in the peripheral circulation. While platelets
are studied for their various roles in inflammation, the role of MKs within the innate immune
system has not been explored. In a series of comprehensive in vitro experiments, we have
demonstrated that both cord blood-derived MKs and MKs from a megakaryoblastic lineage have
innate immune cell functions, including: phagocytosis, formation of extracellular traps, and
chemotaxis towards pathogenic stimuli. MKs were also observed to directionally release platelets
towards pathogenic stimuli. In addition to their primary role as immune cells, MKs were also
shown to contain extranuclear histones, which the MKs release along with budding platelets into
the circulation. These small packages of histones can play a major role in inflammation and
immunothrombosis by promoting inflammation and coagulation. By evaluating blood and tissue
samples from patients diagnosed with sepsis, we demonstrated that there is an increased MK
concentration both in the peripheral circulation, as well as in the lungs and kidneys. Platelets
from patients with sepsis also appeared to have a specific phenotype, including increased DNA
and histone staining. MK number in the circulation and end-organs, as well as platelet histone
expression appeared to be correlated with both prognosis and type of infection. This newly
recognized role of MKs as functional innate immune cells may have significant implications for
the role of MKs in conditions such as sepsis and, pending a more profound mechanistic
understanding, may further lead to the development of novel targets for the treatment of sepsis
Thesis Supervisor: James G. Fox
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Chapter 1
Introduction
Adapted from:
Frydman GH, MetCalf Pate KA, Vitsky A. (2018) Platelets and Hemostasis, In: McQueen CA,
Comprehensive Toxicology, Third Edition. Vol 12, pp. 60-113. Oxford: Elsevier Ltd.
1.1 Abstract
Platelets are circulating, anucleate cells derived from megakaryocytes. While platelets were
originally thought to play a role only in primary hemostasis, these cells have recently been
discovered to participate in a wide variety of pathways, including hemostasis, immunology,
wound healing, and cancer biology. Dependent on their RNA and protein expression profiles,
platelets may also display various phenotypes that play a part in the pathophysiology of specific
diseases, such as sepsis, cancer, and autoimmune conditions. In order to understand platelets and
their roles within the body, it is important to understand the origin and development of the
platelet, starting from the hematopoietic stem cell. This chapter provides a bird's-eye view of the
increasingly complex megakaryocyte-platelet axis and its various roles in the body.
1.2 Platelet Production
Platelets are small (1-3 ptm diameter), circulating anucleate cells derived from megakaryocytes
(MKs). In an adult, there are approximately 100 billion new platelets produced each day, each
with a life span of 8-10 days, maintaining a platelet count of 150-400 x 109 platelets L-.
(Kaushansky, 2005;Italiano, 2007) The production of platelets from megakaryocytes can be
roughly divided into two major stages: megakaryopoiesis, the development and maturation of the
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MK from the hematopoletic stem cell progenitor, and thrombopoiesis, the development and
release of platelets from MKs. Each step in this complex process requires the optimal
combination of physiological conditions, including many different cytokines and growth factors.
Many diseases and drugs that result in changes to the peripheral platelet count and/or function
may be the result of an effect on the megakaryocyte during its multiple stages of maturation and
platelet production. In this section, we will review the basics of platelet production, beginning
with the hematopoietic stem cell.
While platelets were originally thought to have a role only in primary hemostasis, more recently,
these cells have been discovered to participate in a wide variety of pathways, including:
hemostasis, immunology, wound healing, and cancer biology. Dependent on their RNA and
protein expression profiles, platelets may also display various phenotypes that play a part in the
pathophysiology of specific diseases, such as sepsis, cancer, and autoimmune conditions. In
order to understand platelets and their roles within the body, it is important to understand the
origin and development of the platelet, starting from the hematopoietic stem cell.
Platelets and their roles in pharmacology are extremely important. While platelet inhibitors have
been used in a clinical setting for decades, as the understanding of the platelet grows, new
pharmaceutical targets on the platelet are being elucidated and new platelet inhibitors are being
developed. Because the role of the platelet is not always straight-forward, it is also becoming
increasingly apparent that these platelet inhibitors may have unintended downstream effects on
other functions and issues within the body, such as inflammatory pathways and cancer
development. On another note, there are many pharmaceutical chemical compounds and
biologics that have direct, yet unintended effects on platelets, such as antidepressants, including
serotonin reuptake inhibitors (SSRIs), and non-steroidal anti-inflammatory agents (NSAIDs),
including COX-I and COX-2 inhibitors. Due to the platelets' plentiful interactions with various
cell types and organ systems within the body, newer techniques are being developed to utilize the
platelet as a drug delivery tool itself, including direct drug-loading and genetic manipulations of
the megakaryocytes themselves to treat a number of congenital conditions involving the
coagulation system.
1.2.1 Megakaryopoiesis
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It has long been thought that MKs differentiate from hematopoietic stem cells (HSCs) and are
the largest (50-100 pm) and rarest (0.0 1%) progenitor cell in the bone marrow (Nakeff and Maat,
1974). HSCs are primarily present in the bone marrow and lungs, although during early
development, they are also present in the yolk sac, fetal liver, and spleen. (Long et al., 1982,
Gordon et al., 1990, Ogawa, 1993, Morita et al., 2011) The HSC first becomes a common
myeloid progenitor, with the MK-specific myeloid progenitor being called either
MK/erythrocyte bipotent progenitor (MEP) or BFU-E/MK. After the MEP cell becomes
committed to MK differentiation, it is referred to as a hematopoietic progenitor, and it loses self-
renewal capabilities and pluripotency. The BFU-MK then develops, forming colonies of about
50 cells organized into sub colonies. BFU-MKs are in the GO/GI phase of the cell cycle, and
develop within 12 days in the mouse and within 21 days in the human. (Nakorn et al., 2003) The
subsequent progenitor, the CFU-MK has colonies composed of 3-50 cells, are in active cell
cycle, and develop within 5 days in the mouse and within 15 days in the human. (Becker RP
1976) Following the CFU-MK stage, these cells go through further maturation into fully
differentiated megakaryocytes, including the megakaryoblast, promegakaryocyte, granular
megakaryocyte, and the mature megakaryocyte (Figure 1-1). Recent literature suggests that
megakaryocytes can arise from alternate pathways, however, including those lacking a
pluripotent or bipotent development stage. (Woolthuis and Park, 2016)
Megakaryocytes differentiate from HSCs in a thrombopoietin (TPO) -dependent fashion (Kuter,
2013, Bartley et al., 1994). TPO acts on the MK c-MPL receptor, a proto-oncogene of the murine
myeloproliferative leukemia virus and a member of the type 1 hematopoietic cytokine receptor
family, resulting in activation of the JAK and STAT pathways, promoting the growth and
maturation of the MK. (Vigon et al., 1993, Kaushansky, 2005, Kuter, 2013) The levels of
circulating TPO are inversely correlated to the number of circulating platelets, as TPO is
synthesized by the liver then bound and cleared by binding c-MPL on platelets in the peripheral
circulation. (Kuter, 2013) Interleukin-6 (IL-6), which plays a role as an inflammatory mediator,
increases TPO production both in vivo and in vitro. (Kaushansky and Hitchcock, 2013)
Although TPO has been deemed as an important factor in MK differentiation and platelet
formation, c-mpl-/ and TPO-/- mice exhibit a reduction in progenitor cell numbers, a decrease in
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MK ploidy, and a 90% reduction in peripheral platelet numbers, suggesting that other cytokines
and growth factors are involved in the formation of approximately 10% of circulating platelets
(Murone et al., 1998). Other cytokines have also been shown to promote megakaryocyte
maturation and platelet formation in a dose-dependent manner. (Stahl et al., 1991, Wu et al.,
2015) IL-6, for instance, works synergistically with interleukin-3 (IL-3) and stem cell factor
(SCF or kit ligand or steel factor) to increase MK colony formation. (Borde and Vainchenker,
2013) Erythropoietin (Epo) is a cytokine essential for the differentiation of red blood cells, but
MKs also have the Epo receptors; although the function of the Epo receptor on the MK is not
well understood, if it results in MK activation, this may explain why people chronically
administered Epo can exhibit a slight increase in platelet numbers (Borde and Vainchenker,
2013). Stromal cell-derived factor-i or (SDF-1) is also a growth factor for HSCs and increases
MK maturation. (Borde and Vainchenker, 2013) MKs also produce cytokines that stimulate MK
colony formation, including interleukin- 1P (IL-i IP), IL-6, and granulocyte-macrophage colony-
stimulating factor (GM-CSF), suggesting an autocrine signaling mechanism is in place in the
regulation in megakaryopoiesis. (Jiang et al., 1994) Bone morphogenic protein 4 (BMP4) and its
receptor expression have been shown to be induced in MKs by TPO in an autocrine loop fashion,
therefore indicating that BMP4 also plays a role in megakaryopoiesis. (Borde and Vainchenker,
2013)
The molecular mechanisms regulating megakaryopoiesis are under investigation. Though
delving into all of the genetic molecular mechanisms involved in megakaryopoiesis is beyond
the scope of this chapter, one example of the key regulators of MK differentiation is the GATA
transcription factor family and its partners. GATA- 1 is present during normal
erythromegakaryocytic differentiation, and MK-specific GATA- 1 knockout mice present with
profound macrothrombocytopenia as well as a high number of immature MKs in the bone
marrow. (Borde and Vainchenker, 2013) Other transcription factors associated with GATA- 1
and affecting platelet development includes: Friend of Gata-I (FOG-1), Tal-1, and RUNX.
(Borde and Vainchenker, 2013) Abnormalities in the GATA- 1 and FOG-I interaction are
associated with X-linked congenital thrombocytopenias. (Borde and Vainchenker, 2013) A
knockout model of FOG-I produces a similar phenotype as the GATA- 1 knockout but with an
absence of MK progenitors. Knocking out TAL-I causes a complete absence of HSCs and
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subsequent embryonic lethality. Finally, abnormalities in the RUNX-1 gene have been identified
in familial thrombocytopenia and acute myeloid leukemia (AML). (Borde and Vainchenker,
2013)
HSCs differentiate into pro-megakaryoblasts and then megakaryoblasts, also in a TPO-dependent
manner; after which endoreplication commences. Differentiation and maturation during this time
results in distinct changes in cell-surface markers, which can be used on platforms such as flow
cytometry, immunohistochemistry, and immunofluorescence to identify the various cell stages.
(Tomer et al., 2007) MKs first undergo a proliferative 2n stage, followed by endomitosis,
accumulating DNA content ranging up to 128n in a single cell. (Zimmet and Ravid, 2000) The
size and morphology of the diploid precursor resembles that of a small lymphocyte, and this
stage can only be correctly identified by surface marker expression. When evaluating
megakaryocytes by cytology, three maturation stages can be identified without special staining
(Figure 2-1): Type 1, or immature MKs, have basophilic cytoplasm with a large polyploid
nucleus, cytoplasmic blebs, and a large cell volume (> 14 [tm). These cells have a high nuclear to
cytoplasmic (N/C) ratio and thin chromatin. Type II MKs are larger (15-40 tm), have a
polylobulated nucleus, and basophilic-staining cytoplasm. The N/C ratio begins to decrease,
while the amount of cytoplasm increases and becomes more azurophilic with condensed
chromatin. Type 1II, or mature MKs, have low N/C ratio, a dark purple-staining cytoplasm and
distinct nuclear lobes. (Stenberg and Levin, 1989, Borde and Vainchenker, 2013)
During maturation, MKs undergo endomitosis (DNA replication without cellular division),
becoming polyploid and accumulating a large amount of mRNA, proteins, and membrane. MKs
are the only cells that become polyploid during normal differentiation. As they become
polyploid, the amount of cytoplasm also grows, which is thought to allow for the increased
production of platelets. In mice with acute thrombocytopenia, the first change that is seen is an
increase in MK ploidy, from 16N to 32N, with maximal ploidy seen at 48 hours followed by
resolution at 120 hours. (Borde and Vainchenker, 2013) MK ploidy number varies based on the
source of MKs, with cord blood and fetal MKs have a lower average ploidy ( 2-4N in culture)
compared with MKs derived from adult bone marrow and peripheral blood (16-32N in culture).
(van den Oudenrijn et al., 2000, Schipper et al., 2003)
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Polyploidization is related to the degradation of cyclin B-dependent cell division cycle (Cdc)
kinase and a defect in late cytokinesis; there is incomplete formation of the cleavage furrow,
which is dependent on down-regulation of nonmuscle myosin IIB heavy chain (MYH 10) in the
contractile ring by runt-related transcription factor 1 (RUNX 1), preventing cell separation. (Datta
et al., 1996, Garcia and Cales, 1996, Zhang et al., 1996, Zhang et al., 1998, Lordier et al., 2012,
Lordier et al., 2008, Geddis et al., 2007) Utilizing MK-specific double knockouts, protein-
tyrosine phosphatases Src-homology-2-domain-containing protein tyrosine phosphatases 1 and 2
(Shpl and Shp2) have been demonstrated to play an essential role in MK progression beyond the
2-4n stage. (Mazharian et al., 2013) Additionally, it has been shown that the microtubule-
associated guanine nucleotide exchange factor HI (GEF-H) 1 and epithelial cell transforming 2
(ECT2), both playing a role in RhoA localization and activation in the cleavage furrow, are
down-regulated at the mRNA and protein level in the MK. (Birkenfeld et al., 2007, Melendez et
al., 2011, Gao et al., 2012, Petronczki et al., 2007) While these may be essential in preventing
cell division, cell-cycle regulators, such as cyclin D and E, also play an important role in the
continuation of DNA replication during GI/S phase. (Zimmet et al., 1997, Muntean et al., 2007,
Eliades et al., 2010) The exact mechanism and regulation of endoreplication in MKs is still under
study, and it is likely that the complexity of this cell cycle phenomenon will continue to grow.
Recent research in mice demonstrated a potential regulatory role for p21-activated kinase 2
(Pak2), since deletion of this gene results in increased MK ploidy, macrothrombocytopenia,
increased bone marrow MK precursors, and altered MK ultrastructure. (Kosoff et al., 2015)
Another gene that appears to be essential in endomitosis is Polo-like kinase 1 (Plkl); deletion of
this gene results in defective polyploidization accompanied by mitotic arrest and cell death.
(Trakala et al., 2015)
The purpose of MK endoreplication is also under study. A primary hypothesis behind the need
for polyploidy is the increased need for mRNA and protein production for packaging into
platelets, as well as an increased need for cytoplasm, lipids, and cytoskeletal components for the
formation of platelets. (Zimmet and Ravid, 2000) Some studies using IL-6 and
lipopolysaccharide (LPS) show a positive correlation between MK ploidy and platelet formation,
and some hereditary diseases such as Fanconi anemia (FA), have been linked to a decrease in
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MK ploidy as well as peripheral thrombocytopenia. (Pawlikowska et al., 2014) However, other
studies utilizing both nicotimamide and cyclin D3 regulators suggest that platelet count is
independent of ploidy. (Stahl et al., 1991, Wu et al., 2015) (Zimmet et al., 1997, Giammona et
al., 2006, Leysi-Derilou et al., 2012, Konieczna et al., 2013)
The ultrastructure and components of the MK are quite complex and change throughout cell
maturation. As with other eukaryotic cells, MKs also contain Golgi, endoplasmic reticulum,
mitochondria. Megakaryocytes also contain multiple types of granules: a, dense, lysosome, and t
granules; the contents and function of which will be discussed in Section 1.3.7, 'Granules'. The
ER eventually gives rise to the platelet-dense tubular system, which will contain the
cytochemical activity of mature platelets, including NADH-cytochrome c reductase,
cyclooxygenase, thromboxane synthase, Ca2+ Mg2+ adenosine triphosphatase, and platelet
peroxidase. (Borde and Vainchenker, 2013, Breton-Gorius and Guichard, 1972) While
endoreplication is taking place, the demarcation membrane system (DMS; IMS) is developing
within the cell (Figure 1-3). The DMS, a reservoir for platelet formation, is a complex of
cisternae and tubules within the MK cytoplasm. (Yamada, 1957, Radley and Haller, 1982) The
DMS has continuity with the plasma membrane of mature MKs, suggesting that plasma
membrane invagination is involved in DMS formation. (Machlus and Italiano, 2013, Eckly et al.,
2014) A study by Chen et al (2013) identified that CDC42 interacting protein 4 (CIP4), a protein
that bridges the membrane and cytoskeleton and also promotes actin reorganization via its
interaction with Wiskott-Aldrich Syndrome protein (WASP), is essential in platelet formation as
both CIP4 and WASP deficiencies result in thrombocytopenia and decreased cortical actin
tension. (Chen et al., 2013)
1.2.2 Thrombopoiesis
The mechanism for the development of platelets from MKs is another area under continued study
and debate. Understanding the mechanism of platelet formation is important for understanding
biological details, the outcome of drug effects, and for the development and optimization of in
vitro platelet synthesis techniques. Platelet formation occurs in two basic steps: maturation,
which takes about 5 days to complete, and platelet release, which occurs within hours. Platelets
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survive in the bloodstream for 7-10 days in humans. (Aster, 1967, Harker and Finch, 1969,
Jackson and Edwards, 1977)
Current literature is suggestive of the 'shearing hypothesis'. Once mature, MKs migrate towards
the sinusoidal blood vessels and attach to the endothelium in a chemotactic and receptor-
dependent manner, involving cytokines such as stromal cell-derived factor 1 (SDF- 1) and its G
protein-coupled chemokine receptor CXCR4 (Fusin, LESTR). (Hamada et al., 1998) (Takahashi
et al., 1999, Balduini et al., 2011) They are then exposed to the shear force of the blood flowing
through the blood vessels and extend long processes, called proplatelets, which undergo fission
to release platelets into the bone marrow intravascular sinusoidal space. (Richardson et al., 2005,
Tavassoli and Aoki, 1989, Thon and Italiano, 2012) Alternatively, spontaneous platelet
formation also occurs spontaneously in vitro without endothelial cells, SDF- 1, or shear force.
(Thon and Italiano, 2012, Thon et al., 2010, Italiano et al., 1999, Patel et al., 2005a)
The MK cytoskeleton has been suggested to be one of the key components of proplatelet
formation and platelet release, suggested by the marked enlargement and re-organization of the
cytoplasm and DMS in the maturing MK. Actin filaments, which are linked to the plasma
membrane by filamen and bound to a number of glycoproteins, are an integral cytoskeletal part
of proplatelet formation and platelet release, the importance of which has been extensively
demonstrated in scientific literature. Bernard-Soulier syndrome, which is characterized by
macrothrombocytopenia and a decrease or absence of platelet dense granules, is associated with
abnormalities in GPIba, GPIbB, and GPIX, which are also bound to filamin. (Rao et al., 2004)
Defects in the filamin A (FLNA) gene and the GPIX gene have been linked to decreased platelet
counts and decreased surface expression of GPIba. (Li et al., 2015, Wang et al., 2004) Pf1-tubulin
has also been shown to play a key role in the MK cytoskeleton and the formation of platelets, as
mice deficient in 3 1 -tubulin have both fewer platelets, and platelets with structural and functional
defects, and humans with an autosomal dominant P I-tubulin mutation have a
macrothrombocytopenia. (Lecine et al., 2000, Patel et al., 2005b, Kunishima et al., 2009).
Mutations in the MYH9 gene, reducing non-muscle myosin heavy chain Ila activity, have been
linked to May-Hegglin anomaly and macrothrombocytopenias (Italiano et al., 1999, Seri et al.,
2000, Kelley et al., 2000), and utilizing mouse models of MYH9 gene mutations, researchers
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have shown that MKs produce fewer and shorter proplatelets with less branching. (Zhang et al.,
2012) RUNX 1 mutations have also been shown to regulate proplatelet formation via MYL9,
MYHJ0, and MYH9, suggesting a potential link between humans with familial platelet disorders
and acute myelogenous leukemia. (Zhang et al., 2012, Machlus and Italiano, 2013) A study by
Pleines et al (2013) demonstrated the essential role of Rho GTPases RACGAPI (Rac) and
CDC42 in proplatelet formation; knockout mice had severe thrombocytopenia and decreased
platelet surface receptor expression (GPIb, GPV, GPIX, GPVI and GPIIb/IIIa) with normal actin
structures but severely disrupted MK tubulin organization. (Pleines et al., 2013)
The formation of MK granules is a complex process involving many components of the
cytoskeletal machinery. Microtubules are involved in proplatelet elongation and transportation,
as well as assembly of organelles and granules into proplatelet buds. Granule formation begins
with the budding of vesicles off of the Golgi network, after which the vesicles are delivered to
multivesicular bodies for protein sorting and granule formation. (Blair and Flaumenhaft, 2009,
Heijnen et al., 1998, Youssefian and Cramer, 2000) These granules are then transported to the
proplatelet buds via microtubules. (Richardson et al., 2005) Cytoplasmic dynein localizes along
microtubules of the proplatelet and appears to directly contribute to microtubule sliding;
inhibition of dynein, through disassembly of the dynactin complex, blocks proplatelet formation,
demonstrating that this is a key event in proplatelet elongation. (Machlus and Italiano, 2013) The
contents of the various granules and the concept of granule sorting into different platelet
populations remains a controversial topic today, as some studies do show that a-granule protein
composition is heterogenous during platelet activation. (Italiano et al., 2008, Kamykowski et al.,
2011, Jonnalagadda et al., 2012, Peters et al., 2012, van Nispen tot Pannerden et al., 2010)
Platelet size is an important aspect of many pathologies and disease states, with an increase in
platelet size and decrease in platelet count (macrothrombocytopenia) often being correlated with
changes in function. Platelet size is determined by the subcellular structure and size of the DMS.
In addition to some genetic abnormalities resulting in macrothrombocytopenia, autoimmune
thrombocytopenia is also associated with an increase in platelet volume. Acceleration in platelet
production with an associated increase in platelet volume may be a result of changes in the
partition of the constriction zones within the DMS. (Borde and Vainchenker, 2013)
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MKs have many different types of granules, including a, dense, lysosome, and t granules. a -
Granules are present during early MK differentiation, along with the development of the DMS.
Dense granules then appear at the end of MK maturation. (Borde and Vainchenker, 2013) The
multivesicular body, which is present in MKs and rarely present in platelets, is a sorting
compartment, representing the intermediate step between the Golgi network and a- and dense
granule formation. (Borde and Vainchenker, 2013) a-Granules arise from the trans-Golgi
network and acquire proteins by two mechanisms: MK biosynthesis and plasma protein
endocytosis (also thought to occur in platelets).(Borde and Vainchenker, 2013)
The mechanistic study of dense vesicle trafficking and dense granule formation is being explored
in the context of Hermansky-Pudlak and Chediak-Higashi syndromes, diseases in which platelets
lack dense granules. Recent research has suggested that specific genes and proteins (BLOC,
VPS33A, AP3, and BEACH domain-containing protein LYST) play roles in vesicle trafficking
and dense granule formation. The study of a-granules is performed in the context of Quebec
Platelet Disorder, Gray Platelet Syndrome (GPS) and ARC (arthrogryposis, renal dysfunction
and cholestasis) syndrome. NBEAL2 has been identified as the causative gene mutation for GPS,
and a murine model of this disorder has been created. (Albers et al., 2011, Gunay-Aygun et al.,
2011, Kahr et al., 2011, Deppermann et al., 2013, Kahr et al., 2013) The studies of MKs from
Nbeal2-/- mice have resulted in controversial findings. While a study by Kahr et al (2013)
displayed structural abnormalities, delayed maturation, decreased survival, decreased ploidy, and
developmental defects (abnormal extracellular distribution of von Willebrand Factor), a study by
Depperman et al (2013) showed normal differentiation and proplatelet formation. (Kahr et al.,
2013, Deppermann et al., 2013) It is noteworthy that these two papers did use different sources
for their MKs, which could explain the discrepancies between the two studies.
One longstanding hypothesis for platelet formation and release has relied upon the importance of
the intrinsic apoptotic caspase cascade. (De Botton et al., 2002, Clarke et al., 2003) MKs have
been documented to undergo a caspase-3 and -9 mediated apoptosis during thrombopoiesis, and
activation of caspase yields functional platelets with normal lifespans. (De Botton et al., 2002,
Clarke et al., 2003) Further supporting the apoptosis hypothesis, overexpression of BCL2
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inhibited proplatelet formation. (De Botton et al., 2002) However, further probing into the
apoptotic pathway has shown that, although caspase-mediated apoptosis does occur in the MK,
this apoptosis must be restrained for platelet formation. The deletion of BCL-xL (BCL2L1, a
pro-survival signal) triggers apoptosis in MKs but fails to induce thrombopoiesis (Josefsson et
al., 2011). This has been corroborated with a familial thrombocytopenia linked to a mutation in
cytochrome c, which enhances caspase activity. (Morison et al., 2008) A study by Iancu-Rubin
C, et al., (2014) showed that MDM2 inhibition and P53 activation impairs thrombopoiesis by
both promoting MK precursor apoptosis and by blocking DNA synthesis during endomitosis,
impairing platelet production. (Iancu-Rubin et al., 2014) Culture of MKs with recombinant
Chemokine ligand 5 (CCL5, RANTES), a cytokine stored and released by activated platelets,
resulted in increased MK ploidy and proplatelet formation, a finding thought to be secondary to
CCL5's interaction with the Akt pathway with subsequent suppression of apoptosis. (Machlus et
al., 2016) One recent study looked at whether ER stress during MK maturation was enough to
result in apoptosis-mediated thrombopoiesis; transient ER stress was identified during the
maturation of MKs and the inhibition of ER stress induced apoptosis, decreased expression of
MK maturation cell surface markers, and proplatelet formation. (Lopez, 2013) Recently, a study
demonstrated that thrombopoiesis was unperturbed in the absence of caspase-9, providing strong
evidence that the apoptotic caspase cascade is not absolutely required for platelet production.
(White et al., 2012)
An alternate hypothesis of platelet formation is MK rupture, which is postulated to result in the
cytoplasmic fragmentation and release of platelets. (Nishimura et al., 2015) Research has
demonstrated that serum cytokines, such as interleukin- 1 a (IL-i a), are elevated after platelet loss
or inflammation in mice, whereas TPO is not elevated. Additionally, the administration of IL-I a
to mice induced MK rupture-dependent thrombopoiesis and increased platelet count. The MKs in
this study showed increase caspase-3 activation, reduced plasma membrane stability, and
inhibited regulation of tubulin expression and proplatelet formation, which led to MK rupture.
(Nishimura et al., 2015)
Once proplatelets are formed, they are released from the MK. Multiple stages of proplatelets and
platelets have been described in the peripheral circulation, suggesting that platelets may continue
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their maturation while in the blood stream. (Machlus and Italiano, 2013) A pre-platelet stage has
also been identified, ranging from 2-10 pm and capable of the maturing into platelets within the
bloodstream. (Thon et al., 2010, Thon and Italiano, 2012) Additionally, platelets and pre-
platelets have been shown to form progeny within the bloodstream, transforming from a single
platelet into a barbell-shaped structured with two platelet-like structures on each end. This
phenomenon has been demonstrated in vitro and is associated with increased protein synthesis.
(Schwertz et al., 2010, Machlus and Italiano, 2013)
Platelet size (normally approximately 2 pm) is also highly regulated, being dependent on both
microtubule coil diameter and tube thickness. (Thon and Italiano, 2012) Circulating pre-platelets
may become trapped in small capillary beds within the lungs, spleen or bone marrow, where
increased intravascular shear forces are thought to result in terminal formation of platelets of
appropriate size. (Howell and Donahue, 1937) In fact, when MKs are infused into mice, they
have been shown to almost exclusively localize to the lungs, releasing platelets within 2 hours.
(Fuentes et al., 2010) The size of the platelet has also been correlated with platelet reactivity in
different disease states, suggesting that an increase in platelet size is positively correlated with an
increase in platelet aggregation, activation, and risk for cardiovascular diseases. (Bath and
Butterworth, 1996, Kamath et al., 2001, Berger et al., 2010, Chu et al., 2010, Slavka et al., 2011)
1.3 Structure and content of the platelets
Platelets, although anucleate, have many functional organelles and granules. They have active
metabolisms, through their glycogen granules and mitochondria, and also contain their own RNA
and proteins. In fact, they contain the machinery to translate RNA into proteins for cell use and
secretion, including rough and smooth endoplasmic reticulum and Golgi complexes (Figure 1-3).
Platelets play various roles in the body, including promotion and inhibition of inflammation,
neovascularization, wound healing, and even cancer regulation. Their complex physiology
allows them to bind to other cells and substrates, subsequently signaling to them and de-
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granulating, releasing specific proteins into the environment based on the stimulus received. This
section will cover the basic structure of platelets and how they function.
1.3.1 Glycoproteins
Platelet glycoproteins (GPs) are located both on the cell surface and within specific platelet
granules. Glycoproteins are proteins with covalently attached carbohydrate groups and are
activated by the binding of specific ligands, a process that results in activation of specific
pathway(s) within the platelet (Figure 1-4). Glycoproteins are also involved in inside-out
signaling, where pathway activation and platelet activation is not just dependent on ligand
binding, but also on internal cell signaling that induces changes in GP expression on the cell
surface. Many of these GPs can be utilized as cell surface markers for the positive identification
of platelets and their activation in imaging and flow cytometry (Table 1-1). In this section, we
will review the main platelet GPs, including their structure, binding partners, and associated
signaling pathways.
1.3.1.1 Glycoprotein Ib-IX-V
Glycoprotein complex Ib-IX-V is composed of GPIba, GPIbp, GPIX, and GPV. GPIba is the
ligand-binding subunit and is disulfide bonded to GPIbp, and non-covalently associated with
GPIX and GPV. (Andrews et al., 2003b, Modderman et al., 1992, Clemetson and Clemetson,
1995) GPIba is shed from circulating platelets, with shedding and plasma concentrations
increasing upon platelet activation. GPIb-IX-V plays a central role in hemostasis, with many
human and animal studies demonstrating abnormalities in hemostatic function upon the absence
or blocking of this complex or one of its' subunits. (Ozaki et al., 2005, Li and Emsley, 2013)
Bernard Soulier Syndrome (BSS) is an inherited platelet disorder where there is a deficiency or
dysfunctional GPIba subunit; affected patients exhibit mild to severe bleeding phenotypes, along
with macrothrombocytopenia. (Lopez et al., 1998) Animal models have demonstrated that vWF-
GPIb axis plays an important role in the formation of blood clots, arterial thrombosis, ischemic
stroke, and venous thromboembolism. (Denorme and De Meyer, 2016, Takahashi et al., 2009,
Bergmeier et al., 2006, Momi et al., 2013, Berndt and Andrews, 2013) Several non-hemostatic
roles of GPIb-IX-V have also been identified, including the support of cancer metastasis,
positive regulation in systemic inflammation, the binding of Mac-1, playing a role in
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macrophage transmigration, and interaction with bacterial components. (Suter et al., 2001,
Corken et al., 2014, Jain et al., 2007, Bemdt et al., 2001, Berndt and Andrews, 2013)
The primary binding ligand for GPIb-IX-V is von Willebrand Factor (vWF). Soluble vWF is
always present in the plasma and is also secreted from a number of cells, including platelets and
endothelial cells. (Berndt and Andrews, 2013, Clemetson and Clemetson, 1995) Recently, a
mechano-sensitive mechanism by which GPIb-IX-V is activated by bound vWF was elucidated
when investigators demonstrated that pulling of the vWF Al domain that is engaged to GPIb-IX
induces unfolding of an unidentified structural domain in GPIba. (Zhang et al., 2015) Other
binding ligands to GPIba includes P-selectin (CD62P), which is expressed and shed by activated
platelets and endothelial cells, and aMP2, which is expressed on leukocytes. (Bergmeier et al.,
2006) (Berndt and Andrews, 2013) GPV has also been documented to bind to collagen. (Moog et
al., 2001, Berndt and Andrews, 2013) A number of coagulation factors from both the intrinsic
and extrinsic pathway can bind to GPIba, including high molecular weight kininogen, FXII, FXI,
and thrombin. (Berndt and Andrews, 2013)
There are other GPs that are involved in GPIb-IX-V binding and activation. The collagen
receptor, GPVI, interacts with GPlba as an accessory protein to a noncovalent complex between
GPVI and Fc receptor y chain (FcRy). (Jarvis et al., 2002, Nieswandt and Watson, 2003) (Berndt
and Andrews, 2013) Calmodulin also binds to separate regions of the GPIb-IX-V complex and
the dissociation of calmodulin from this complex regulates the ectodomain shedding of GPIba of
GPV by a disintegrin and metalloproteinase domain-containing protein 10/17 (ADAM 10/17).
(Gardiner et al., 2007, Mo et al., 2010, Andrews et al., 2001, Berndt and Andrews, 2013)
Thrombin, ADAM 10, and ADAM17 all cleave at GPV, and therefore, absence of GPV enhances
platelet activation to thrombin via GPIba. (Berndt and Andrews, 2013)
Once GPIb-IX-V is bound and activated, it results in an intracellular signaling cascade, which
activates sarcome (Src) kinase, spleen tyrosine kinase (Syk), Lymphocyte cytosolic protein 2
(SLP-76), phosphoinositide 3(PI3) kinase, Bruton's tyrosine kinase (Btk), protein kinase C, and
phospholipase Cy. There is an increase in cytosolic Ca", activation of CIMbp3 as well as dense and
a-granule release. (Berndt and Andrews, 2013) Calmodulin-bound GPIbP can also bind TNF
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receptor-associated factor 4 (TRAF4), which enhances platelet activation via the assembly of
NADPH oxidase and ROS. (Arthur et al., 201 1)(Andrews et al., 2001) (Berndt and Andrews,
2013) GPIb-IX-V also interacts with actin-binding protein filamin-A, which helps regulate
membrane stability under high shear conditions. (Andrews and Fox, 1992, Nakamura et al.,
2006, Li and Emsley, 2013, Berndt and Andrews, 2013) Newer research suggests that the
interaction between GPIba and filamin-A is involved in force transmission, while the interaction
between GPIba and the Al domain of vWF mediates the force transmission; this bond-
transmitting force allows a strengthening of the bond and helps explain how platelets attach to
sites of vascular injury via internal forces produced by cytoskeletal tension. (Feghhi et al., 2016)
1.3.1.2 Glycoprotein GPIlb-IJIa
Platelet integrin aUbfP3 (GPIIb-IIIa) plays an integral role in platelet aggregation, hemostasis, and
thrombosis. Two glycoproteins, GPIIb and GPIIIa, form a non-covalent heterodimer, which
represents the most abundant protein on the platelet surface. (Coller and Shattil, 2008, Calvete,
1995, Jennings and Phillips, 1982, Berndt and Andrews, 2013, Kunicki et al., 1981) Integrin
alIbP3 is also located in the membrane of a-granules, and can be translocated to the surface of the
cell following platelet activation. aIIbP3 is reported to default into a bent (closed) form, which,
upon the appropriate stimulus, can open to an extended closed form and an extended open form
(the active state). (Suzuki et al., 1994, Wencel-Drake et al., 1986, Berndt and Andrews, 2013)
The transition from one conformation to another reveals different epitopes. The exact mechanism
and utility of the different conformations of a11pb3 is still heavily researched and under debate,
however, antibodies have been developed to target conformation-specific a11bP3 for flow
cytometric evaluation. (Berndt and Andrews, 2013)
Integrin UMb03 plays a critical role in hemostasis. A variety of agonists, including collagen, ADP,
and thrombin, all stimulate platelets and activate signaling cascades that cause UnbP3 to open into
its' activated form. When Uarb3 is in its open form, it has a very high affinity for a variety of
platelet aggregation components, including fibrinogen, fibronectin, and vWF. (Reininger, 2008,
Marguerie et al., 1979, Berndt and Andrews, 2013) Following agonist stimulation, there can be
activation of phospholipase Cp by Ca , which then results in downstream activation of protein
kinase C, calcium- and diacyglycerol-regulated guanine factor 1, phophoinositide 3-kinase, and
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ultimately, Ras-related protein lB (RAPIB). RAPI binds to talin, forming a complex that targets
and activates UubfP3. (Knezevic et al., 1996, Crittenden et al., 2004, Bergmeier and Stefanini,
2009, Cifuni et al., 2008)(Stefanini et al., 2009, Berndt and Andrews, 2013) In vitro and animal
models demonstrate that absence of talin causes severe defects in platelet aggregation, as well as
agonist-stimulated clIbp3 activation and frequent pathologic bleeding. However, whereas agonist
stimulation of a11j3-deficient platelets can still result in talin re-distribution, demonstrating that,
although talin is imperative for platelet hemostatic function, talin it is not dependent on aclbP3.
(Bertagnolli et al., 1993, Escolar et al., 1995, Petrich et al., 2007, Watanabe et al., 2008,
Nieswandt et al., 2007) The kindlin family also plays a role in the activation of aIMP3, both
directly and as well as indirectly, via talin. Some studies have shown that kindlins increase
multivalent ligand binding via the promotion of talin-activated integrin clustering, while other
show that Kindlin-3 is an essential element for integrin activation. (Ye et al., 2013, Moser et al.,
2008, Shattil et al., 2010)
Once QlbfP3 is ligand bound, there is further conformational change of the integrin complex and
subsequent intracellular signaling is activated; at this time, granule secretion, platelet activation,
platelet adhesion, platelet spreading, and clot retraction occur. The conformational change and
cUb1P3 clustering at this time allow transmission of signals from outside-in. One of the primary
outside-in signaling cascades involves Src family kinases (SFK), where c-Src is bound to the
distal P subunit. (Wu et al., 2015, Arias-Salgado et al., 2003, Senis et al., 2014, Obergfell et al.,
2002) SFK phosphorylates the Tyr773 and Tyr785 residues, which protects it from cleavage by
proteases, resulting in enhancement of ligand-binding events. Mice with Tyr747 and Tyr759
mutations (the equivalent to humanTyr773 and Tyr785 mutations) show increased tail bleeding
times and impaired clot retraction, demonstrating the importance of these signaling cascades.
(Phillips et al., 2001, Ablooglu et al., 2009, Law et al., 1999, Ye and Ginsberg, 2013) Src and
Syk work together to phosphorylate and modulate p190 Rho GTPase activating protein, SLP-76,
Adhesion and Degranulating Adapter Protein (ADAP), and Vav, resulting in further platelet
activation and clot retraction. (Arthur et al., 2000, Ren et al., 1999, Flevaris et al., 2007,
Obergfell et al., 2002, Miranti et al., 1998) More recently, Syk and Src have been identified
shown to work together in the regulation of C-type lectin receptor 2 (CLEC-2)-mediated platelet
adhesion to lymphatic endothelial cells. (Huveneers and Danen, 2009, Pollitt et al., 2014, Ye and
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Ginsberg, 2013) Tying in talins with Src, ADAP, a hematopoietic-restricted adapter protein that
promotes integrin activation, also promotes platelet activation and irreversible fibrinogen binding
to platelet U1bp3 via an interaction with talin and kindlin-3. (Kasirer-Friede et al., 2014)
Due to the inside-out and outside-in signaling that plays a role in aubp3 activity, there are
multiple mutations that can result in hereditary bleeding disorders. Glanzmann thrombosthenia
(GT) is a disease associated with aubfp3 deficiency or mutations, which results in bleeding
disorders. (Lee et al., 1981, Nurden et al., 1987, Phillips and Agin, 1977) In some cases of GT,
mutations affect the post-translational processing and transport of aI1bP3, resulting in decreased
surface expression or decreased binding affinity for ligands. Mutations in kindlin-3, a protein
that works with talin to regulate integrin activity, can also result in bleeding disorders.
(McDowall et al., 2010, Moser et al., 2008) People with leukocyte adhesion deficiency syndrome
(LADIII) have kindlin-3 mutations, and subsequent defective platelet aggregation and clot
retraction. (Manevich-Mendelson et al., 2009, Meller et al., 2012) (Ye and Ginsberg, 2013)
1.3.1.3 Glycoprotein GPJa/IIa
Integrins are heterodimers composed of an a and P subunit (Hynes, 2002, Barczyk et al., 2010).
There are 12 known a and 8 known P subunits, allowing for 24 possible pairings. (Barczyk et al.,
2010, Takada et al., 2007) Integrin Q2pl, (VLA-2; ECMR-I1; GPIa/IIa) is the only known platelet
integrin receptor for collagen, although it must be activated in order to reveal its high affinity
binding site; for collagen, with the resting state showing shows almost no affinity for collagen.
(Depraetere et al., 1997, Staatz et al., 1990, Tuckwell et al., 1995) Other integrins, such asa5 P 1,
a63p1, and a11b 3p3 bind fibronectin, vitronectin, laminin, and/or fibrinogen. GPIa/IIa has also been
found to be present on many cell types, including lymphocytes, mesenchymal cells, fibroblasts,
and cancer cells. (Zwolanek et al., 2015, Pischel et al., 1988, Sottnik et al., 2013, Li et al., 2013b,
Watson et al., 2013)
1.3.1.4 Glycoprotein GPVI
Platelets have two collagen receptors, a2p i and GPVI. a2p i has a high affinity for collagen but
requires prior activation for expression, whereas GPVI has a lower binding affinity for collagen.
Platelet receptor GPVI is thought to work synergistically with a2p i; with a2p supporting
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adhesion, and GPVI supporting activation. (Nieswandt and Watson, 2003) GPVI, which is
encoded in the leukocyte receptor complex on chromosome 19, is composed of an N- and C-
terminal extracellular Ig domain and is a member of the immunoglobulin superfamily.
(Clemetson et al., 1999, Jandrot-Perrus et al., 2000) A peptide strand links the extracellular
domains and a glycosylated stem connects to a transmembrane and cytoplasmic domain that can
bind calmodulin. The transmembrane domain has an arginine residue salt bridge, which supports
its association with Fcrylla. Co-expression is required for cell-surface expression of GPVI on
platelets. (Moroi and Jung, 2004, Watson et al., 2013)
The platelet GPVI receptor interacts with multiple other factors, resulting in platelet activation.
The Fc receptor y-chain, for instance, is associated with GPVI and is a critical component of the
collagen signaling pathway within and activation of platelets. (Berlanga et al., 2002, Watson et
al., 2013) GPVI is considered to be the major signaling receptor for collagen, while the key
functional motif is an immunoreceptor tyrosine-based activation motif (ITAM) on the FcyRIIa
chain. (Moroi and Jung, 2004, Gibbins et al., 1997, Tsuji et al., 1997, Watson et al., 2013) GPVI
forms specific structure dimerization necessary for its' binging to collagen fibrils. (Jung et al.,
2009) Studies have shown that GPVI mainly binds to collagen types that can form large collagen
fibrils, such as collagen type III, resulting in the formation of large platelet aggregates during
flow adhesion studies. (Jung et al., 2008)
Platelets control their responsiveness via receptor shedding; primarily mediated by two
metalloproteinases, ADAM 10 and ADAM 17 (TACE). (Andrews et al., 2007, Gardiner et al.,
2007, Bender et al., 2010, Watson et al., 2013) GPVI -FcyR expression is sufficient to confer
both adhesion and signal processing of collagen. GPVI-mediated collagen response is
proportional to density-dependent at the receptor level, with GVI being rapidly shed from the
platelet surface following activation of both receptors, GPVI and FcyRIla. (Chen et al., 2002)
Anti-GPVI antibodies can induce receptor shedding, internalization, and transient .
thrombocytopenia in multiple mouse models, utilizing mechanisms that are independent of
ADAM10/17 but regulated by intracellular cAMP. (Boylan et al., 2008, Bender et al., 2010,
Newman, 2010, Nieswandt et al., 2001, Takayama et al., 2008) One new mechanism of platelet
GPVI shedding is liver-mediated, in which the inhibitory Fc receptor, FcyRIIB, on mouse liver
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sinusoid endothelial cells mediate antibody-induced GPVI trapping and shedding. (Berndt and
Andrews, 2016)
Other ligands that bind to GPVI include, collagen-related peptide (CRP), which is thought to
stimulate tyrosine phosphorylation in platelets, similar to collagen, laminin, a basement
membrane component, and snake toxins. (Newman, 2006, Polanowska-Grabowska et al., 2003,
Andrews et al., 2003a, Wijeyewickrema et al., 2007, Asazuma et al., 2001, Watson et al., 2013,
Inoue et al., 2006) There are many different signaling mechanisms and regulatory proteins
involved with the GPVI receptors that are still being explored, including Platelet endothelial cell
adhesion molecule-I (PECAM-1), Src homology region 2 domain-containing phosphatase-I and
-2 (SHP-1 and SHP-2), and others. (Moraes et al., 2010, Cicmil et al., 2002, Pasquet et al., 2000,
Mazharian et al., 2013) (Watson et al., 2013)
1.3.2 Immunomodulatory receptors and antigens
Platelets have been increasingly recognized to play an active role in the immune system. They
display a number of receptors on their cell surface for various cytokines and chemokines, and
they also express immunoglobulins (FcyRI, 11, III; FceRI, FcaRI/CD89). Platelets also exhibit
non-self-infectious detection molecules, including Toll-like receptors (TLRs). In this section, we
will review some basics about these cell surface molecules and their proposed roles through the
platelet. A summary of some of these proinflammatory receptors and signaling molecules
associated with platelets is summarized very nicely in a paper by Garraud, et al. (Garraud and
Cognasse, 2010)
1.3.2.1 HLA antigens
Human leukocyte antigen (HLA) encodes for the major histocompatibility complexes (MHC).
HLA (Class I) antigens play a function in major histocompatibility complex (MHC) events,
presenting peptides from inside of the cell. Cosgrove et al., reported that several anti-HLA
monoclonal antibodies, including anti-beta 2 microglobulin antibody) selectively effects platelet
function and can result in both platelet aggregation and release of 14C-seratonin. (Cosgrove et
al., 1988) Additionally, anti-HLA antibodies also blocked the binding of platelets agonists,
including collagen, adrenalin, and ADP. A possible association between GPIIb/IIIa and HLA
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Class I antigens was also postulated. More recent studies have demonstrated that platelets
express T cell co-stimulatory molecules, process and present antigens (Ag) using MHC class I
molecules, and directly activate naYve T cells in a platelet MHC class I-dependent manner.
(Chapman et al., 2012) Chapman et al., utilized a mouse model of cerebral malaria to
demonstrate that platelets are capable of presenting pathogen-derived Ag to promote T cell
responses and that platelets can be used in a cell-based vaccine model to induce protective
immunity. (Chapman et al., 2012)
More recently, MHC class-II molecules, which allow antigen presentation to other immune cells,
were identified as being expressed on human megakaryocytes. (Finkielsztein et al., 2015)
Megakaryocyte progenitors, but not platelets, produced in vitro from mobilized peripheral blood
hematopoietic stem and progenitor cells of healthy subjects were found to function as
professional antigen presenting cells (APCs). (Finkielsztein et al., 2015) The presence and role of
MHCs on both platelets and their progenitors is still being explored and will likely have a major
impact on the understanding of the role of the platelet within the immune system.
1.3.2.2 Fc Receptors (FcyRIJa)
The Fc receptor (FcR) is a membrane receptor for immune complexes and immunoglobulin (Ig)
aggregates that is expressed on many cells types, including platelets, which express IgG Fc
receptors (FcyRIIa). (Rosenfeld et al., 1985, Moore and Nachman, 1981, Shido et al., 1995)
FEcyRIla mediates the activation of platelets exposed to immune complexes, Ig-opsonized
bacteria, or autoantibodies targeting specific platelet membrane proteins. (Lopez, 2013) The Fc
receptor plays a role in platelet activation through the presence of an immunoreceptor tyrosine-
based activation motif (ITAM) in its cytoplasmic domain, which phosphorylates when ligands
bind to GubP3. (Boylan et al., 2008) Zhi H, et al., demonstrated that platelets from mice
expressing human FcyRIIa spread better on fibrinogen, retracted clots better, formed larger
thrombi, displayed increased fibrin deposition within injured vessels, and had increased Syk
phosphorylation. (Zhi et al., 2013)
The Fc receptor for IgG, FcyRIla, is expressed on both macrophages and platelets and may play
an important role in immune-mediated thrombocytopenia. A study in mice has demonstrated that
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the human Fc receptor FcyRIIa plays a significant role in the in vivo role in the immune
clearance of platelets. (McKenzie et al., 1999) It has also been previously reported that
circulating immune complexes (CIC) inhibit fibrinogen binding to platelet GPIIb/IIIa, and
FcyRIIs were demonstrated to have a close relationship to GPIIb/IIIa, resulting in transmission of
an 'outside-in' signal when bound to ligands such as fibrinogen and vWF. (Shido et al., 1995,
Boylan et al., 2008) Additionally, GP Ib-IX-V has been shown to be in close physical proximity
to the population of FcyRIIa that mediates platelet activation through circulating immune
complexes arising from infection with two strains of viridans group streptococci. (Sullam et al.,
1998, Shrimpton et al., 2002)
1.3.2.3 CD40L (CD40L/CD]54)
CD40L (CD 154) is a type II transmembrane protein belonging to the Tumor Necrosis Factor
(TNF) superfamily and is a dominant platelet-secreted factor. (Aloui et al., 2014) It is expressed
on the cell surface of a variety of cells and plays a role in both the adaptive and innate immune
response. (Grewal and Flavell, 1998, Elgueta et al., 2009) In platelets, CD40L is found in the a-
granules within the platelet cytoplasm. (Charafeddine et al., 2012) RNA-seq experiments have
shown that CD40L mRNA is not present in platelets, suggesting that the protein is acquired only
from the parent megakaryocyte. (Gnatenko et al., 2003, Rowley et al., 2011, Simon et al., 2014,
Nagalla et al., 2011) Interestingly, platelets do not maintain CD40L on their surfaces for long
periods of time, rather, the protein is cleaved and released in soluble form, and it may also be
carried in their microparticles. (Leroyer et al., 2008)
The main receptor for CD40L is CD40, which is constitutively expressed by platelets, antigen
presenting cells (APCs), neutrophils, endothelial cells, and T-cells. (Aloui et al., 2014) Platelets
express CD40 on their cell surface, regardless of activation status. (Henn et al., 1998, Inwald et
al., 2003) It is currently hypothesized that the soluble form acts as a competitive inhibitor for the
membranous form. (Esposito et al., 2012) CD40L can also bind to GPIIb/IIIa, U5f31
(CD49e/CD29), and Mac-I (Complement Receptor 3, CR3, CD lIb/CD18). (Aloui et al., 2014)
Additionally, there may be an essential role for these integrins, as patients with Glanzmann
thrombocytopenia fail to release sCD40L upon platelet activation. (Furman et al., 2004)
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The CD40-40L system functions in an autocrine, paracrine, and endocrine fashion and is
associated with both proinflammatory and prothrombotic effects. (Aloui et al., 2014) CD40L
may be cleaved into the soluble form (sCD40L) that has cytokine-like activity, such as activating
the classical and alternative NF-kB pathways. (Chen et al., 2006) Platelets are the main source
for sCD40L in the circulation. (Danese et al., 2003, Viallard et al., 2002) sCD40L is a master
inflammatory cytokine involved in mediating the inflammation in cardiovascular disease, such as
the production of atheroma plaques, as well as adverse transfusion events, including transfusion
related acute lung injury (TRALI). (Engelmann and Massberg, 2013, Aloui et al., 2014) sCD40L
also induces platelet release of reactive oxygen species (ROS) and nitrogen species through
activation of AKT and MAPK signaling pathways. (Chakrabarti et al., 2005, Freedman, 2008)
The interaction between CD40-CD40L has also been shown to play a role in the production of
auto-antibodies in a number of autoimmune diseases, including systemic lupus erythematous
(SLE) and rheumatoid arthritis (RE). (Toubi and Shoenfeld, 2004, Zhang et al., 2013)
When evaluating the autocrine effects of sCD40L on platelets themselves, two receptor
interactions are important to consider: CD40 and cdlbP3. (Aloui et al., 2014) When sCD40L
activates platelet via CD40, this involves a CD40-dependent TRAF2/RACi/ps8 MAPK signaling
pathway that concurrently triggers the NF-kB pathway. (Hachem et al., 2012, Yacoub et al.,
2010) When sCD40L binds to a1bfP3, thrombus formation is enhanced via induction of platelet
spreading. (Prasad 2003; Andre P 2002) It has also been identified that soluble CD14 (sCD 14)
from plasma contributes to lipopolysaccharide (LPS) and toll-like receptor 4 (TLR4) signaling in
platelets to allow for significant release of sCD40L. (Damien et al., 2015) LPS binding protein
(LBP) and CD14 are considered obligate partners for TLR4 ligation to LPS; however, platelets
do not express CD 14, therefore sCD 14 in the plasma environment is essential. In eukaryotic
cells, LPS is transferred from CD14 to a complex between TLR4 and MD2. (Damien et al.,
2015)
1.3.2.5 Toll-like Receptors (TLRs)
The Pathogen Recognition Receptor (PRR), of which Toll-like receptors are a part, are involved
in the innate immune system and are expressed on cell surfaces and secreted into extracellular
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compartments, resulting in opsonization, blood clotting, phagocytosis, and activation of
complement and proinflammatory cascades. (Garraud and Cognasse, 2010, Janeway and
Medzhitov, 2002) Studies have identified that platelets express mRNA for all 10 TLR transcripts
and that all transcripts are co-expressed. (Koupenova et al., 2015) Studies have also confirmed
the presence of a functional TLR/MyD88 pathway in platelets, similar to that in nucleated
eukaryotic cells. (Garraud and Cognasse, 2010) The TLR transduction pathway is composed of a
number of receptors, including the Toll/Interleukin- 1 receptor (TIR), the Myeloid differentiation
factor-88 (MyD-88), amongst many others. (Garraud and Cognasse, 2010) Following ligand
binding, TLRs dimerize and recruit MyD88 through their TIR domains, resulting in the
expression of multiple inflammatory signals, such as NF-kB and interferon-regulatory factors
(IRFs). (Garraud and Cognasse, 2010, Moynagh, 2005, Pasare and Medzhitov, 2004)(Akira and
Takeda, 2004) Soluble CD14 (sCD14) in plasma is also required for optimal response to LPS
stimulation via TLR4 signaling. (Damien et al., 2015) Differences in expression patterns have
been noted between men and women, with women having more abundant transcripts and distinct
associations with cardiovascular risk and inflammatory biomarkers. (Koupenova et al., 2015)
The role of TLRs in the platelet is still under active investigation. Typically, TLR activation in
other cell types results in the release of immunomodulatory factors and the sequestration of
pathogens. Zhang G, et al., demonstrated that LPS simulates platelet secretion and aggregation
via TLR4/MyD88 and cGMP/PKG-dependent pathways. (Zhang et al., 2009) They have also
shown that the effect of LPS on platelet aggregation is abolished by anti-TLR4 blocking
antibody and in MyD88-deficient mice. TLR2 has also been studied and has been documented to
activate P13K, Akt, ERKI.2, and p38, and it has also been shown to promote platelet-dependent
thrombosis. (Blair and Flaumenhaft, 2009) Experiments in mice have demonstrated that platelet-
derived TLR-4 is sufficient to promote microvascular thrombosis in endotoxemia. (Stark et al.,
2012) A TLR4-dependent mechanism has also been reported in LPS-induced thrombocytopenia,
TNF-a production, and neutrophil-dependent pulmonary sequestration in mice. (Andonegui et
al., 2005, Aslam et al., 2006) Recent experiments have also demonstrated that bacteria, such as
Streptococcus (S.) pneumonia, can activate platelets through a TLR-independent mechanism. (de
Stoppelaar et al., 2016)
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1.3.3 Protease-activated receptors (PARs)
Protease-activated receptors (PARs) are G protein-coupled receptors (GPCRs) that are highly
expressed throughout the body, with two forms expressed on platelets: PARI and PAR4. It is
important to note that there are a four PARs (PAR1-4), and that they are highly expressed in a
number of tissues throughout the body, including immune and epithelial cells, neurons, and
vascular cells. (Alexander et al., 2008, Coughlin, 2005)(Russo et al., 2009) These receptors are
activated via the binding of the PAR-activation peptide (PAR-AP), collagen, and serine protease,
thrombin (Factor II). Upon activation, proteolysis cleaves a part of their extracellular domain,
which results in an intracellular signaling cascade. (Soh et al., 2010)
PAR receptors play a major role in thrombin signaling, with cleavage of its amino-terminal
extracellular domain, exposing a new N terminus that binds intramoleculary to the body of the
receptor, resulting in transmembrane signaling. (Vu et al., 1991, Rasmussen et al., 1991) While
PAR1, 3 and 4 are all activated by thrombin, only PARI and 4 are expressed on human platelets,
while only PAR 1 and 3 are expressed on murine platelets. (Coughlin, 2000) In human platelets,
collagen and thrombin binding, at different sites, results in matrix metalloprotease- 1 (MMP-1)
activation, resulting in the cleavage and activation of PAR1. (Trivedi et al., 2009, Blackburn and
Brinckerhoff, 2008) Other metalloproteases, including ADAM 17, can cleave PARI and render
the receptor unresponsive to thrombin, whereas plasmin, cleaves PARI and can either activate or
render it unresponsive as well. (Ludeman et al., 2004, Kuliopulos et al., 1999)
PAR 1 and 4 have also been demonstrated to regulate Factor V (FV) association with the platelet
surface. PAR4 stimulation was found to result in a faster and more robust thrombin generation,
compared to PARL stimulation, which is attributed to more efficient FV release and
microparticle production upon PAR4 stimulation. (Duvernay et al., 2013) A recent study by
Carrim N, et al., demonstrated that, when activated, GPIba and PAR4 work together, resulting in
thrombin-induced reactive oxygen species (ROS) production. (Carrim et al., 2015) PARI can
also have an effect on sphingosine 1-phosphate (SIP) receptor and platelet-activating factor
receptor (PAFR). (Soh et al., 2010) Thrombin binding and PAR4 activation has also been shown
to play a role in cermide-NF-kB signaling in platelet activation. (Chen et al., 2013) PAR3 binds
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to thrombin, but instead of resulting in platelet activation, localizes thrombin for the dimerization
to PARi and subsequent PARi activation. (Nakanishi-Matsui et al., 2000)
While PAR4 has traditionally been thought to play a smaller role than PAR1. Racial differences
in the expression and functionality of PAR4 have recently been elucidated, with healthy black
people demonstrating significantly higher thrombin-induced platelet aggregation and calcium
mobilization. This result has been attributed to differentially expressed RNAs, including
phosphatidylcholine transfer protein (PC-TP). (Edelstein et al., 2013) Edelstein LC, et al.,
identified that a single nucleotide polymorphism (SNP), rs773902, determines whether residue
120 in transmembrane domain 2 is an alanine (Ala) or a threonine (Thr), with the Thr120 residue
being more prominent in black subjects versus white subjects, and resulting in higher PAR4-
induced platelet aggregation and calcium mobilization. (Edelstein et al., 2014) Although there
are very limited studies evaluating platelet and receptor function in different races and
ethnicities, these studies demonstrate that it is a factor that should be taken into consideration
during the development and clinical trials of new anti-platelet therapies.
1.3.4 Adrenergic receptors
Adrenergic receptors (adrenoreceptors) belong to the family of receptors coupled to GTP-
binding proteins and come in two subtypes: alpha (encompassing alpha-1, Al; alpha-2, A2) and
beta (encompassing beta-1, BI; beta-2, B2; beta-3, B3). The alpha-2 and beta-2 adrenergic
receptors, which have been identified on platelets, are coupled to adenyl cyclase via Gi or Gs
regulatory proteins. (Strosberg, 1993) Alpha-2 adrenoreceptors, which are present on platelets,
mediate the effects of epinephrine and norepinephrine, and receptor agonists are commonly
administered for the treatment of hypertension, pain and panic disorders, as well as other
conditions. (Hein, 2001, Giovannitti et al., 2015) Catecholamine stimulation, specifically
dopamine (but notably not adrenaline) stimulation, resulted in a modification of platelet behavior
in a rabbit model; thrombin-induced platelet accumulation was potentiated by dopamine at low
concentrations and is inhibited at high concentrations. (Emerson et al., 1999) A rabbit model of
endotoxemia-associated disseminated intravascular coagulation (DIC) investigated the effects of
catecholamine administration, and found that catecholamines acting on alpha-adrenoreceptors
resulted in the expected effect of glomerular capillary thrombosis, while beta-adrenergic
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stimulation counterbalanced the alpha-adrenergic effects that occur during endotoxemia
prevented this phenomenon. (Latour and Leger-Gauthier, 1987) Beta-adrenoreceptors, on the
other hand, are most commonly known for their overall regulation of cardiac function. (Wachter
and Gilbert, 2012) Binding of this receptor results in intracellular signaling through cyclic
adenosine monophosphate and protein kinase A. (Johnson, 2006, Kerry and Scrutton, 1983,
Klysner et al., 1984, Winther et al., 1985) These receptors have also been identified and
characterized as beta 2-subtype (B2) receptors on human platelets, and binding of the beta-2
adrenergic receptor is widely distributed in tissues of the respiratory tract. This receptor has long
been documented to play a role in platelet aggregation, with inhibition of this aggregation
occurring secondary to the addition of isoprenaline, and or other beta-agonists. (Kerry and
Scrutton, 1983, Klysner et al., 1984, Winther et al., 1985, Winther and Trap-Jensen, 1988) In a
rat model, catecholamines were shown to counteract a beta-adrenoreceptor-mediated platelet
inhibition via the alpha 2- adrenoreceptor site. (Koutouzov et al., 1985)
Changes in alpha- and beta- adrenoreceptors on platelets during disease are currently under
investigation, with several connections having been made between the levels of expressions of
these receptors during common medical conditions. Patients with anorexia nervosa have been
shown to express changes in adrenergic platelet receptor concentration and in [45Ca2+] uptake.
(Gill et al., 1992) Adrenoreceptor-linked [45Ca2+] uptake studies in platelets from rat models
suggest that diabetic conditions may be associated with an increase in alpha-adrenergic and
decrease in beta-adrenergic receptors on platelets, although the influence of adrenoreceptor
stimulation on platelet aggregation is not influenced by diabetes. (Gill et al., 1994, Austin et al.,
1995) A systemic review and meta-analysis evaluating the effect of beta-blockers on platelet
aggregation by Bonten TN, et al., (2014) concluded that beta-blockers do significantly reduce
platelet aggregation and that non-selective lipophilic beta-blockers seem to have more
pronounced effects. (Bonten et al., 2014) Although less commonly investigated, studies on
platelet alpha 2-adrenergic receptor activity have shown them to be dynamic, and that they may
then contribute to increased platelet reactivity reported in patients with stable coronary artery
disease following administration of dual antiplatelet therapy, suggesting other possible
therapeutic targets; this observation may provide opportunities for novel therapeutic targets.
(Beres et al., 2008)
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1.3.5 Prostanoids
Prostanoids, including prostaglandins (PGs) and thromboxane A2 (TXA 2), are lipid hormones
that act on GPCRs near the site of their formation. They are formed via the action of the
cyclooxygenase (COX) pathways and prostanoid synthases (Figure 1-5). (Bos et al., 2004, Smyth
et al., 2009) TXA 2 is synthesized and released via the COX-l pathway in activated platelets,
resulting in amplification of activity and further platelet activation and recruitment, as well as
vasoconstriction, proliferation, and mitogenesis at the site of thrombus and inflammation.
(Smith, 1980, Matsuoka and Narumiya, 2008, Grosser and FitzGerald, 2013) Arachidonic acid is
metabolized by three groups of enzymes, with the COX enzyme being expressed on platelets and
its' precursors. There are two isoforms of COX, COX-I and COX-2, both of which both convert
arachidonic acid to prostaglandin H2 (PGH 2). While COX-1 is the only isoform present in
mature platelets, COX-2 is expressed in both megakaryocytes and prematurely released platelets.
(Rao et al., 1985, Reiter et al., 2001, Patrignani et al., 1999, Zetterberg et al., 2003, Tanaka et al.,
2004, Grosser and FitzGerald, 2013)
Platelet agonism and subsequent activation results in generation of TXA 2 by Group (G) IVA
phospholipase (PL) A2 along with a calcium signal within the platelet cytosol. (Ballou et al.,
1986, Bartoli et aL., 1994) This pathway can also be activated by adhesion of vWF to GPIb-V-IX
on the platelets, binding of aUbP3, as well as vascular wall cells PLA2 isoforms resulting in
release of arachidonic acid for prostanoid formation. (Prevost et al., 2009, Liu et al., 2005,
Grosser and FitzGerald, 2013) Prostanoids have a short half-life and are rapidly hydrolyzed to
the stable, biologically inactive compound, TXB 2, in biological fluids; therefore, TXA2 is likely
not present in the circulation, but instead exerts action upon GPCRs on their target cells.
(Schuette et al., 1984, Dubin et al., 1982, Grosser and FitzGerald, 2013) TXA2-induced platelet
activation is likely restricted to the site of vascular injury and platelet activation. Modulation of
this signal can occur in many ways, including heterodimerization with other GPCRs, as well as
with inhibitors such as PGI2, nitric oxide, flavonoids, dietary vitamin E, and lipoproteins. (Beitz
et al., 1990, Karpen et al., 1981, Fitzgerald et al., 1988, Guerrero et al., 2007, Roberts et al.,
2008, Wilson et al., 2004, Grosser et al., 2006)
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Patients deficient in the TXA2 pathway, who display mild bleeding disorders, illustrate the
importance of prostanoids in hemostasis. (Matijevic-Aleksic et al., 1996, Dube et al., 2001,
Defreyn et al., 1981, Remuzzi et al., 1983, Grosser and FitzGerald, 2013) Additionally, a number
of COX inhibitor drugs also suppress this pathway, including aspirin; some are administered to
decrease platelet contribution to thrombus formation, although these medications can also lead to
bleeding diatheses such as gastrointestinal and intracranial hemorrhage. (Warner et al., 2011,
Schafer, 1995, Schafer, 1999, Grosser and FitzGerald, 2013) Prostacyclin (PGI2) is the major
platelet inhibitory prostanoid, which results in vasodilation and also has anti-mitogenic and anti-
arthrogenic properties. PGI 2 functions as a platelet inhibitor by restraining the effect of collagen,
thrombin, or TXA 2 and raising cAMP within the platelet. (Ehrman and Jaffe, 1980, Hawiger et
al., 1980, Graber and Hawiger, 1982, Grosser and FitzGerald, 2013, FitzGerald et al., 2000)
Non-steroidal anti-inflammatory drugs (NSAIDs) can preferentially target the COX-2 pathway.
Since inhibition of the COX-2 pathway results in reduced formation of PGI 2, these compounds
result in a demonstrated prothrombotic state, which may be associated with adverse events,
including myocardial infarction, stroke, and venous thromboembolism. (Ungprasert et al., 2015,
Howes, 2007, Alcorn and Madhok, 2015, Grosser et al., 2010)
Other types of prostanoid synthesis that the platelet is involved in are PGD 2, which is produced
via platelet COX, plasma PGD synthase, and PGE 2. Increased concentration of PGE2 in the
circulation may inhibit platelet function, while lower concentrations may activate platelets.
(Smith, 1981, Cooper and Ahern, 1979, Grosser and FitzGerald, 2013) Furthermore, COX-2
inhibitors, although thought to have no effect on platelet function and expression of aggregation
markers, can stimulate the release of TXB 2 from activated platelets. It is thought that the
combined decrease in vasodilatory PGE2 and PGI 2 together with increased TXA2 may
contribute to COX-2 inhibitor pro-aggregation effects. (Graff et al., 2007) Finally, it has also
been shown that immature, reticulated platelets have uninhibited COX- 1 and -2, even in the
presence of the COX-1 inhibitor aspirin, indicating aspirin resistance. (Guthikonda et al., 2007)
A close look at the prostanoid pathway within platelets also highlights an important possible role
for white blood cells. Aspirin has been shown to have an inhibitory effect on the formation of
platelet-neutrophil complexes (PNCs), and the formation of PNCs is an important part of platelet
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activation and the immune system. (Lopez-Farre et al., 1995) With respect to PNC formation and
its role in the arachidonic acid pathway, it appears as though there is platelet-mediated regulation
of neutrophil function that is still under study. Platelets support the synthesis of reactive
arachidonic acid metabolites, which modulate oxygen radical production in neutrophils.
(Herbertsson and Bengtsson, 2001) Upon stimulation, platelet-derived arachidonate can serve as
a precursor for neutrophil-derived eicosinoids (including leukotriene B4 (LTB4) and 5-
Hydroxyeicosatetraenoic acid (5-HETE)), platelet-derived product 12-HETE (which can be
metabolized to DHETE), and lipid mediators, including the anti-inflammatory lipoxins (LXs).
(Marcus et al., 1984, Antoine et al., 1992) Recent research has shown a contradictory role for the
PNC, where platelets may inhibit the neutrophil 5-lipoxygenase activities at the integrin level
and may result in decreased production of LTB4 during inflammation. (Chabannes et al., 2003)
This cell-cell interaction suggests an important role for the PNC in the formation of thrombi and
in inflammation.
1.3.6 P2 Receptors
Prostanoids also interact with a very important class of platelet receptors: P2YI and P2Y 12.
These receptors bind to adenosine 5'-diphosphate (ADP), which is important for thrombosis and
hemostasis. (Leon et al., 1996, Gachet, 2001) ADP on its own is a weak platelet agonist and
induces a reversible response. However, ADP is in very high stores within platelet dense
granules, and is released upon platelet activation, playing the role of a secondary agonist,
amplifying platelet aggregation at the site of vascular injury. (Hechler and Gachet, 2011) The
P2Y1 receptor initiates activation and aggregation via mobilization of calcium stores, and the
P2Y12 receptor is coupled to adenyl cyclase inhibition for ADP response. (Gachet, 2001, Gachet
et al., 1995) (Dorsam and Kunapuli, 2004, Jagroop et al., 2003) The P2Y1 receptor also plays a
role in collagen-induced platelet activation and shape change in the face of absent TXA2
formation. (Leon et al., 1999, Mangin et al., 2004)
Both the P2Y 1 and thromboxane-prostanoid-a (TPa) initiate platelet activation through the
phospholipase C-beta (PLCp) pathway, with TXA 2 being produced during arachidonic acid
metabolism and ADP being stored in the dense granule pool. (Jin et al., 1998, Nurden et al.,
2003) The P2Yl and TPa receptors on platelets are part of the GPCR family; they are part of a
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major pool associated with the membranes of a-granules and the open canalicular system.
(Nurden et al., 2003) While stimulation of the P2Y1 receptor can initiate platelet aggregation, it
is P2Y12 receptor stimulation that results in completion of aggregation. (Hechler et al., 2005,
Soulet et al., 2005, Savi et al., 1998) P2Y12 receptors have become a common drug target for
platelet inhibition, including compounds such as clopidogrel and prasugrel. (Hechler et al., 1998)
Stimulation of this receptor potentiates platelet secretion, independent of TXA 2 generation and
aggregate formation, and it can mediate the stabilization for the platelet aggregation induced by
thrombin or TXA2. (Cattaneo et al., 1997, Cattaneo et al., 1990, Cattaneo et al., 2000) Both
receptors also indirectly play a role in CD62P exposure and platelet-leukocyte aggregate
formation, as well as the exposure of phosphatidylserine (PS) on the platelet surface. (Leon et al.,
2004, Leon et al., 2001, Leon et al., 2003, Storey et al., 2000)
Another set type of P2 receptors on platelets are the ATP-gated P2X Receptor Cation Channel
(P2X) receptors. There are seven P2X subunit isoforms that have been identified, with each
subunit having two transmembrane domains, intracellular amino and carboxy termini, and a large
extracellular ligand-binding loop. (Mahaut-Smith et al., 2011) P2X receptors are ligand-gated
cation channels that are activated by adenosine triphosphate (ATP). (Hechler et al., 2005) P2X1
receptor stimulation results in a significant increase in intracellular calcium, a rapid and
reversible platelet shape change, activation by collagen under shear stress, and low levels of
alIlbP3 activation. (Hechler et al., 2005, Hechler and Gachet, 2011, Mahaut-Smith et al., 2011)
Although it is thought that all platelet contain functional P2X 1 receptors, research has shown that
only 40% of platelets alter their shape in saline, have a large increase in intracellular calcium,
and/or are activated by maximal ATP concentrations, which is all thought to be secondary to
desensitization in vitro.(Rolf and Mahaut-Smith, 2002) In addition to ATP, P2X1 receptors have
other potential (albeit less potent) agonists which are commonly found in the circulation and
specifically in platelet dense granules, including: diadenosine polyphosphates and adenosine
polyphophoguanosines. (Mahaut-Smith et al., 2011) In reality, most of these receptors and
agonists likely work together to result in optimal platelet function; for example, there is
amplification of ADP-induced P2Y 1 receptor activation and platelet aggregation via the calcium
influx through the P2X 1 receptor.
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1.3.7 Granules
Platelets play a variety of roles within the body, including hemostasis, inflammation, wound
healing, atherosclerosis, and tumor angiogenesis. A key contributing factor to these activities are
platelet granules, which are released upon platelet activation. Upon encountering vascular
damage, or a variety of other stimuli, platelet surface receptors bind to agonists, triggering an
intracellular signaling cascade and resulting in an increase in intracellular calcium and activation
of several GTP-binding proteins and protein kinases. (Blockmans et al., 1995, Plow and
Ginsberg, 1995) Platelet granules are then centralized by cytoskeleton rearrangement, fuse with
one another, and empty into the open canalicular system, resulting in the release of their granule
contents. (Blockmans et al., 1995, Geanacopoulos et al., 1993, Greenberg-Sepersky and Simons,
1985)
Platelet granules and their contents originate within the parent megakaryocyte, where they are
packaged up and deployed within the resultant platelets and microparticles. When stimulated,
platelets secrete contents from four granular stores: a-granules, dense granules, t-granules, and
secretory lysosomes. In the section below, we will give a brief overview of the different platelet
granules and their related cargo (Table 1-2).
1.3.7.1 Alpha granules
Alpha granules are the most abundant granules within the platelet with 50-80 granules per
platelet, each about 200-400 nm in diameter. (Blair and Flaumenhaft, 2009) Their heterogenic
content performs many roles in hemostasis, inflammation, and angiogenesis. Patient who have a
genetic deficiency in alpha granules biogenesis, known as Grays Platelet syndrome (GPS), have
a diverse bleeding phenotype, ranging from mild to severe (Figure 1-6). (Gunay-Aygun et al.,
2010, Bottega et al., 2013, Kahr et al., 2011, Maynard et al., 2010) The internal structure of the
granule contains an electron-dense nucleoid and a less-dense peripheral area that contains many
factors. (Blair and Flaumenhaft, 2009, Harrison and Cramer, 1993) It is currently debated
whether differential release of specific a-granule populations, or if different granule populations
are simply distributed in geographically distinct regions of the organelle. (Sehgal and Storrie,
2007, Ye and Whiteheart, 2013) One recent study, utilizing microfluidic techniques,
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demonstrated that the geometric orientation of the underlying matrix and platelet spreading
regulates a-granule secretion. (Sakurai, 2015)
The way in which platelets acquire their a-granule content is also quite complex and is under
study. Platelets have been documented to both inherit them from their parent megakaryocyte as
well as through endocytosis from the plasma compartment. (Handagama, 1990)(Suehiro et al.,
2005, Flaumenhaft, 2012, Italiano and Battinelli, 2009, Ye and Whiteheart, 2013) For example,
factor V, vWF, fibrinogen, and vascular endothelial growth factor (VEGF), which were once
thought to be solely inherited from the parent megakaryocyte, are now recognized to be acquired
via endocytosis from the surrounding environment. (Suehiro et al., 2005, Salgado et al., 2001,
Roussi et al., 1995, Harrison et al., 1989) In addition, the platelet concentration of a-granule Ig is
dependent on the plasma pool concentration. (George et al., 1985) It is also important to note,
that some of the factors that are incorporated into the megakaryocyte via endocytosis have been
shown to undergo proteolysis prior to being packaged into the platelet-pool. (Ayombil et al.,
2013)
The sole role of the platelet as a component of hemostasis is now being redefined, especially
when the a-granule contents are taken into account. These granules have been found to promote
everything from liver regeneration to nerve growth. (Chacon-Femandez et al., 2016, Fujimura et
al., 2002, Lisman and Porte, 2016, Starlinger et al., 2016) Because they also contain pro-
angiogenic, proinflammatory, and anti-inflammatory components, platelets are also being
recognized as potential therapeutics for wound healing, bum treatment, and bone and cartilage
repair. (Sakata and Reddi, 2016, Mussano et al., 2016, Venter et al., 2016, Pallua et al., 2010,
Findikcioglu et al., 2009, You et al., 2007)
1.3.7.2 Dense granules
Release of dense granule content is also important in homeostasis. Each platelet carries
approximately three to eight, - 150 nm diameter, electron-dense granules. (Ye and Whiteheart,
2013) The dense granule membrane contains H' pumping ATPase, which maintains the granule
at an acidic pH of~ 6.1. (Ye and Whiteheart, 2013) Dense granules serve as storage for a variety
of cargo, including calcium polyphosphates, sphingosine- 1-phosphate, epinephrine, serotonin,
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GPIb, GPIIb/IIIa, ADP and ATP (Youssefian et al., 1997, Chatterjee et al., 1990). There are
platelet-based bleeding disorders that are attributed all, or in part, to deficiencies in dense granule
formation. Patients with Hermansky-Pudlak syndrome (HPS) have a genetic defect in dense
granule and lysosome biogenesis, and have subsequent predilection to bleeding diatheses. (Feng
et al., 2002, Di Pietro and Dell'Angelica, 2005) Recent studies in mice have also shown that
platelet dense granule secretion may be essential to normal lysosome and a-granule secretion.
(Meng et al., 2015, Harper et al., 2015)
The roles of the dense granule cargoes are varied and their release is commonly used in the
testing of platelet function and degranulation. Serotonin (5-hydroxytryptamine, 5-Ht) is released
from platelets upon activation and can then bind to 5-HT2A receptors on the platelet surface to
promote platelet aggregation. (Siess, 1989) The importance of serotonin in platelets is
demonstrated with the increased use of serotonin reuptake inhibitors (SSRIs), which many
studies suggest is correlated with a decreased risk for cardiovascular disease (in contrast with
other tri-cyclic antidepressants, which are correlated with an increased risk of ischemic stroke).
(Schlienger and Meier, 2003, Juang et al., 2015) (Lee et al., 2013) Platelet serotonin has also
been shown to promote neutrophil recruitment to sites of inflammation in mice. (Duerschmied et
al., 2013) ADP and ATP are present in high concentrations, with ADP being dominant. Outside
of the granules, within the cytoplasm of the platelet, ATP is dominant over ADP. Upon platelet
activation, the ADP-containing dense granules move towards the open canalicular system and
release their ADP, with the concentration of ADP outside of the platelet resulting in nearby
platelet activation. (Fogelson and Wang, 1996, Fukami et al., 1978)
Polyphosphates (polyPs) were recently identified as components of platelet dense granules.
Interestingly, inorganic polyPs are present in bacteria, fungi, algae, and protozoa, as well as
eukaryotic cells. (Ruiz et al., 2004) PolyPs are present in acidocalcisomes, which contain
calcium, pyrophosphates (PPi), and other ions and proton-accumulating membranes with high
density on electron microscopy. (Ruiz et al., 2004) Platelet polyPs are under investigation and
have been found to be localized to the dense granules. (Ruiz et al., 2004) They play many roles
in both platelet activation and the coagulations cascade, activating the contact pathway of blood
clotting, accelerating factor V activation, and abrogating the anticoagulant function of tissue
51
factor pathway inhibitor (TFPI). (Morrissey et al., 2012, Choi et al., 2011, Muller and Renne,
2011) Additionally, although outside the scope of this section, platelet polyPs have been
identified to be proinflammatory, as well as prothrombotic, via the factor XII activation triggered
release of bradykinin, an inflammatory mediator of the kallikrein family. (Muller et al., 2009)
1.3.7.3 Lysosomes
Primary lysosomes have been identified in both the maturing megakaryocyte and the resultant
platelets. (Bentfeld-Barker and Bainton, 1982) When platelets are sufficiently activated, they
undergo two waves of exocytosis; the first wave is the release of a- and dense granules and the
second is the release of the lysosome contents. This process requires both ADP and the general
membrane fusion protein, N-ethylmaleimide sensitive factor, which then choreographs with
specific target membrane SNAL receptor (t-SNAREs) proteins to facilitate release. (Chen et al.,
2000)
Lysosomes are thought to release hydrolytic enzymes that aid in thrombus remodeling. Platelet
lysosomes contain a variety of acid hydrolases and glycohydrolases. (Holmsen and Weiss, 1979)
Upon platelet activation, degranulation of lysosomes appears to take place at a slower rate than
a- and dense granules, and requires stronger agonists. (Holmsen, 1989) Lysosome contents
contribute to vascular damage, the growth inhibition of smooth muscle cells via the cleavage of
heparin-like molecules by heparinases, and to the degradation of glycoproteins, glycolipids, and
glycosaminoglycans by glycohydrolases. (Ciferri et al., 2000, Zhang et al., 2001, Castellot et al.,
1982)
When defining a granule as a lysosome, however, one must take into account the definition of a
lysosome. Lysosomes are typically characterized by an acidic interior, however mepacrine, a
lysosome labeling drug, was also found to accumulate within a- and dense granules due to their
acidic interiors. (Polasek, 2005) Additionally, dense granules have recently been called
lysosome-related organelles, as they exhibit lysosomal membrane glycoprotein marker CD63
and LAMP2. (Polasek, 2005) Dense granules also share CD62P, GPIb, and GPIIb/IIIa with a-
granules and the multivesicular bodies that give rise to a- and dense granules, are also lysosomes
that contain acid hydrolases and express CD63. (Polasek, 2005) Additionally, HPS, which is
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associated with decreased platelet dense granule and lysosomes, is a generalized lysosomal
storage disorder involving multiple other tissue types. (Polasek, 2005) The endocytic nature of a-
granules further puts them closer to the lysosomal family as well. This information provides
support to the current hypothesis that all granules within the platelet are, ultimately, a type of
lysosome. (Polasek, 2005)
1.3.7.4 T-granules
The t-granule was described by Thon et al. (2012) as being a unique granule compartment within
the platelet for the localization and signaling of toll-like receptor 9 (TLR9). (Thon JN, 2012) The
T granule is a novel electron-dense tubular system-related compartment, where TLR9 colocalizes
with protein disulfide isomerase and associates with Vamp 7/8, to regulate its distribution in
platelets upon activation and spreading. TLR9 is most commonly expressed within monocytes,
macrophages and dendritic cells and functions as a receptor for bacterial and viral unmethylated
CpG islands in DNA. (Hennessy 2010, Thon 2012) More recent studies exploring TLR9 in
platelets show a possible function in oxidative stress, innate immunity, and thrombosis.
(Panigrahi S, 2013) The t-granule will likely be under further study throughout the coming years.
1.4 The role of platelets in hemostasis
The function of the platelet in hemostasis is perhaps its best known and most extensively studied
role. Platelets interact with the vascular wall, other platelets, soluble and membrane-bound
coagulation factors, leukocytes and fibrin to build a hemostatic plug, or thrombus, that bridges a
defect in the vascular wall. This thrombus acts to prevent excessive release of vascular contents
into the surrounding space, thus preventing hemorrhage and ultimately death. Though many cell
types and soluble factors contribute to the process, platelets are key for the initiation and
maturation of such thrombi under arterial flow, essentially coordinating the ordered construction
of this biological bandage. Furthermore, by gathering at the site of injury, platelets localize the
thrombogenic response and coordinate the fibrinolytic process, preventing the development of
pathologic thrombi.
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1.4.1 An overview of hemostasis
Hemostasis is the process of stopping blood loss from a vessel with an injured wall through the
construction of an insoluble thrombus to bridge the vascular defect. This process is classically
described in terms of primary and secondary hemostasis, and requires flawless integration of the
response of the platelet and of the coagulation cascade to tissue injury. Primary hemostasis refers
to formation of the platelet plug, while secondary hemostasis refers to the deposition of the end
product of the coagulation cascade, cross-linked insoluble fibrin, into and around the platelet
plug to strengthen and stabilize the resultant thrombus. Rather than occurring temporally as two
distinct stages of hemostasis, these happen simultaneously and are a mechanistic continuum,
with platelets central to both. This process is in many ways analogous to the construction of a
brick patch to bridge a hole in a wall, with platelets serving as the bricks essential for structure
and fibrin as the mortar essential for strength. The process is summarized in Figure 1-7.
The process of hemostasis begins with endothelial injury, whereupon the subendothelial
environment is exposed to components contained within the flowing blood. Exposed collagen
from the subendothelial environment admixed with von Willebrand factor (vWF) released from
the Weibel-Palade bodies of the endothelial cells interact with each other and with platelets,
resulting in tethering, activation and adhesion of the platelets to the subendothelial environment.
Downstream signaling from the receptors results in platelet activation, with subsequent release of
factors such as adenosine diphosphate (ADP) and thromboxane A 2 (TXA 2) that cause activation
of neighboring platelets in an autocrine fashion. Inside-out signaling resulting from these
agonists additionally primes the platelet to bind to fibrinogen by causing the integrin aIbrP3 to
adopt an active confirmation.
Meanwhile, tissue factor (TF) from the subendothelial environment binds to activated Factor VII
(VIIa) to initiate the extrinsic coagulation pathway. The thrombin that is generated by the
activated factor Xa (Xa) formed by the extrinsic Xase of this pathway serves to activate a
number of factors of the intrinsic coagulation pathway, which ultimately generates an intrinsic
Xase that is 50-100 times more efficient in converting the zymogen factor X to its active form
Xa, and thus more efficient in ultimately producing thrombin than its extrinsic equivalent,
thereby amplifying the response. The extrinsic and intrinsic coagulation pathways converge in
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the common coagulation pathway, in which the thrombin that is generated serves to catalyze the
conversion of soluble fibrinogen to insoluble fibrin. Insoluble fibrin polymers bridge the gaps
between platelet membranes by binding to the active conformation of integrin a1bP3 on two or
more platelet surfaces, thus facilitating the process of aggregation. The end product is a mass of
platelets admixed with fibrin and "innocent bystander" leukocytes and erythrocytes that bridges
the defect in the endothelial monolayer of the vessel wall.
1.4.2 Platelets respond to endothelial damage by laying a foundation for a thrombus
The healthy vessel wall is composed of a confluent sheet of endothelial cells lining the inner
surface of a tube composed of a basement membrane encased in additional cellular layers (the
tunica media and tunica adventicia). The intact endothelium contains an ADPase (CD39) and
secretes factors, such as PG!2 and nitric oxide, that prevent the activation of platelets in the
circulation. (Tateson et al., 1977, Marcus et al., 1991, de Graaf et al., 1992) Upon injury, the
confluency of the endothelial monolayer is disrupted and the basement membrane exposed.
This basement membrane is an insoluble sheet of highly cross-linked glycoproteins, including
multiple types of collagen. Von Willebrand factor (vWF), which is stored in Weibel-Palade
bodies of endothelium and released upon activation, binds to the basement membrane matrix by
binding predominantly to collagen types I, III and VI, (Pareti et al., 1987, Hoylaerts et al., 1997)
and the activation step of the adhesion process results from binding of the platelet GPIb-IX-V
and GPVI to vWF and collagen, respectively.
Platelet binding to vWF has been shown to be essential for the timely adhesion of platelet to a
vascular defect.(Ni et al., 2000b) Once anchored to the basement membrane, the Al domain of
vWF serves as a ligand for glycoprotein (GP) Iba (CD42) of the GPIb-IX-V receptor complex
that is specific to passing platelets under shear conditions, thus facilitating the process of
Tethering of the platelet to the vascular wall.(Ruggeri, 2009, Savage et al., 1996) The association
of vWF with this receptor tyrosine kinase initiates outside-in signaling by activating PI-3 kinase
via the Syk/Src pathway, resulting in activation of phospholipase (PLC) y, mobilization of IP3,
and release of calcium (Ca+2) from intracellular dense tubular system.(Mazzucato et al., 2002,
Nesbitt et al., 2002) This initial elevation in intracellular Ca+2 is compounded by a second influx
55
from the extracellular environment.(Nesbitt et al., 2002, Mazzucato et al., 2002) Mice deficient
in vWF demonstrate a delay in the initiation of thrombus formation but do eventually form stable
thrombi.(Ni et al., 2000a)
Another receptor exclusive to platelets, GPVI, complexes with FcRy dimers on the platelet's
surface and occupies membrane lipid rafts that it shares with GPIb-IX-V.(Tsuji et al., 1997) The
C-terminal D2 domain of GPVI binds to collagen while GPIba binds vWF.(Horii et al., 2006,
Auton et al., 2010) Signaling downstream of this receptor tyrosine kinase's immunoreceptor
tyrosine-based activation motif (ITAM), FcRy, amplifies the outside-in PLCy signaling and
further compounds the rise in intracellular Ca+2 levels.(Blake et al., 1994, Daniel et al., 1994)
Elevated levels of intracellular Ca+2 within the platelet instigate inside-out signaling to stimulate
changes from an inactive to active conformation in integrin U20 1 (GPIa-IIa, homologous to
VLA2 on lymphocytes).(Margadant et al., 2011) Though activation is not a prerequisite for
collagen binding by this integrin, this active integrin's U2-subunit I domain is able to bind to
collagen's GFOGER motif with increased affinity following activation.(Emsley et al., 2000,
Smith et al., 2000) Collagen binding results in additional outside-in PLCy signaling that
produces peaks in Ca+2 levels distinct in duration and form from those produced through GPVI
signaling, (Mazzucato et al., 2009) as well as providing a third point of structural integrity to the
adhesion of the platelet to the defect in the vessel wall.(Sarratt et al., 2005)
The inside-out signals produced during platelet activation similarly result in a change from an
inactive to active conformation to the main integrin, LIUbP3, that mediates the platelet-platelet
interactions necessary for stable thrombus formation and connects the actin skeleton of adjacent
platelets to allow for clot retraction. UI11p3 comprises 3% of the total protein mass of the platelet
and 17% of the total plasma membrane bound protein, and as such is the most prevalent integral
plasma membrane protein.(Phillips et al., 1988) Platelet activation results in tethering of alb p3 to
actin filaments through interactions with cytoskeletal accessory proteins including talin,
(Knezevic et al., 1996) filamin, (Pavalko et al., 1989) a-actinin, (Pavalko et al., 1991) and
others.(Burridge and Fath, 1989) Platelet activation induced talin and kindlin binding of the P3
subunit furthermore results in unclasping of the cytoplasmic tails of the aclb and p3 subunits,
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leading to a change in the spatial orientation of the extracellular domains into an active
conformation recognized by the PAC-l antibody.(Critchley and Gingras, 2008, Montanez et al.,
2008, Ma et al., 2006) A groove between this active integrin's A-like domain of the p3 subunit
and P-propeller of the alIb subunit binds to the RGD peptide sequence of multivalent vWF or the
KQAGDV peptide sequence at the C-terminus of divalent fibrinogen's y chain.(Plow et al.,
1985, Ruoslahti, 1996) The active conformation of this integrin is necessary for ligand binding,
and ongoing platelet activation is required for the maintenance of the active conformation of this
integrin.(Goto et al., 2006) Inside-out signaling from this integrin helps to maintain ongoing
platelet activation through similar mechanisms to those outlined above, as does autocrine
platelet-platelet signaling as outlined below. Platelet activation additionally results in alpha-
granule fusion with the platelet's surface, leading to increased surface expression of aIUbP3 as the
subpopulation of this integrin that is resident in the alpha granule membrane is exposed.(Wencel-
Drake et al., 1986) Hereditary defects in this integrin are responsible for the prolonged bleeding
times observed in patients with Glanzmann's thrombasthenia.(George et al., 1990)
1.4.3 Platelets localize the coagulation cascade to the site of injury
While the platelets interact with the subendothelial environment and each other to begin to lay
the structure of the thrombus, a series of enzymatic reactions simultaneously serves to produce
the insoluble fibrin that will serve as a mortar to stabilize the platelet-platelet interactions. In
these reactions, serine proteases (thrombin, and factors VII, IX, X, and XI) partner with
membrane-bound glycoprotein cofactors (TF and factors V and VIII) to catalyze the activation of
additional zymogens or cofactors. The liver is the primary producer of the coagulation factors V,
VII, VIII, IX, X, XI and thrombin (factor II) in addition to fibrinogen (factor I),(Olson et al.,
1966) while the subendothelial fibroblasts and pericytes produce the integral membrane protein
TF (factor III, CD142).(Wilcox et al., 1989) The ultimate end product is the cleaving of soluble
fibrinogen into insoluble fibrin by thrombin (factor II).
This process is traditionally described as the interplay of three coagulation pathways: the
extrinsic coagulation pathway initiates the process, the intrinsic coagulation pathway amplifies
the response, and the common pathway represents the convergence of the extrinsic and intrinsic
pathways to form the complex of factors V and X (known as "prothrombinase") that catalyzes
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the conversion of prothrombin into thrombin.(Schenone et al., 2004) Significant redundancy
across these pathways allows for deficiencies in factor VIII (hemophilia A) or factor IX
(hemophilia B) to be viable, though affected individuals suffer from mild to severe bleeding
diatheses.(Pavlova and Oldenburg, 2013)
The subendothelium and platelet surface as an essential scaffold for facilitating and localizing
the enzymatic cascade. To operate at maximum efficacy, many of these enzymatic reactions
must occur either on the scaffold of the subendothelial environment (those catalyzed by VII/TF)
or at the activated platelet surface (those catalyzed by IX/VIII, X/V and thrombin).(Scandura and
Walsh, 1996, Baglia and Walsh, 2000) These associations are mediated by interactions of the
serine protease with the negatively charged surface (tissue factor on the subendothelial space, or
activated platelet phospholipid); binding to specific receptors that are expressed on activated
platelets may also play a role, especially for the binding of factor Xa.(Bouchard et al., 1997)
Vitamin K is required for the post-translational carboxylation of the glutamic acid residues that
allows these factors (VII, IX, X, and thrombin) to bind to these surfaces.(Furie et al., 1999) This
requirement for ongoing interactions with an activated platelet surface effectively localize the
coagulation cascade to the core of the thrombus.
The coagulation cascade is initiated at the site of vascular injury by exposure of TF to
subnanomolar levels of circulating activated factor VIIa.(Eichinger et al., 1995) Extrinsic Xase is
the product of this interaction, and activates the zymogen forms of factors X or IX with a
relatively low efficacy.(Lawson and Mann, 1991, Komiyama et al., 1990) The resultant enzymes
Xa or IXa serve to amplify the coagulation response by associating with their respective
coenzymes (Va or VIlla) on the platelet surface scaffold and by initiating the common or
intrinsic coagulation pathways, respectively, in addition to activating additional factor VII.(Rao
et al., 1985, Komiyama et al., 1990) The association of Xa with platelet-bound Va to produce
prothrombinase results in increased production of thrombin in the microenvironment of the
activated platelets.(Nesheim et al., 1979) This thrombin initiates the intrinsic coagulation
pathway, in addition to augmenting platelet activation, increasing the pool of activated factor V,
and cleaving fibrinogen to fibrin, as discussed further below (4.1.4).
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Thrombin initiates the intrinsic coagulation pathway by catalyzing the activation of factors XI,
VIII and V.(Pieters et al., 1989, Gailani and Broze, 1991) Factor XIa then augments the
production of factor IXa, which is already being produced by factor VIta bound to TF.(Gailani et
al., 2001) Factor IXa binds to the newly minted, membrane-bound cofactor VIIla on the
activated platelet surface to form intrinsic Xase. Intrinsic Xase is 50 to 100 times more efficient
than extrinsic Xase (Factor VIIa/TF) (Ahmad et al., 2003), and thus further increases production
of factor Xa, which binds to factor Va and to the activated platelet surface (Bouchard et al.,
1997) and subsequently produces more thrombin from prothrombin.
The extrinsic and intrinsic pathways both converge in the common pathway with the formation
of thrombin by prothrombinase (Xa/Va). The enzymatic activity of prothrombinase substantially
differs when it is associated with an activated platelet membrane when compared with unbound
forms or forms bound to synthetic vesicles. The reactions that produce thrombin by
prothrombinase on an activated platelet surface proceed through an inactive intermediate,
prethrombin-2, rather than the active intermediate meizothrombin.(Wood et al., 2011) Since the
latter is able to competitively bind to thrombin binding sites but has markedly reduced efficacy,
(Doyle and Mann, 1990) the localization of the prothrombinase complex has implications not
only for the activity of the prothrombinase but also for the activity of thrombin.
Though fibrinogen, the substrate for thrombin, is synthesized by the liver, it is concentrated in
the vicinity of platelets in both intracellular and membrane-associated forms.(Gokcen and Yunis,
1963) Fibrinogen that binds to inactive cLarm3 is endocytosed and stored in alpha granules to be
released upon platelet activation.(Harrison et al., 1989) Fibrinogen is a linear protein composed
of three chains, Au, B$ and y, that exists soluble in the plasma as dimers stabilized by disulfide
bonds. Thrombin hydrolyzes RG bonds at the N terminus of the Aa and BP chains, resulting in
the production of a fibrin molecule with exposed sites in the a and P chains that allow for
interaction with a site on the C terminus of the y chain, (Scheraga, 2004) thus allowing for the
formation of the fibrin polymers that serve as mortar between the platelets.
It is also important to note that other cell types have been shown to have the capacity to produce
coagulation factors in vitro, (Dashty et al., 2012) and additional sources such macrophages are
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important sources of coagulation factors like VII and TF in disease states such as atherosclerosis
and other inflammatory states.(Wilcox et al., 2003, Lindmark et al., 2000) Furthermore, the
ultimate downstream substrate for the product of these pathways, fibrinogen, is an acute phase
protein with upregulated production by the liver in inflammatory states.(Mayer and Schomerus,
1975) Such increased production of these factors in the face of inflammation may contribute to
the development of pathologic hypercoagulable states.
1.4.4 Platelet Activation Provides Autocrine Signaling to Localize and Amplify Response
The first layer of bricks has thus been laid through the process of adhesion of the platelets to the
subendothelial environment, and the fibrin has been generated that will act as mortar to bind the
platelets together. An additional consequence of the outside-in signaling that occurs is platelet
activation. Activation results in platelet shape change and release of alpha and dense granule
contents into the surrounding microenvironment, as well as activation of cyclooxygenase (COX)-
1. As a result of these events, the local concentration of the essential components of that mortar,
fibrinogen and vWF, and the surface density of their ligand, Q11bp3, increases. ADP and TXA 2
are released from the platelet, and join thrombin generated by the common coagulation pathway
in a series of autocrine signaling events. The sum consequence of these events is to amplify,
sustain and localize the platelet activation, with the end product of a focal stable thrombus that
acts as a wall to bridge the defect in the endothelium.
Activation stimulates a reorganization of the actin cytoskeleton that drives a change in shape
from a resting discoid to an activated spherical platelet and subsequent development of filapods
and platelet spreading. This process is initiated by intracellular calcium binding to and causing a
conformational change in gelsolin, which severs actin filaments and creates new negative (-, or
pointed) ends to existing actin filaments.(Fox et al., 1987) Additionally, Arp2/3 complex is
upregulated in activated platelets,(Falet et al., 2002) and when bound to actin serves as a
surrogate - end and nidus for the growth of the actin filament along the + end.(Machesky and
Gould, 1999) P-thymosin outcompetes the - ends of actin filaments in affinity for free actin
subunits in the cytoplasm, thus preventing cytoskeletal reorganization in the resting
platelet.(Carlier et al., 1996) However, these new + (or barbed) ends have a greater affinity for
binding free actin subunits than P-thymosin, and their exposure allows for actin assembly and
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subsequent reorganization of the cytoskeleton.(Hartwig et al., 1995) Cytoskeletal reorganization
brings the cytoplasmic alpha and dense granules into close proximity with the open canicular
system, allowing for SNARE-mediated fusion and exocytosis of their contents which
subsequently diffuse into the microenvironment surrounding the platelet.(Stenberg et al., 1984)
Both alpha and dense granules are membrane bound intracellular vesicles that are trafficked into
developing platelets along microtubules in the parent megakaryocyte.(Richardson et al., 2005)
a-granules outnumber dense granules tenfold, and can be more than twice the size.(Frojmovic
and Milton, 1982) Alpha granules originate from the multivesicular bodies formed by fusion of
outbuddings of the Golgi apparatus and endosomes in megakaryocytes.(Handagama et al., 1990)
The contents of a-granules thus include proteins from the extracellular environment, such as
factor Va and prothrombin, and integral membrane proteins recycled from the platelet surface,
such as aIIbP3, GPIba-IX-V and GPVI, in addition to factors that may be synthesized by the
megakaryocyte, such as fibrinogen and vWF.(McRedmond et al., 2004) u-granule fusion with
the platelet membrane thus contributes to ongoing platelet activation by increasing the
concentration on the platelet surface of integrins that facilitate adhesion to the subendothelium
and sustain outside-in signaling (GPIba-IX-V and GPVI), or that are essential ligands for
platelet-platelet interaction (Ulbfp3). Alpha granule fusion also results in an increased
microenvironmental concentration of the proteins necessary to bridge interactions between
platelets in the core of the thrombus, whether through direct release (vWF), or release of the
components necessary for synthesis of fibrin by the coagulation pathway (prothrombin,
fibrinogen and factor Va).
Interestingly, these platelet-derived proteins generally have enhanced activity compared with
those from other origins. For example, platelet derived vWF consists predominantly of high-
molecular-weight multimers vWF with greater adhesive activity in comparison to lower
molecular weight counterparts.(Gralnick et al., 1985) Additionally, platelet-derived factor Va,
which exists in either membrane-bound or unbound forms and is released in a partially active
form from alpha granules, demonstrates enhanced cofactor activity following activation by
thrombin,(Monkovic and Tracy, 1990) and decreased susceptibility to inactivation by activated
protein C (APC) compared to its plasma-derived counterpart.(Camire et al., 1995) Upon release
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of a-granule contents, the concentration of factor Va in the microenvironment can exceed that of
the plasma by 600 fold.(Nesheim et al., 1986)
The downstream product of the association of Va with Xa, thrombin, thus becomes concentrated
within the core of the thrombus where it serves as a potent platelet activator. Thrombin is a
serine protease that cleaves the N-terminal extracellular domain of protease-activated receptors
(PARs), resulting in a novel N-terminus that serves as a tethered ligand for these G-protein
coupled receptors;(Vu et al., 1991) peptide agonists of the PARs, such as SFLLRN as an agonist
for PAR1, thus act as surrogate PAR N-termini rather than thrombin analogs.(Ramachandran and
Hollenberg, 2008) Thrombin acts on PARt on human platelets and PAR3 in mice to initiate
reversible aggregation.(Ishihara et al., 1997) Signaling through G12/13 triggers shape change and
granule release, including dense granule ADP release, through activation of Rho kinase and
subsequently cofilin and myosin light chain kinase,(Klages et al., 1999) while signaling through
Gq triggers the initial release of Ca+2 from intracellular stores.(Covic et al., 2000) Thrombin also
acts on PAR4 in both species via G 12/13 and Gq signaling to result in further granule release and a
sustained Ca+2 influx, ultimately resulting in ongoing platelet activation and irreversible
aggregation.(Covic et al., 2000) The process of a-granule fusion thus serves to concentrate the
components necessary for sustained platelet-platelet interactions within the stable core of the
growing thrombus, where the platelets are p-selectin positive and closely packed.(Stalker et al.,
2014) It is no wonder that patients with a deficiency in a-granules, known as Gray Platelet
Syndrome due to the appearance of their platelets by electron microscopy, demonstrate mild to
moderate bleeding diatheses.(Raccuglia, 1971)
In contrast, dense granules are similar to lysosomes as they originate in megakaryocytes from the
early endosome rather than directly from the golgi.(Raposo et al., 2007) The contents of dense
granules, such as ADP and serotonin, are imported through active transport by membrane pumps,
including multidrug resistance protein (MRP)-4 and vesicular monoamine transporter (VMAT)-
2, respectively; the concentration of dense granule contents is thought to increase as the dense
granules mature.(Jedlitschky et al., 2004, Fukami et al., 1984) ADP in the dense granule
releasate serves as an autocrine signal to sustain and localize platelet activation around the
thrombus. ADP acts by binding P2Y i or P2Y 12 on the platelets' surface. These G-protein
62
coupled receptors serve to initiate and sustain adoption of the active conformation by aIIbP3,
with Gq signaling downstream of P2Y1 contributing to the initiation of activation and Gi
signaling downstream of P2Y12 synergistically contributing to the maintenance of
activation.(Remijn et al., 2002, Fabre et al., 1999) Such mechanisms synergize and compound
the consequences of thrombin activation, and are essential to initiating and maintaining the
activation in the outer shell of the thrombus, where the platelets are more likely to be p-selectin
negative and loosely associated with each other through dynamic membrane tethers.(Stalker et
al., 2014, Nesbitt et al., 2009, Dopheide et al., 2002) In humans with a deficiency in dense
granules, such as is found in Hermansky-Pudlak syndrome, or a defect in dense granule function,
such as in Chediak-Higashi syndrome, minor bleeding diatheses are observed in conjunction
with myriad other symptoms.(Buchanan and Handin, 1976, White et al., 1971)
Platelet activation is additionally amplified through the action of thromboxane A 2 (TXA2).(Brass
et aL., 1987) TXA 2 is synthesized by platelets following their activation. The increase in
cytosolic calcium in the activated platelet results in activation of phospholipase A2, which
hydrolyzes platelet membrane phospholipids to produce arachidonic acid. Arachidonic acid is
then converted to prostaglandin (PG) G2 by cyclooxygenase-1 (COX-1), then into PGH2 by
hydroperoxidase, then into TXA 2 by the platelet-specific isomerase thromboxane
synthase.(Moncada and Higgs, 1986) TXA2 is a small molecule that freely diffuses across the
platelet membrane; the effect of TXA 2 is localized as a result of the molecule's 30 second half-
life. (FitzGerald, 1991) When TXA2 binds the G-protein coupled thromboxane receptor (TP), the
downstream effects that are mediated by Gq and G12/13 signaling are analogous to that seen
following stimulation by thrombin or ADP.(Knezevic et al., 1993, Offermanns et al., 1994,
Djellas et al., 1999) Inhibition of these pathways, either by blocking TXA 2 synthesis by
irreversibly inhibiting COX-1 with aspirin treatment, or by knocking out TP in a mouse model,
results in prolonged bleeding times. However, bleeding diatheses are rarely noted secondary to
defects in these pathways.(Gerstein et al., 2015, Thomas et al., 1998) This may be due to the fact
that TXA 2 mediated platelet activation appears to be most essential under shear stress conditions
consistent with venous rather than the high shear stress conditions associated with arterial
flow.(Moake et al., 1988)
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1.4.5 Cross-linked fibrin stabilizes interactions between activated platelets to form the
thrombus
The monomeric fibrin generated from fibrinogen by the enzymatic activity of thrombin binds to
the active conformation of integrin albJ3 with high affinity.(Litvinov et al., 2016)
Polymerization of this platelet-bound fibrin with neighboring fibrin monomers occurs through
interactions of the N terminal lysine residues that are exposed following cleavage of the Au and
BP chains by thrombin with glutamate residues on the y chain.(Scheraga, 2004) This bond is
catalyzed by a transglutaminase, factor XIIIa, which is present in the circulation in zymogen
form and activated by thrombin following binding of fibrin.(Curtis et al., 1974) Thus, the platelet
bricks that were laid over the endothelial defect are stabilized by the formation of an insoluble
fibrin mortar, all under the control of paracrine signaling provided by factors localized to the area
by activated platelets.
It is important to note that this initial mass of platelets is heterogeneous in structure, with
classically activated p-selectin + platelets embedded within this cross-linked fibrin mortar acting
as the nuclear hemostatic core, and gradients of levels of activation driven by shear stress of
vascular flow and localized thrombin, ADP and TXA2 signaling radiating from that core to form
a shell with a tear-drop structure.(Stalker et al., 2014) Discoid p-selectin - platelets with
filamentous tethers concentrate along the lagging edge of that structure, and primarily depend
upon shear stress rather than paracrine signaling for their activation.(Nesbitt et al., 2009) Growth
of the thrombus beyond these confines is inhibited by prostacyclin (PGI2), endothelial-ADPase
(CD39), and nitric oxide from the surrounding intact endothelium.(Tateson et al., 1977, Marcus
et al., 1991, de Graaf et al., 1992)
1.5 Platelets in inflammation
Platelets play key roles in hemostasis and immunity. Despite the seeming disparity between these
two systems, there is considerable redundancy in the roles that platelets play and the mechanisms
through which they fulfill their function. In both hemostasis and immunity, platelets promptly react
to stimuli through post-translational mechanisms, and directly interact with endothelium,
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leukocytes and other platelets to modulate their behavior and release factors from their a- and
dense granules to locally amplify a response. Though the initiating stimuli substantially differ, the
downstream mechanisms echo each other and overlap, and as a result, pathologic thrombi are not
uncommon as a sequela to the immune response to pathogens. This section will concentrate on the
mechanisms that underlie what we currently understand about the platelet's role in inflammation.
1.5.1 Direct functions
1.5.1.1 Sequestration and thrombus formation
It is not surprising that platelets likely have direct interactions with pathogens, as they are one of
the most numerous blood cell type in the peripheral circulation. Upon contact with pathogens, such
as bacteria, platelet can bind these invaders via many different mechanisms, dependent on the type
of pathogen (bacteria, virus, etc.). They are capable of directly binding to pathogens and also
indirectly binding them through bridging molecules. (Fitzgerald JR, 2006) As discussed in Section
1.3.2, 'Immunomodulatory receptors and antigens', platelets have many immune receptors, which,
when bound, subsequently activate the platelets. This activation leads to a signaling cascade, which
results in the activation of other nearby platelets and the activation of the coagulation system. This
enables the platelets to sequester the pathogens, usually bacteria, within a cross-linked fibrin clot
which subsequently holds the pathogen 'hostage' until the nearby leukocytes come and finish the
job. The platelets themselves also contain a number of antimicrobial peptides within their granules,
such as their lysosomes, and when sufficiently activated, the platelet can degranulate and release
these toxins onto the bacteria, resulting in bacterial killing.(Yeaman MR) In some cases, platelets
can be activated by bacterial toxins without direct interaction with bacteria; this can result in
peripheral thrombocytopenia and/or sterile thrombus formation within the body, such as in the
case with Helicobacter pylori (H. pylori) and haemolytic uremic syndrome (HUS) caused by
Escherichia coli (E. coli). (Hambleton J, 2002; Proulx F, 2001)
Platelets have multiple bacterial-response mechanisms, including responding to antigen-antibody
complexes, antigens alone, and complement. (Humphrey JH, 1955; Hawiger J, 1972; Weksler
BB, 1971) One of the most studied platelet-bacterial interactions is with Staphylococcus aureus
(S. aureus), which triggers platelet activation via secreted a-toxin, protein A, IgG, and the
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FeyRIla platelet receptor. (Fitzgerald JR, 2006) S. aureus even has its' own surface receptors that
can directly bind to platelets and fibrinogen, such as clumping factor A (ClfA) and fibronectin-
binding proteins (FnBPA and FnBPB), propagating aggregation and thrombus formation.
(Schwarz-Linek U, 2003; Massey RC, 2001). Streptococcus sanguis (S. sanguis) and
Streptococcus pyogenes (S. pyogenes) also activate platelets in a complement- and antibody-
dependent fashion. S. sanguis expresses platelet-aggregation-associated protein (PAAP), which
results in rapid platelet activation and aggregation. Another example includes Porphyromonas
gingivalis (P. gingivalis), which can both accelerate the generation of atherosclerosis as well as
directly secrete platelet-activating proteases. (Fitzgerald JR 2006) Some bacteria can bind to
platelet surface receptors, such as in the case of Borrelia burgdorferi (B. burgdorferi) binding to
c1lMP3, either directly or through plasma protein linkers. Escherichia coli (E. coli) results in
platelet activation via both FcyRIIa and albfp3, although bacterial killing was dependent on IgG
opsonization. (Watson CN 2016; Riaz AH 2012) There are even differences in bacterial-platelet
interactions dependent on the specific strain of bacteria. (Fitzgerald JR, 2006) E. coli 0111 has
been shown to activate platelets in a TLR4-dependent manner, resulting in an increase in tissue
factor expression and faster thrombin generation, as well as an increase in platelet adhesion to
endothelial cells. (Matus V 2017; Matus V 2014) Studies of platelet interactions with a wide
range of bacteria, including various different strains, has been explored, although is beyond the
scope of this chapter.
1.5.1.2 Antimicrobial peptides
Platelets harbor a wide variety of antimicrobial peptides within their granule stores, which they
can release upon appropriate stimulation; in fact, platelets are considered granulocytes, similar to
neutrophils, eosinophils, and basophils. (Yeaman ME 2014) When platelets detect and bind to
bacteria or bacterial pathogens they release a multitude of factors, including: ADP and ATP, which
further stimulate platelet activation, and platelet microbicidal proteins (PMPs) and kinocidids,
which both activate neighboring leukocytes and kill the inciting pathogen. (Yeaman 2014;
Hamzeh-cognasse H 2015) The microbicidal proteins that platelets have been shown to contain
include, kinocidins (CXCL4, CXCL7, and CCL5), defensins (BD2), and thymosin P4. (Yeaman
2014) Kinocidins are capable of acting as both chemokines and antimicrobials. (Yeaman 2014;
Yeaman 2007; Yount NY 2004) Platelets are also capable of generating and releasing reactive
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oxygen species (ROS), such as hydrogen peroxide. (Dorit M, 2009) These factors can have potent
effects on a variety of pathogens, including bacteria, viruses, fungi, and protozoans. (Yeaman
2014)
1.5.1.3 Pathogen internalization
The ability of platelets to internalize pathogens has been widely debated and is partially dependent
on the type of pathogen. Thrombocytes, the nucleated, primitive relative of the platelet, which are
present in non-mammalian vertebrates, have been shown to phagytose bacteria; suggesting that
this may be a conserved function. (Negasawa T 2014) While various studies on the ability of
mammalian platelets to phagocytize bacteria have shown internalization, one study by White JG
(2000) concluded that platelets are, in fact, not phagocytes but are covercytes; bacteria appear to
passively enter the platelet through the open canalicular system but are not actively phagocytosed.
(White JG, 2000 and 2004; Absolom DR 1982; Youssefian T 2002) This topic is still currently
under debate.
A separate mechanism by which pathogens can be found in platelets is as a sequela to the infection
of their 'parent' MK cell. Viruses and viral genetic material, as one example, are frequently found
in circulating platelets, but the entry of these pathogens into the platelet is via another mechanism:
internalization by the 'parent' MK and subsequent development and release of 'daughter' platelets
with viral particles or RNA/DNA. (Lee TH 1998; Kopko PM 2001; Youssefian T 2002; Sakaguchi
M 1991) Dengue virus has been found to infect megakaryocytes and be found in circulating
platelets. (Noisakran S 2012; Hsu AY 2015; Clark KB, 2012) Anaplasma phygocytophilium (E.
phagocytophilium), an obligate intracellular bacterium, has been shown to infect megakaryoblasts
(Meg-01 cells) and is somewhat dependent on the presence of sialylated ligands and PSGL-1
(CD 162); although this infection results in a peripheral thrombocytopenia, it appears to be antigen-
dependent as this bacterium is not located within the platelet itself. (Granick JL 2008) Anaplasma
platys (A. platys; formerly Ehrlichia platys), on the other hand, is known to result in both
megakaryocyte infections within the bone marrow and platelet intracellular inclusion bodies in the
peripheral blood. (Inokuma H 2002; Loeffelholz MJ 2014) Although the 'infected' platelets are
not always infectious, they can still be bound by anti-virus IgG and be subsequently targeted by
leukocytes, resulting in a peripheral thrombocytopenia. (Assinger A 2014)
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1.5.2 Indirect functions
1.5.2.1 Platelet-leukocyte aggregates
Activated platelets have a powerful tool belt of cytokines and chemokines which, upon appropriate
stimulation, they release into the surrounding blood and tissue for the subsequent recruitment and
activation of nearby leukocytes. While platelets themselves are able to detect all four structural
classes of cytokines (C, CC, CXC, and CX3C) and potentially undergo chemotaxis towards these
signals towards sites of infection and injury, one primary way for platelets to migrate into these
stimulated location is by hitching a ride on a nearby leukocyte. (36-38 of and Yeaman 2014) This
interaction is primarily mediated by the CD62P-CD162 interaction. (Frydman GH 2017) Platelets
can release microbicidal chemokines (aka kinocidins), such as CXC chemokine ligand 4 (CXCL4;
PF-4) and CCL5 (RANTES), attracting neighboring granulocytes. (Yeaman 2014)
When platelets bind to leukocytes it is called a platelet-leukocyte aggregate; these are reported to
be increased in the peripheral circulation in a number of inflammatory conditions and infections.
(Michelson AD 2007; Semple JW 2011) These aggregates can have multiple functions within the
body, ranging from serving as a nidus for thrombus formation to serving as a vehicle for platelet
and leukocyte diapedesis and extravasation into peripheral organs and sites of infection and injury.
(Semple JW 2011; Mueller WA 2013; Zuchtriegel G 2016) Depending on the type of stimulation
and the specific white blood cell type, platelets can stimulate antigen presentation by antigen
presenting cells, stimulate degranulation, and even stimulate extracellular trap formation. (Semple
JW 2011; Morrell CN 2014) Extracellular traps are discussed further in the section 1.6,
'Extracellular traps and histones'.
1.5.2.2 Antigen presentation
Both the platelet and the megakaryocyte have important roles in antigen presentation (AP); while
platelets are known to activate dendritic cells (DCs), promoting their maturation and pathogen
presentation to B and T cells, megakaryocytes have been shown to act as antigen presenting cells
(APCs) themselves. (Yeaman MR 2014; Kang HK 2012) Platelets are able to propagate AP in
dendritic cells by attracting cells to the antigen and also binding to the pathogen, even clustering
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the pathogen, in order to increase the accumulation of the pathogen in the vicinity of the APC cells.
(Yeaman MR 2014) This clustering and sequestration of the bacteria by platelet binding can
enhance their processing and AP to T cells. Binding to Listeria monocytegenes (L. monocytogenes)
was also shown to expand CD8' cytotoxic T cell expansion. (Verschoor A, 2011) In the case of
MKs, bipotent megakaryocyte/erythroid progenitors (MM cells) in the bone marrow and those
derived from peripheral blood mononuclear cells, were demonstrated to be MHC Class II-
presenting cells and have the capability of inducing Th17 in response to lupus autoantigens and
foreign antigens, including Candida albicans. (Kang HK 2012; Finkelstein A 2015)
1.6 Extracellular traps and histones
1.6.1 Extracellular traps
Extracellular traps (ETs) are entangled net-like structures, derived from leukocytes and composed
of DNA, histones, and other intracellular contents, such as cell-specific granule contents and
mitochondria. ETs were originally discovered to be a controlled form of cell death performed by
neutrophils (neutrophil extracellular trap; NET) in response to pathogenic stimuli. The formation
of NETs is distinct from both apoptosis and necrosis, and is a reactive oxygen species (ROS) -
dependent cell death. (Fuchs TA 2007) Upon sufficient stimulation, neutrophils undergo a shape
change and homogenization of their eu- and heterochromatin, followed by nuclear envelope and
granule membrane disintegration which allows for mixing of cytoplasmic and nuclear cell
components; these mixtures are then released into the extracellular space through a break in the
cell membrane. (Fuchs TA 2007)
One of the earliest and most essential steps of ET formation is the re-organization of nuclear
contents by the manipulation of histone post-translational modifications (PTSMs). Histones (His;
H) are highly positive proteins that are in the form of octamers (H2A, H2B, H3 and H4) and linkers
(HI and H5) that attach to and condense DNA within the nucleus. On a more molecular level,
peptidylgarginine deiminase 4 (PAD4) is an essential component of successful NET formation,
playing a role in histone hypercitrullination and leading to chromatin decondensation during early
NET formation. (Li P 2010; Rohrbach AS 2012) NETosis can be triggered by direct stimulation
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of TLRs, Fc receptors, complement receptors, and other pathogenic stimulus such as bacteria.
Once sufficiently activated, an intracellular calcium flux activates NADPH oxidase, resulting in
the formation of ROS. (Yang H 2016) Upon bacterial stimulation, NET formation appears to be
dependent on the lipoxygenase pathway. (Clark SR 2011)
The effects of ETs within the body appear to be both beneficial and dangerous. While they appear
to perform an integral function in the defense against pathogens, by entrapping them and killing
them, they are considered very 'sticky' and 'irritating', both instigating and perpetuating
thrombosis and inflammation. (Kaplan MJ 2012) The presence of ETs has been detected in a
number of acute and chronic inflammatory conditions and are thought to serve as a nidus for
intravascular clot formation as well as a source of danger-associated molecular patterns (DAMPs),
such as extracellular histones, which is discussed in Section 1.6.2, 'Extracellular histones'. (Lee
KH 2017; Wright TK 2016; Jorch SK 2017) The contents of the released cytokines and
chemokines is directly related to the cell of origin, where NETs release myeloperoxidase (MPO)
and neutrophil elastase (NE) and EETs release eosinophil granule contents. (Ueki S 2013)
1.6.2 Extracellular histones
Histones are the proteins that hold together DNA in the form of nucleosomes. There are 6 types of
histones (HI, H2A, H2B, H3, H4, and H5) which all work together to form an octamer and linkers
tightly condensing DNA into chromatin. In addition to their role as DNA 'glue', they also function
as guides for DNA expression based on their own post-translational modifications (PTSMs), either
activating or silencing transcription. Although histones are traditionally located within the nucleus
of the cell, they have recently been found to be in other cellular compartments, such as in the
cytoplasm and cell membrane during cellular apoptosis, or possible even attached to mitochondria
as functional proteins. (Zanin MK, 2010; Choi YS, 2011) With the discovery of ET formation,
extracellular histones have been more recently explored for their role in the immune and
coagulation system. (Chen R 2014)
Histones, once outside the protective shell of the cell membrane, can act as DAMPs and be highly
prothrombotic and proinflammatory. Histones can be present within the circulation attached to
extracellular traps, attached to DNA in the form of nucleosomes, or be completely free. Histones
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have been shown to interact with TLRs, activating platelets and leukocytes, complement,
activating the coagulation system, and even the phospholipids of endothelial and epithelial cells,
resulting in cytotoxicity. (Silk E 2017) It is postulated that extracellular histones are part of the
pathophysiological mechanism of intravascular coagulation and end organ injury, not only being
prothrombotic, but also being anti-fibrinolytic. (Silk E 2017; Varju I 2015; Allam R 2014)
Interestingly, recent research has been elaborating on the differences between free dsNDA, free
histones, and bound histones and DNA in the form of nucleosomes. (Marcsman G 2016) Currently,
neutrophil DNA and histones are both pro-coagulant, but the pro-coagulant properties of
neutrophil extracellular traps is being debated. (Noubouossie DF 2017)
1.7 Sepsis
Sepsis was first described by the Greeks in 700 BCE, recognizing a cause of death as 'rotting'
blood, and terming the condition 'sepsis', the Greek work for decomposition or rot. (Abraham E
2016) Sepsis is the result of the body's response to an infection. It is not uncommon for this
inflammatory response to become out of control and result in life-threatening complications,
including shock, disseminated intravascular coagulation (DIC) and end organ dysfunction, which
can include multiple organ dysfunction syndrome (MODS), acute respiratory distress syndrome
(ARDS), and acute kidney injury (AKI). Although originally, the pathophysiology of sepsis was
thought to be a result of a hyper-inflammatory response to a pathogenic stimulus, currently, there
appears to be a shift in this paradigm, where the heterogeneity of patient's immune systems and
the dynamic phases of sepsis challenge this paradigm; while some patients are immuno-stimulated,
others present as immuno-suppressed. (Remick DG 2007) Changes involved in sepsis range from
cellular to metabolic derangements, leading to cellular apoptosis, necrosis, and stimulation of the
immune, complement, and coagulation system. (Remick DG 2007) Currently, the definition of
sepsis is overly-broad and fluid, with treatment recommendations are symptomatic and supportive
at best.
1.7.1 Clinical diagnosis and treatment
When diagnosing a patient with sepsis, it is important to keep in mind that the term 'sepsis'
describes a syndrome and not a specific condition. What this means, is that an individual will
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typically display a combination of individual symptoms that are suggestive of a serious, systemic
reaction to a confirmed or suspected infection. In addition to diagnosing a patient with sepsis, there
are multiple levels of sepsis, with septic shock being a more critical level, indicating active or
impending hypoperfusion and end organ damage. (Howell MD, 2017) The current clinical
definition of sepsis, as determined by the American Medical Association in 2016, is: evidence of
infection plus life-threatening organ dysfunction, clinically characterized by an acute change of 2
points or greater in the Sequential [Sepsis-related] Organ Failure Assessment Score (SOFA).
Septic shock is defined as sepsis with circulatory and cellular/metabolic abnormalities profound
enough to increase mortality, characterized by the need for vasopressor therapy and elevated blood
lactate after adequate fluid resuscitation. (Abraham E, 2016; Singer M 2016; Shankar-Hari M,
2016)
Once a patient is diagnosed with sepsis, the earlier treatment is started the lower the chance of
long-lasting morbidity and mortality. Currently, sepsis is a leading cause of morbidity, mortality,
and expense in hospitals, and can be accountable for up to half of the deaths of hospitalized
patients. (Howell MD 2017) Most recently, a meta-analysis of sepsis clinical studies demonstrated
a mortality rate between 38.5-51.7%. (Shankar-Hari M, 2016) The major recommendations
include: infection management with broad-spectrum intravenous antimicrobials within 1 hour after
sepsis recognition, infection source control, fluid resuscitation with a target mean arterial pressure
(MAP) of 65 mm Hg, with vasopressors administered as needed, and mechanical ventilation in
patients with sepsis-related ARDS. (Howell MD 2017) Despite the vast improvements in science
and medicine, the complex pathophysiology and heterogeneity of sepsis has doctors and scientists
continuing to struggle in the identification and understanding of the mechanisms underlying this
deadly syndrome. Uncovering the cellular and molecular mechanisms underlying sepsis and its'
acute and chronic complications are imperative in the development of new and better therapeutic
tools moving forward.
1.7.2 Platelets in sepsis
Platelets have long been identified as a key player in the pathophysiology and diagnosis of sepsis.
Changes in platelet indices have not only been associated with sepsis, but also correlated with
prognosis. Thrombocytopenia (decreased platelet count), macrothrombocytopenia (giant platelets
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in conjunction with a decreased platelet count), and reticulated platelets (platelets that stain RNA-
positive with thiazole orange stain) have all been identified as negative prognostic indicators. (Gao
Y, 2014) There are many hypotheses for the mechanism of these platelet changes, including
decreased platelet production, secondary to decreases in mature megakaryocytes, and
sequestration, from platelets forming platelet-leukocyte aggregates (PLAs) or from disseminated
intravascular coagulation. (Semple JW, 2011) Platelet activation and function has also been
superficially evaluated in patients with sepsis, demonstrating increased spontaneous activation
concurrent with a decrease in platelet aggregation in response to various agonists. (Hurley SM
2016; Yaguchi A, 2004) Additionally, similar to other cell types, platelet have been shown to
display mitochondrial dysfunction during sepsis, which coincides with general platelets hypo-
responsiveness to agonists. (Protti A 2015)
Due to the heterogeneity of human patients with sepsis, various animal models are used in research,
with the role of platelets during various stages and complications of sepsis being multifaceted in a
number of studies. A recent mouse model of S. pyogenes sepsis demonstrated the dynamics of
platelet activation during sepsis, with CD62P and integrin expression not increasing during
bacterial dissemination, but platelet-neutrophil complexes (PNCs) increasing during early sepsis
and decreasing to significantly lower levels during late sepsis. Additionally, the removal of these
PNC complexes coincided with a significant increase in organ damage and the accumulation of
platelets in the liver sinusoids. (Hurley SM, 2016) Another S. pyogenes study demonstrated that
platelets may actually promote bacterial dissemination, with thrombocytopenia also coinciding
with platelet activation, PNC formation, and neutrophil activation. (Kahn F 2013) A model of
pneumonia-derived sepsis, utilizing Klebsiella pneumonia, showed that platelets are essential in
the survival of gram negative sepsis, with severe thrombocytopenia resulting in infection-site
hemorrhage, enhanced coagulation and endothelial cell activation, and increased proinflammatory
cytokine levels. (de Stoppelaar SF 2015) While severe thrombocytopenia may promote activation
of coagulation, platelets themselves play an essential role in coagulation, with platelets even
working with neutrophil extracellular traps in the promotion of intravascular coagulation.
(McDonald B 2017) Platelets have also been shown to be protective from septic shock, through
mechanisms such as the inhibition of macrophage-dependent inflammation and activation through
the COX 1 signaling pathway. (Xiang B, 2013) Together, these results demonstrate that the role of
73
the platelet is complex and dynamic during sepsis, and may be dependent on both the type of
infection and the model species.
While changes in platelet count and function appears to be a consistent factor in the diagnosis and
pathology of sepsis, interestingly, the administration of platelet inhibitors also appears to have a
protective effect, reducing mortality in both animal models and human patients. (Akinosoglou K
2014; Toner P 2015) Studies of sepsis have demonstrated that platelets can rapidly accumulate in
the lungs and liver, resulting in life-threatening complications. (Zhao L 2002; Yadav H 2015) In
light of these studies, it is not surprising that there is complimentary data to suggest that the
reduction of platelet activation can be protective. For example, a mouse model of
lipopolysaccharide (LPS) -induced sepsis has elucidated that inhibition of the GPIb-IX receptor
complex results in decreased thrombosis in the renal glomeruli. (Yin H 2013) Clopidogrel, a
P2Y12 inhibitor, was also shown to be protective in mouse models of polymicrobial sepsis. (Siedel
M 2009) Many human studies also demonstrate the benefit of anti-platelet therapy on patients with
sepsis, with some reports even demonstrating high-on-treatment platelet reactivity (HPR);
although, the mechanism of protective effects is currently under debate. (Valerio-Rojas JC 2013;
Akinosoglou K 2017; Storey RF 2014; Kiers HD 2016)
1.7.3 Megakaryocytes in sepsis
The role of megakaryocytes in sepsis is a bit more nebulous than the role of platelets.
Traditionally, the only role of the MK has been the production of platelets, primarily within the
bone marrow niche, as well as in the lung and other sites of extramedullary hematopoiesis (liver,
spleen, and lymph nodes). MKs have been shown to potentially have other roles, such as
emperipolesis (the presence of an intact cell within the cytoplasm of another cell), which has
been described in conditions such as hematolymphoid disorders, including myeloproliferative
and myelodysplastic disorders, and non-hematological malignancies, including multiple
myeloma and neuroblastoma (Rastogi V 2014; Cashell AW, 1992). MKs may also play a more
significant role in the immune system; they have recently been demonstrated to serve as a
primary antigen presenting cell (APC) stimulating the Thl7 response in Lupus. (Kang HK,
2012). While there are many animal models of infection that have demonstrated MK infection
with viruses, such as HIV and Dengue virus, their interaction with bacteria and fungus is less
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explored (Sato T 2000; Noisakran S 2012). There are rare clinical case reports that describe the
presence of pathogens such as Histoplasma and Cryptococcus within MKs in the bone marrow
(Ferry JA 1991). Whether this is a rare occurrence or whether it is just not investigated more
frequently is not known at this time.
In the context of sepsis, there is a dearth of research into the megakaryocyte. In neonatal sepsis
and necrotizing enterocolitis (NEC), thrombopoietin (TPO), the growth factor that stimulates
differentiation and maturation of hematopoietic stem cells (HSCs) into MKs, has been reported
to be elevated; this was more common in gram negative sepsis. This elevation in TPO was
correlated with an increase in circulating MK progenitor concentrations and reticulated platelets.
(Brown RE 2008) It is important to note, that there are differences in cord blood-derived MKs
and adult peripheral blood derived MKs, therefore studies in the neonate may not be completely
translatable to adults. (Mattia G 2002) Circulating MK fragments have been reported in adult
patients with sepsis as well; the presence of these MK fragments were also demonstrated to be
misidentified by the automated hematology analyzer. (Sanford D 2013) MKs are known to be
increased within the lungs in the case of ARDS and their numbers have also been shown to be
significantly increased within the renal glomeruli of patients with sepsis. (Broghamer WL Jr,
1981; Mandal RV 2007) Taken together, these findings suggest that changes in
megakaryopoiesis and thrombopoiesis may be a factor in sepsis and that abnormal circulating
MK progenitors and fragments are likely missed with automated analyzers.
Up until now, very limited controlled studies have been performed to explore the potential effect
of sepsis on megakaryocyte development and maturation. There have recently been a few studies
looking at the effect of lipopolysaccharide (LPS) on megakaryocyte and platelet biology. While
typically, MKs bud off platelets through a controlled apoptosis mechanism, when exposed to
inflammatory cytokine IL-la they have been shown to undergo a new 'rupture' mechanism of
platelet development. (Nishimura S 2015) A mouse model of sepsis also showed a molecular
change within MKs during sepsis, displaying altered mRNA profiles with changes in platelet
phenotype, allowing them to mediate lymphocyte toxicity through a granzyme B mechanism.
(Freishtat RJ 2009). Further supporting this concept of sepsis-induced changes in the MK with
subsequent platelet phenotype change is a study evaluating both the interaction of platelets with
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pathogens and platelets directly from human patients with sepsis, which revealed that Tissue
factor mRNA is spliced and results in a pro-coagulant platelet phenotype. (Rondina MT 2011)
Based on the dynamic role of platelets in sepsis, as discussed in the section 1.7.3, 'Platelets in
sepsis', the role of the MK both inside and outside the bone marrow niche and deviations in
megakaryo- and thrombopoiesis in the context of sepsis warrant further study.
1.7.4 Extracellular traps and histones in sepsis
Recently, the formation of extracellular traps (ETs) has been discovered. Extracellular traps are
extracellular 'webs' of DNA, histones, and other cellular contents that form in response to a
number of stimuli, ranging from pathogenic stimulus to contact with hydrophobic surfaces.
(Sperling C 2016; Delgado-Rizo V 2017) The role of extracellular traps ranges from protective,
allowing for the entrapment of pathogens such as bacteria, to pathologic, stimulating and
propagating intravascular thrombosis. (Sorensen OE 2016) ETs were originally described as a
phenomenon performed by neutrophils (NETs); although more recently, this behavior has been
demonstrated in other cell types, such as eosinophils (EETs). (Ueki S 2013) These ETs are
currently under investigation and have been correlated to a number of conditions, including
sepsis, autoimmune disease, and chronic inflammatory diseases.
Current research suggests that NETs are of great importance in the pathogenesis of sepsis, with
NETs being significantly increased in both the peripheral circulation and end organs. (Camicia G
2014; Yang S 2017) These NETs are thought to result in further stimulation of inflammation and
coagulation, potentially leading to further cell death and intravascular thrombosis, which can
lead to end organ dysfunction and, ultimately death. (Sorenson OE 2016) In specific, platelets
have been shown to interact with and stimulate NET formation in the context of sepsis. (Carestia
A 2016; McDonald B 2017) The detection and quantification of ETs is somewhat difficult, with
DNA and histones usually being rapidly degraded in the plasma and the histopathologic
evaluation of NETs in tissue is rudimentary at best. (Ekaney ML 2014) Additionally, the
identification of the cellular origin of free DNA and histones is not possible, as all mammalian
cells are composed of the same DNA and histones; at this point in time, it is an assumption that
the majority of extracellular DNA and histones during sepsis originate from neutrophils.
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Extracellular (EC) histones play a large role in the pro-coagulant and proinflammatory
phenotype of many conditions, and they are an essential part of ETs. (Chen R 2014) In addition
to direct stimulation of white blood cells and activation of the coagulation system, EC histones
are able to stimulate the complement system and can even result in direct cytotoxicity of
endothelial and epithelial cells. (Chen R 2014; Silk E 2017) In autoimmune conditions, such as
lupus, auto-histone antibodies have also been detected as part of the pathophysiology of the
disease. (Liu CL 2012) EC histones, including H3 and H4, have been shown to be significantly
increased during sepsis. (Kawasagi K 2015; Ekaney ML 2014) In specific, citrullinated histone 3
(citH3) has been shown to be necessary for NET formation and increased in the blood of septic
patients. (Pan B, 2017; Li Y 2011) Studies inhibiting citH3 have even been shown to be
protective and improve survival in mouse models of sepsis. (Li Y 2014) One caveat to the study
of EC histones in both the research and the clinical setting is the lack of consistent and accurate
histones detection assays available; specifically, one study shows that quantification of citH3
using various commercially-available and laboratory-made assays result in very different
concentration measurements. (Neeli L 2016) More reliable assays have been developed, such as
MALDI-TOF and other mass spectrometry methods, but are cost and training restrictive.
(Garcia-Gimenez JL 2017) Additionally, there appears to be a difference in the effect of histones
and DNA that is dependent on whether they are truly free or bound to each other, such as in the
form of a nucleosome. (Marsman G 2016) At this time, there are no reliable methods to
differentiate between free and DNA-bound EC histones. As more tools are developed for the
evaluation of EC histones, in addition to quantitation, post-translational modifications (PTSMs)
should also be explored in the context of sepsis.
1.8 Approach and aims of this thesis
The cumulative work described in this thesis was intended to explore the potential role of the
megakaryocyte as an innate immune cell, investigate how it can transfer immune cell function to
its' platelet progeny, and explore how these novel findings may play a role in the pathophysiology
of end organ function in the context of sepsis. Platelets have been demonstrated to play an integral
role in the pathophysiology of sepsis, in both human and animal models, while the potential role
of the megakaryocyte as an immune cell has been largely ignored. (Semple JW 2011) Although
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megakaryocyte and platelet number have been shown to be prognostic indicators in sepsis, the
associated change in phenotype is just starting to be explored. (Rondina MT 2012) Combining the
common knowledge that platelets have innate immune cell functions and that they derive their
cellular contents and functions from their 'parent' megakaryocytes, our primary goal with this
work was to demonstrate that the megakaryocyte must therefore also have innate immune cell
functions.
The second chapter in this thesis describes the testing of megakaryocyte immune cell function. In
order to test whether MKs have innate immune cell functions, we utilized a combination of in vitro
methods, using both cord blood-derived megakaryocytes (CB MKs) and cells from a
megakaryoblastic lineage (Meg-01). Experiments included a combination of approaches to
determine whether MKs were capable of phagocytosis, chemotaxis, and MK extracellular trap
(MET) formation to a variety of pathogenic stimulus. Although MKs were demonstrated to have
many immune cell functions, the physiological relevance of these findings were somewhat
questionable if the MKs are primarily constrained to the bone marrow stroma. Therefore, we
utilized a combination of imaging flow cytometry on whole blood and immunohistochemistry on
histopathology samples from patients with sepsis to explore whether MKs were present in the
peripheral circulation and end organs during sepsis. Through retrospective evaluation of the patient
medical records, we were also able to explore whether the circulating MKs had any relationship
with end organ damage and prognosis, as well as with the type of infection present. Putting these
results together, we then developed a hypothesis towards the mechanisms of megakaryocyte
immune cell function and their role in the pathophysiology of sepsis-related complications such as
end organ damage.
In chapter three, we continue with exploring the observation that CB MKs and Meg-0 1 cells
frequently have extranuclear histones. Taking into account that platelets are pre-packaged buds of
the MK cell membrane and cytoplasm, we then explored whether platelets contained histones, and
whether these histones could be derived directly from their 'parent' MK cell. Using a combination
of immunofluorescence, flow cytometry, and transmission electron microscopy with immuno-gold
labeling, we were able to investigate whether MKs do indeed have extranuclear histones and
whether their progeny platelets have histones as a result. Additionally, we used imaging flow
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cytometry to evaluate the platelet phenotype of patients with sepsis, testing for the presence of
histones, DNA, and platelet activation. By retrospectively reviewing patient medical records, we
were then able to correlate the platelet phenotype with both, patient prognosis and the type of
infection present. With this information, we were able to add on to the role of the megakaryocyte
and platelets in the pathophysiology of sepsis and end organ damage.
In chapters four and appendix chapter one, we developed a new tool for the evaluation of platelet
phenotypes and performed preliminary experiments on the effect of endotoxin on megakaryocyte
phenotype. In order to further the exploration of megakaryocyte and platelet phenotypes in
inflammation and sepsis, we had to develop a novel approach for the evaluation of platelet-
leukocyte interactions. In order to do this, we utilized a microfluidic approach, where the platelet-
neutrophil interaction could be analyzed in vitro on a single-cell level. Combining this technique
with fluorescent imaging and cell-tracking software, we characterized the neutrophil chemotaxis
phenotype when alone, when in the presence of platelets, and when attached and carrying a platelet.
In appendix chapter one, we then cultured and differentiated megakaryocytes in the presence of
Escherichia coli (E. coli) endotoxin and evaluated whether this pathogenic stimulation resulted in
an altered megakaryocyte phenotype. Using both imaging and flow cytometry, we were able to
morphologically characterize cell changes. These preliminary experiments and results demonstrate
that phenotype changes in megakaryocytes most likely occur during systemic infections and
further warrant exploration of resultant platelet phenotypes.
Overall, our results indicate that the megakaryocyte does have an active role in the innate immune
system and that properties of the megakaryocyte are passed on to its' progeny platelets. Taken
together, the in vitro and ex vivo experimental results suggest that both MKs and platelets likely
play an important role in sepsis and end organ damage.
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Figure 1-1: Megakaryocyte maturation and signaling.
This figure describes the maturation of the megakaryocyte originating from the hematopoietic stem cell to
the proplatelet-forming mature megakaryocyte. The aqua arrows label the stage of nuclear development
and cell cycle. The blue boxes include some of the markers expressed on the cell surface at various time
points. The large green arrows include various stimulants to both cell proliferation and megakaryocyte
commitment and maturation. The red bullets at the bottom are examples of some important pathways
involved in megakaryocyte development. The listed signals, factors, and pathways in this figure are not
all-inclusive and only include a few select important pathways.
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Figure 1-2: Megakaryocyte maturation.
This figure shows cytology pictures of maturing megakaryocytes from two different sources: cord blood
(CB) and peripheral blood (PB). The cord blood-derived megakaryocytes are smaller and have a lower
nuclear ploidy than the peripheral blood-derived cells. On the right side of the figure, the megakaryocyte
type is labeled: Type I have basophilic cytoplasms with a large nuclear to cytoplasmic ratio (N:C); Type
II are larger, a smaller N:C, and more azurophilic; Type III have a low N:C and distinct nuclear lobes.
These maturation differences are easier to distinguish with the PB-derived cells, as the CB-derived cells
maintaining a small size and somewhat resemble activated lymphocytes. Adapted from: Mattia G,
Vulcano F, Milazzo L, et al. Different ploidy levels of megakaryocytes generated from peripheral or cord
blood CD34' cells are correlated with different levels of platelet release. Blood, 2002;99:888-897.
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Figure 1-3: Megakaryocyte EM
Electron microscopy image of a cord blood-derived megakaryocyte with components labeled: nucleus,
red arrow; multivesicular body, blue arrow; demarcation membrane system (DMS), green arrow;
mitochondria, yellow arrow; rough endoplasmic reticulum (RER), white arrow; alpha granule, red arrow
head; dense granule, yellow arrow head.
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Figure 1-4: Platelet receptors and activation.
In this figure, a platelet is depicted with multiple surface receptors (purple) and some of their primary
agonists (orange). The P2Y I/P2Y 12 and PAR I/PAR4 receptors are shown to play a part in intracellular
signaling (inside-out). Activation of the platelet via many of these receptors results in an increase in
intracellular calcium and also TXA2 synthesis, in a receptor-dependent fashion. Based on which agonist is
bound to which receptor and the amount of stimulus, the platelet may then continue on to a reversible
shape change or to an irreversible granule secretion and platelet aggregation, via the cross-linking of
fibrinogen with glycoprotein receptor GPIIb/IIIa. This figure does not include all pathways, including
many of the immuno-modulatory receptors.
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Figure 1-5: Prostanoids and the COX Pathway in Platelets
On the left of the diagram, the synthesis of thromboxane A 2 (TXA 2) is shown. Upon platelet stimulation
and subsequent phospholipase A2 (PLA 2) activation, TXA2 is synthesized. PLA 2 cleaves membrane
phosphoglycerides to release arachidonate acid (AA), which is converted by COX enzymes (primarily
COX-1) to endoperoxides prostaglandin H 2 (PGH2) and prostaglandin G2 (PGG 2). TXA2 is then
synthesized via the conversion of these endoperoxidases by TXA 2 synthase. TXA 2 then passively
diffuses across the platelet membrane, where it may interact with other cell types and activate surrounding
platelets. The right side of the diagram depicts the direct interaction between TXA 2 and the platelet. A
proposed model of the binding sites identified by GR32191 in human platelets and their effector systems
is shown here, where reversible, high affinity binding event, results in an increase in intracellular calcium
and shape change, whereas an irreversible, low affinity binding event results in platelet granule secretion
and aggregation. DAG: diacylglycerol; PKC: protein kinase C; IP3: inositol triphosphate; TXA 2:
thromboxane A 2 ; phospholipase A 2 : PLA2 : prostaglandin H 2 : PGH 2 ; prostaglandin G2 : PGG2 . Adapted
from: Platelets in thrombotic and non-thrombotic disorders. Edited by: Paolo Gisele et al. 2002
Cambridge University Press.
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Figure 1-6: Platelets from humans and animal models with GPS and MYH9 disorders.
(Ai) EM of thin sections of a platelet from a patient showing absence of a-granules and abundant
channels of the open canalicular system (labeled as OCS) in comparison with EM of a control platelet
(Aii) showing normal alpha granules (labeled as AG). DTS: Dense tubule system. (Bi) Light microscopy
of the peripheral smear of a GPS patient showing a large pale gray platelet (yellow arrow) without the
cytoplasmic color of a-granules, in comparison with a normal smear (Bii). (Ci) Wide-field electron
micrographs of mouse platelets showing the heterogeneous content of Myh9-' platelets (right) as
compared with WT cells (left) (Cii). Arrows point to low-content platelets and the arrowhead to a high-
content platelet. Ultrastructure of human platelets from a control individual (Di) as compared with a
MYH9-RD patient (Dii-iii). GPS images adapted from: Gunay-Aygun M, Zivony-Elboum Y, Gumruk F,
et al. Gray platelet syndrome: natural history of a large patient cohort and locus assignment to
chromosome 3p. Blood, 2010; 116:4990-5001. MYH9A images adapted from: Pertuy F, Eckly A, Weber J,
et al. Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and
platelets. Blood, 2014;123:1261-1269.
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Figure 1-7: Mechanisms underlying normal hemostasis.
The intersection between primary platelet plug formation, platelet activation and the coagulation cascade
is illustrated. The processes of platelet adhesion, activation and aggregation are highlighted in different
color boxes, as are the extrinsic, intrinsic and common coagulation pathways. The brown lines represent
the platelet surface, with the palisading lines representing the activated platelet surface. Brown arrows
indicate processes that rely on the platelet surface to occur at maximum efficacy; blue arrows indicate
processes that require the subendothelial environment; purple arrows indicate processes that are calcium
dependent; processes that are vitamin K dependent are noted. Gray circles represent hepatic derived
factors; white circles activated coenzymes; red circles activated enzymes.
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Tables:
Table 1-1: Platelet Cell Surface Markers
CD41
CD42a
CD42b
CD61
PAC-1
CD62P
CD31
CD63
Mepacrine
Anexin V binding
HLA-ABC
HLA-DR
CD34
CD32a
CD123
U
PF4
CD162
vWF
Platelet-leukocyte
complexes
GPilb/llla
GPIX
GPlb
GPIIIa
GPIlb/Illa
P-selectin
PECAM
quinacrine
Phosphateidylserine
MHC Class I
Suface marker
Surface marker
Surfacemarker
Surface marker; Vitronectin receptor
Activation marker; against fibrinogen bindingsite exposed by
conformational change In GPIlb/1lla
Activation marker; component of a-granule membrane, mediates
adhesion to neutrophil and monocytes
Activation marker
Activation marker; protein in dense granuleand lysosomal membrane
Activation marker; taken up by platelet dense granules and emitsa
green fluorescence (FLI) -washingstep is required
Activation marker; Calcium-dependent phospholipid protein, allowsthe
detection of PS exposure on cell surface (fluorescent conjugated annexin
V)
Surface marker; antigen presentation
MHC Class i
CD34
FcyRlla
L3Ra
Platelet Factor4
PSGL-4; P-selectlnglycoproteanllpnd-1; SELPG
Von Willebrand Factor
Any platelet/eukocytemarker, example:
CD45/CD42b positive events
Surface marker (early differentiation); antigen presentation
Hematopoletic stem cell marker
IgG Receptor
IL-3 Receptor
alpha granule content
Ce adheAm moleculw; binds tOP-and L-selectin
alpha granule content
Platelet and leukocyteactivation; activated platelets adhere to isolated
fractionsof monocytes and neutrophils, mediated primarllythrough
CD62P
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Table 1-2: Platelet granule contents.
a-granules
GTP binding Proteoglycans: betaTG, PF4,
proteins: rab4, serglycln, HRGP
GMP33, Rapib
GPiibillas, b Adhesive: fibronectin,
vitronectin, vWF,
thrombospondin
GPIb-iXb Haemostasis: fibrinogen,
FV/VlI/ia/XIXii, kininogen,
protein S, plasminogen
GPIV (CD63)b Cellular mitogens: PDGF,
TGFbeta, ECGF, EGF,
VEGF/VPF, IGF, ilbeta
P24 (CD9)b Proteaseinhibitors: a2-
macroglobulin, a2-
antitrypsin, PDCl, a2-
antiplasmin, PA1l, TFPI, PN-
2/APP,Cl inhibitor
P-selectin immunoglobulins: IgG, igA,
(CD62P)a. b IgM
PECAM (CDgl Albumin
GLUT-3 GPiI/multimerin
Vitronectin Bindsvitronectin: can alter
receptor bindingtofibrinogen,
decreaseagg, bindto
endothellum
Osteonectin Binds thrombosponding:
adhesive platelet
glycoprotein
dense-granules
Membrane Matrix Membrane Matrix Membrane Matrix
GTP binding
protein: Rail
Glycoproteins:
GPibBb, iiblilab
Granuipphysin
(UMPI/CD63)C
LAMP 2c
Srcd
P-selectin
(CD62P)a.b
lysosomes
Adenine nucleotides:
ATP,ADP
Serotonin (5-HT)
Calcium, magnesium
Pyrophosphate
Guanine nucleotides:
GTP, GDP
Histamine
UMPI/CD638 Cathepsin D, E
LAMPI, LAMP2 Carboxypeptidases(A,B)
Prolinecarboxypeptidase
Collagenase
Acid phosphatase
Arylsulfatase
Heparinase
Glycohydrolases
Table modified from Chart 7.1-7.3 in: Platelets in thrombotic and non-thrombotic disorders. Edited by:
Paolo Gisele et al. 2002 Cambridge University Press.
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Chapter 2
Megakaryocytes as Functional Innate Immune Cells
2.1 Abstract
Megakaryocytes (MKs) are precursors to platelets, the second largest cell population in blood.
While platelets are under investigation for their role in inflammation, the role of MKs within the
innate immune system has not yet been explored. We have performed a set of comprehensive in
vitro experiments demonstrating that both cord blood-derived MKs and MKs from a
megakaryoblastic lineage (Meg-01 cells) have innate immune cell functions. MKs can
phagocytose bacteria, form extracellular traps, and chemotaxis towards pathogenic stimuli.
Evaluation of samples from patients with sepsis revealed increased numbers of CD61' cells in the
kidneys and lungs, and an increased number of CD41'CD61 cells in the peripheral blood. Overall,
our study suggests that MK cells participate in the immune responses during severe inflammation
and infection.
2.2 Introduction
Megakaryocytes (MKs), the largest and rarest cell in the bone marrow, are commonly recognized
as key participants in the hemostasis processes through the production of platelets. (Kaushansky
K, 2005; Machlus KR, 2013) In addition to their presence in the bone marrow, MKs are
frequently located in the lungs, lymph nodes, spleen, and liver during times of increased extra
medullary hematopoiesis. (Alamo IG, 2017; Lefrancais E, 2017; Yacoub A, 2013; Yassin MA,
2016; Hill AD, 2000) Notably, MKs have also been reported to be significantly increased in the
lungs during severe pulmonary inflammation, such as in acute respiratory distress syndrome
(ARDS), where they are believed to promote inflammation via the release of platelets. (Weyrich
As, 2013; Mandal RV, 2007; Yadav H, 2015) The current paradigm by which MKs are increased
in the lungs during ARDS revolves around passive escape from the bone marrow, secondary to
vasodilation and increased vascular permeability, where they enter the arterial circulation and,
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due to their large size, become trapped within the microcirculatory bed of the alveoli. (Lefrancais
E, 2017; Sharma GK, 1986; Kaufman RM, 1965)
An alternate or complimentary paradigm, where MKs have immune functions, is suggested by
several observations; however, this has not been tested systematically. At various points of
maturations, MKs have been shown to express both major histocompatibility complex (MHC)
class I and II molecules, and a variety of toll-like receptors (TLRs) on their cell surface.
(Finkelstein A, 2015; Undi RB, 2016; D'Atri LP, 2015; Beaulieu LM, 2010; Shiraki R, 2004;
Beulieu LM, 2011) MKs, just as platelets, are considered granulocytes and contain various
granule types, including lysosomes, which are typically present in most mammalian cells and
participate in the endocytosis and degradation of pathogens by innate immune cells (Bentfeld-
Barker ME, 1982). Recent studies have elucidated the role of the MK as a primary antigen-
presenting-cell (APCs) in stimulating the Th- 17 response in Lupus. (Finkelstein A, 2015; Kang
HP, 2012) Thrombocytes, the amphibian equivalent of the mammalian MK and plt, have been
demonstrated to actively phagocytose pathogens, both in vitro and in vivo; although, there is still
debate as to whether mammalian platelets are phagocytes or covercytes. (White JG, 2005; Lewis
JC 1976; Absolom DR, 1982) In mammals, MKs have been documented to internalize various
viruses, including dengue virus and HIV, and there are two case reports demonstrating
internalization of fungal organisms. (Zucker-Franklin 1989; Ferry JA, 1991; Clark KB, 2016;
Clark KB, 2012) These reports provide support for the participation of MKs in the immune
response against infection.
Here, we explore the ability of human MKs to phagocytize pathogens, form extracellular traps,
and undergo chemotaxis towards pathogenic stimuli. Moreover, we find that during sepsis
CD617CD41' cells are increased in the peripheral circulation and CD61' cells are increased in
the peripheral organs. The number of these cells appears to correlate with the type of infection
and prognosis, being elevated during acute kidney injury (AKI) and ARDS, as well as in
disseminated intravascular coagulation (DIC).
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2.3 Materials and Methods
2.3.1 Cell culture
Cord blood CD34' hematopoietic stem cells and Meg-Ol cells were cultured and differentiated
into megakaryocytes (CB MKs). Cord blood CD34' hematopoietic stem cells were purchased
and cultured in StemSpanII media with the megakaryocyte supplemental cytokines, according to
the culture and differentiation protocols from Stemcell Technologies (Stemcell Technologies Inc.
Cambridge, MA). A megakaryoblastic cell line (Meg-0 ) was purchased and cultured in RPMI
with 10% FBS, according to the standard cultures protocols from ATCC (American Type
Culture Collection, Manassas, VA).
2.3.2 Flow cytometry
Flow cytometry was performed in order to verify appropriate cellular differentiation and for the
evaluation of cell surface markers. Briefly, cells were stained with antibodies at a concentration
of 1:200 for 15 minutes, with the exception of CD4 1, which was at a concentration of 1:100.
Cells were then stained with Draq5 (Thermo Fisher Scientific, Waltham, MA) at a concentration
of 1:10000 for 5 minutes. Antibodies included: anti-human CD41, HLA-ABC (MHC class I),
HLA-DR (MHC class II), CD162 (p-glycoprotein-1; SELPG), CD61 (GPIIa), CD41 (GPIIb),
CD34 (Biolegend, San Diego, Ca), CD66b, and CD62P (P-selectin) (BD Biosciences, San Jose,
CA). Data was obtained through the Amnis ImageStreamX Mark II imaging flow cytometer and
INSPIRE Software (EMD Millipore, Billerica, MA). The accompanying IDEAS Software was
used to perform data analysis. Data is reported as the percent of the total cell population that
stained positive for the specific marker.
2.3.3 Bacterial preparation
Bacteria, including Escherichia coli (F. coli), Staphylococcus aureus (S. aureus), and
Streptococcus pyogenes (S. pyogenes), were conjugated to pHrodo for phagocytosis experiments.
Bacteria was provided by the Division of Comparative Medicine at the Massachusetts Institute of
Technology (Cambridge, MA). For the killed-bacteria experiments, organisms were heat killed at
75"C for 25 minutes. Bacteria were then conjugated to pHrodo succinimidyl ester dye (Thermo
Fisher Scientific) according to the manufacturer's protocols. Briefly, bacteria were pelleted from
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cultures by centrifugations at 5100 rpm for 10 minutes. Pellets were resuspended in PBS (pH
9.0) at a concentration of Ix108 per mL. 200 ptL of this suspension was then added to 5 PL of 10
mg/mL pHrodo succinimidyl ester dye and mixed thoroughly by pipetting. Bacteria were then
stained for 30 mins in the dark with gentle shaking. Following staining, 1 mL of PBS (pH 8.0)
was added to the solution, and bacteria were pelleted at 13,400 rpm for 3 minutes in a benchtop
centrifuge. The supernatant was removed and the pellet thoroughly resuspended in Tris Buffer
(pH 8.5). The bacteria were then pelleted at 13,400 rpm for 3 mins in a benchtop centrifuge, the
supernatant was removed, and the bacteria were resuspended in 1 mL of PBS (pH 7.4), and
stored at 40C in the dark.
2.3.4 Immunofluorescent imaging
MKs were co-incubated with either the pHrodo-conjugated bacteria, Zymosan A S. cerevisiae
BioParticles (ThermoFisher Scientific), or various concentrations of E. coli lipopolysaccharide
(011 1:B4; Sigma Aldrich, St Louis, MO) for 60 minutes at 370C on poly-lysine coated slides
(Sigma Aldrich, St Louis, MO, USA). The slides were then rinsed gently three times with PBS
and the adhered cells were subsequently stained for live imaging or fixed and then stained. For
evaluation of live cells, cells were stained with Hoechst (Thermo Fisher Scientific) at a
concentration of 1:2000 for 5 minutes. For the calcein green-stained cells, cells were also stained
with calcein (Thermo Fisher Scientific) at 1:1000 for 5 minutes. For extracellular trap evaluation,
cells were also stained with SYTOX orange (Thermo Fisher Scientific) at 1:50 for 5 minutes. For
histone staining of extracellular traps, cells co-incubated with E. coli LPS for 60 minutes at 370C.
They were then fixed with 4% paraformaldehyde (Santa Cruz Biotechnology, Dallas, TX, USA)
for 30 minutes and then concentrated onto a poly-lysine coated slide using the Cytospin 4
cytocentrifuge (Thermo Fisher Scientific), for 5 minutes at 1250 rpm, rinsed once with di-water
and stored at -800C until staining and evaluation. For staining, the slides were thawed at room
temperature and blocked with 5% donkey serum (Jackson Immunoresearch) for 2 hours. The
slides were rinsed three times with PBS and then treated with the following primary antibodies
for three hours: mouse anti-human neutrophil elastase (NE; ELA2) antibody (950334, Novus
Biologicals, Littleton, CO, USA) at 1:300, rat anti-Histone H3 (phospho S28) antibody (HTA28,
Abcam, Cambridge, MA, USA) at 1:500, and rabbit anti-human myeloperoxidase (A039829-2,
Dako, USA) at 1:300. The slides were then rinsed three times with PBS and incubated with
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secondary antibodies, including donkey anti-rabbit 488, donkey anti-rat 647, and donkey anti-
mouse 568 (Life Technologies) at 1:500 for 30 minutes. Slides were then rinsed three times with
PBS and then covered with Vectashield antifade mounting medium with DAPI (Vector Labs,
Burlingame, Ca, USA). The cells were then images with one of two fluorescent microscopes:
Life Technologies EVOS FL (Thermo Fisher Scientific) or Nikon Eclipse 90i microscope (Nikon
Instruments Inc., Melville, NY). Composites and videos were made and images were analyzed
using either Fiji or GIMP software. (Schindelin J, 2012)
2.3.5 Extracellular trap induction
Meg-01 cells underwent various treatments to induce extracellular trap formation. Meg-01 cells
were co-incubated with various pathogenic stimuli, including E. coli LPS and live pHrodo
conjugated E. coli, for 30-60 minutes at 370c on a polylysine-coated slide. The poly-lysine slide
was outlined with a hydrophobic pen prior to the experiment to set a boundary for the liquid. The
slide was then rinsed three times in PBS. The slides were stained with 1:1000 Hoechst and 1:500
SYTOX orange and cover slipped. For the GFP-H2B experiments, Meg-01 cells were transfected
with CellLight Histone 2B-GFP (Bacmam 2.0, ThermoFisher Scientific) for 48-72 hours and
then labeled with MitoSox Red mitochondrial superoxide indicator (ThermoFisher Scientific)
and Hoechst. Unstained slides were stored and evaluated with immunofluorescence techniques,
as described above. The cells were imaged using one of two fluorescent microscopes: Life
Technologies EVOS FL (Thermo Fisher Scientific) or Nikon Eclipse 90i microscope (Nikon
Instruments Inc., Melville, NY).
2.3.6 Free double stranded DNA (dsDNA) quantification
Meg-01 cells were co-incubated with various concentrations of E. coli LPS (20 pg/mL to 2
ug/mL) for 30 minutes at 370C. The cells were then pelleted down at 1900 g for 10 minutes and
the supernatant was immediately stored at -800c. The experiment was performed in biological
triplicates (cells from 3 different culture flasks) and in technical triplicates, on two different days.
Double stranded DNA (dsDNA) was quantified using the Quant-iTTM PicoGreenTM dsDNA
Assay Kit (Thermo Fisher Scientific) following the recommended protocol. Briefly, the
supernatant samples were thawed and 50 uL was placed in a 96-well plate, followed by 50 uL of
the aqueous working solution. A standard curve using the provided DNA standard was created
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for a reference. The plate was incubated at room temperature for 5 minutes and then read at
standard fluorescein wavelengths (excitation ~480 nm, emission -520 nm) on a SpectraMax
Gemini XS plate reader (Molecular Devices, Sunnyvale, CA, USA). The mean fluorescent
intensities (MFIs) were then converted to free dsDNA concentration according to the standard
curve.
2.3.7 Transmission Electron microscopy
Meg-01 cells were co-incubated with live bacteria for 1 hour at 37'C. The cells were then
pelleted down at 1900 g for 10 minutes. Immediately after removal of the culture medium, KII
fixative (2.5% glutaraldehyde, 2.0% paraformaldehyde, 0.025 % Calcium Chloride in a 0.1M
Sodium Cacodylate buffer, pH 7.4) was added to the cell/bacteria pellet, mixed, and allowed to
fix for 20 minutes. A rubber tipped cell scraper was then used to gently remove the fixed
monolayer from the plastic substrate. The samples were centrifuged, the fixative removed,
replaced with buffer, and stored at 4'C until further processing. To make a cell block, the
material was centrifuged again and resuspended in warm 2% agar in a warm water bath to keep
the agar fluid. The material was then centrifuged again and the agar allowed to gel in an ice
water bath. The tissue containing tip of the centrifuge tube was cut off resulting in an agar block
with the material embedded within it. This agar block was then processed routinely for electron
microscopy in a Leica LynxTM automatic tissue processor. Subsequent processing was done
using a Lieca LynxTM automatic tissue processor. Briefly, they were post-fixed in osmium
tetroxide, stained En Bloc with uranyl acetate, dehydrated in graded ethanol solutions, infiltrated
with propylene oxide/Epon mixtures, embedded in pure Epon, and polymerized overnight at
60'C. One micron sections were cut, stained with toluidine blue, and examined by light
microscopy. Representative areas were chosen for electron microscopic study and the Epon
blocks were trimmed accordingly. Thin sections were cut with an LKB 8801 ultramicrotome and
diamond knife, stained with lead citrate, and examined in a FEI Morgagni transmission electron
microscope. Images were captured with an AMT (Advanced Microscopy Techniques) 2K digital
camera.
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2.3.8 Transwell chemotaxis
Meg-01 cells were used for chemotaxis experiments in both transwell plates and in a custom-
made microfluidic device (described in the following section). SDF 1 a was used as a positive
control, cell culture media was the negative control, and experimental condition consisted of
various concentrations of E. coli LPS and zymosan particles. Growth factor reduced (GFR)
matrigel coated transwell inserts with 8 um pores (Biocoat Matrigel Invasion Chambers,
Corning, New Jersey, USA) were thawed for 30 minutes at 37 c. 1 million Meg-01 cells were
loaded in a total volume of 200uL of RPMI with 10% FBS in the top chamber, while the bottom
chamber was loaded with 600 uL of various conditions, including: RPMI with 10% FBS
(negative control), 200 ng/mL SDFlc (CXCLI2, Peprotech, New Jersey, USA) (positive
control), 220 pg/mL and 2.2 ng/mL E. coli LPS, Zymosan particles alone, and zymosan particles
with 220 ng/mL E. coli LPS or with 200 ng/mL SDF I a. The wells were incubated for 24 hrs. at
370C. The cells in that migrated through the transwell insert into the bottom chamber were
counted using Cellometer Vision automated cell counter (Niexcelom, Bioscience LLC.,
Lawrence, MA, USA).
2.3.9 Microfluidic device fabrication
The microfluidic devices were manufactured using standard microfabrication techniques.
Briefly, a two-layer photoresist design (SU8, Microchem, Newton, MA), with a first and second
layer that were 3 and 50 im thick, were patterned on one silicon wafer via sequential
photolithography masks and processing cycles according to the manufacturer's protocols. The
resulting patterned wafer was then used as a mold to produce PDMS (Polymidemethylsiloxane,
Fished Scientific, Fair Lawn, NJ) devices, which were subsequently irreversibly bonded to glass
slides (1x3 inches, Fisher). The microfluidic device was designed to allow the formation of a
chemical gradient in two steps, as previously described (Caroline JN, 2014). First: an array of
circular wells (50 [tm diameter, 50 ptm height), connected to a side channel (10 Pim width, 5 pim
height) by orthogonal side-combs (5 pm width, 5 pm height), were primed. During the second
step, the central channel was extensively washed with cell culture media (RPMI + 10% FBS).
The diffusion of the chemoattractant from the circular wells, serving as sources, to the central
channel, serving as sink, produced the guiding gradient for the cells in the central channels.
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2.3.10 Microfluidic chemotaxis
The cellular nucleic acid was stained with Hoechst at 1:2000 (Thermo Fisher Scientific Inc,
Grand Island, NY). The microfluidic chip was placed under vacuum for 10 minutes. The media
and conditions were loaded into each microfluidic device. Various concentrations of . coli LPS
were co-incubated with Meg-01 cells in order to determine the optimal concentration at which
immediate cell death was not instigated. The conditions included the following: RPMI with 10%
FBS (negative control), 200 ng/mL SDFlca (CXCL12, Peprotech, New Jersey, USA) (positive
control), 22 pg/mL, 220 pg/mL and 2.2 ng/mL F. coli LPS, zymosan particles, zymosan particles
(1 million/mL) with 220 ng/mL E. coli LPS and zymosan particles (1 million/mL) with 200
ng/mL SDFI a. 200 uL RPMI +10% FBS was used to wash the main channel. Cells were then
loaded into the main channel at 30 million/mL. The chip was imaged for 18 hrs. every 10
minutes using time-lapse imaging on a fully automated Nikon TiE microscope with the
biochamber at 37'C and 80% humidity, and in the presence of 5% carbon dioxide gas. Images
were acquired automatically from distinct locations on each microfluidic device, with each
image including a minimum of 3 circular wells. A minimum of 18 wells per condition were
analyzed. ImageJ manual tracking software (NIH) was used for the analysis of MK and platelet
migration and behavior. The videos were tracked for cells migrating into the (1) comb -
attempts, (2) channel, and (3) well - through. The platelets in the well were counted at the final
frame to determine platelet budding into the well.
2.3.11 Megakaryocyte quantification in patient blood samples
Venous blood from patient diagnosed with sepsis was collected and evaluated for circulating
megakaryocytes (IRB protocol numbers, MGH No: 2014P002087; MIT No: I 50100681R001). A
patient was categorized as sepsis when one of the diagnoses for the patient was 'sepsis' and
when there was a confirmed infection. Twenty-one samples were evaluated with 13 sepsis
samples (age 34-75 yrs., 4 females, 9 males) and 5 control samples (age 25-50 yrs., 3 females, 1
male) (Table 2-1). Three of the sepsis samples (1 female and 2 males) had follow-up blood
evaluation 3 days later. Cell surface markers were selected to determine cell type by differential
marker expression. CD 162 was utilized in order to break up any platelet-leukocyte aggregates
prior to analyzing the samples. (Frydman GH, 2017) White blood cell concentration was used as
an internal control for the quantification method and whole blood spiked with MKs were used to
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validate surface marker identification of MKs in samples (Figure 1-1). Sample preparation and
staining methods are described in the Supplemental Methods section.
Cell surface markers were selected to determine cell type by differential marker expression:
CD41 (glycoprotein Ib; GPIIb) and CD61 (glycoprotein IIb; GPIIIb) are found on the cell
surface of platelets and megakaryocytes, where they form a GPIIb/IIIa complex and find to
fibrinogen and von Willebrand Factor (vWF) during platelet activation. CD45 (protein tyrosine
phosphatase, receptor type, C; PTPRC; leukocyte common antigen; LCA) and CD162 (P-selectin
glycoprotein ligand-1; PSGLI; SELPLG) are both present on leukocytes where CD45 hi and lo
populations can be used to identify both neutrophils and lymphocytes. Draq5 is a nuclear marker
that was used to differentiate between CD41CD61 anuclear platelets and nucleated
megakaryocytes.
First, white blood cells were identified and quantified and were then compared to the total white
blood cell count in the complete blood cell count (CBC) that was performed on the same blood
sample at the Massachusetts General Hospital clinical pathology lab as part of the patient's
routine diagnostics in order to verify our concentration calculation methods (Figure 1-1 A-C).
Once white blood cell count was verified, cellular events staining positive for megakaryocyte
markers were then collected and quantified. The concentrations of MKs and leukocytes in the
patient samples were then back-calculated, taking into account the total volume of sample
analyzed and the initial 1:200 dilution of the blood.
In order to quantify circulating megakaryocytes in peripheral venous samples, blood collected in
EDTA vacutainer tubes was diluted 1:200 in calcium-free hepes-tyrode buffer (Boston Scientific,
Boston, MA, USA) with 20% volume of acid citrate dextrose (ACD, Boston Scientific). The
diluted blood was then stained with CD41 PacBlue, CD61 FITC, CD45 CY5/594, and CD162
PE at 1:100-1:200 for 20 minute, and 1:1000 Draq5 for 5 minutes. The samples were then run
using the Amnis flow cytometer and the data was analyzed with IDEAS software.
Megakaryocytes were defined as CD41 'CD61Draq5' cells. Leukocytes were defined as
CD162'CD45'Draq5' cells. The concentrations of MKs and leukocytes in the patient samples
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were then back-calculated, taking into account the total volume of sample analyzed by Amnis
and the initial 1:200 dilution of the blood.
As a control, venous blood collected in EDTA was spiked with various concentrations of Meg-
01 cells and cord-blood derived megakaryocytes (day 14 of differentiation) in order to verify the
accuracy of megakaryocyte detection in whole blood patient samples. Pure megakaryocytes and
the spiked whole blood samples were analyzed with flow cytometry, as described above and also
run on the automated CBC analyzer in order to determine whether an automated analyzer detects
megakaryocytes and how it categorizes them. Pure MKs were counted manually with a
hemacytometer to compare with the automated analyzer (Figure 1-1 D-E).
2.3.12 Histopathology
Histopathology samples from patients that underwent autopsies were retrospectively collected
and evaluated. All samples and patient information were collected and handled according to
MGH and Massachusetts Institute of Technology (Cambridge, MA, USA) IRB protocol (MGH
No: 2014P002087; MIT No:150100681R001). A patient was categorized as sepsis when the
cause of death was determined to be sepsis by the official pathology report. Control patients were
defined as having primary cardiac disease as the cause of death. Fifteen samples were evaluated
with 9 sepsis samples (age 60-90 yrs., 2 females, 3 males) and 5 control samples (age 68-87 yrs.,
7 females, 2 males) (Table 2-3). Paraffin embedded tissue samples, including kidney, and the
right middle lung lobe were sectioned and stained with either Haematoxylin & Eosin (H&E),
gram stain, or with HRP-labeled CD61 antibodies by the Division of Comparative Medicine
(MIT, Cambridge, MA, USA) and the Massachusetts General Hospital (Boston, MA, USA),
respectively. The percent of CD61 staining per renal glomerulus was quantified using Fiji
software. Twenty renal glomeruli were evaluated for each patient. For evaluation of the lungs,
the number of MKs were counted in ten 40x magnification views of the right middle lung lobe
for each patient.
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2.3.13 Statistical Analysis
Statistics were performed using both Microsoft Excel and GraphPad Prism Software (GraphPad
Software, Inc.). Either one-way ANOVA or student t-tests were performed to compare between
conditions. A p-value of <0.05 was considered significant.
2.4 Results
2.4.1 Megakaryocyte are capable of phagocytosis
CB MKs and Meg-01 cells are able to phagocytize multiple types of pathogens (Figure 2-2).
Cells were co-incubated with either E. coli, S. aureus, S. pyogenes, or zymosan particles and
subsequently imaged. Light microscopy showed bacteria very closely associated to the cell wall,
while electron microscopy imaging showed bacterial association with both MK and platelets, as
well as internalization of pathogens (Figure 2-2 A-B and Videos 2-1 and 2-2). Electron
micrograph images of a contaminated CB MK culture at day 14 of differentiation uncovered a
large cell with multiple bacteria of unknown origin within a large vacuole inside of the MKs
(Figure 2-2 B). We confirmed internalization of E. coli, S. aureus, and S. pyogenes bacteria by
CB MKs and Meg-01 cells using pHrodo as a marker for pathogen acidification and association
with a phagosorne or lysosome. depicted by the fluorescent orange-red bacteria within the cells
(Figure 2-2 C). CB MKs were then incubated with bacteria during different stages of
differentiation (day 0-14). Flow cytometry of these cells was performed during these various
stages of differentiation in order to profile their surface-marker expression and confirm
appropriate megakaryocyte maturation (Figure 2-3). CB MKs were observed to be capable of
phagocytosis starting at day 3 of differentiation (Figure 2-4). Interestingly, the CB MKs appear
to start expression of p-selectin glycoprotein ligand 1 (CD 162) and MHC Class II (HLADR) on
day 3 as well (Figure 2-3).
2.4.2 Megakaryocytes undergo chemotaxis towards pathogenic stimuli
Meg-01 cells are able to undergo chemotaxis towards LPS and zymosan particles, both in a
microfluidic assay as well as in a traditional transwell format (Figure 2-5). In the transwell
experiments, chemotaxis to SDF 1c, as positive control, was between 13.7-20.4 %, consistent
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with the previous literature. (Hamada T, 1998) Chemotaxis was pronounced towards LPS
concentrations of 220 pg/mL and 2.2 ng/mL (4.1-8.5 % and 16.0-21.0 %, respectively), as well
as zymosan particles (7.6-21.8%). When LPS or SDFIx was combined with zymosan particles,
the amount of chemotaxis was increased (7.1-33.7%). The trends in Meg-Ol chemotaxis towards
the various stimuli were consistent between the traditional transwell assay and the new
microfluidic assay (Figure 2-5 E-F). The cell migration within the microfluidic device was
separated into 3 groups: the cells that entered the circular cell, the cells that remained in the side
channels, and the cells with projections inside the side channels (Figure 2-5 B-C and Figure 2-6).
Cells (some up to 75 tm in diameter) were observed actively migrating through 5 pim channels,
displacing both their nuclei and organelles as they crawled through the narrow tunnels (Video 2-
3 through 5), sometimes taking zymosan particles with them (Video 2-6). A fraction of cells did
not fully go through the channel, but were observed to extend proplatelets and release platelets
into the side channels with the chemoattractant; indicating a possible directed release of platelets
towards the stimulus (Figure 2-5 D and Video 2-7). This phenomenon of platelet-budding could
not be quantified, as the visualization of platelets within the device was not consistently possible
in the same plane of focus of the cells in the videos. Another unique observation included cells
migrating into the side channels and then budding platelets, essentially obstructing the side
channel and preventing other cells from migrating (Video 2-8). The microfluidic assay allowed
for visualization of cells extending pseudopods and proplatelets as well as re-arrangement of
cellular components, which would be much more difficult with the transwell assay.
2.4.3 Megakaryocytes form extracellular traps in response to pathogenic stimuli
Megakaryocytes form extracellular traps (METs) in response to both LPS and live bacteria
(Figure 2-7). When Meg-01 cells were co-incubated with live bacteria, the cell morphology
changed significantly and resulted in what appeared to be extracellular traps associated with
bacteria (Figure 2-7 A). In order to explore whether MKs were able to form extracellular traps to
various pathogenic stimuli, in vitro experiments were performed using multiple techniques. Meg-
01 cells were co-incubated with various concentrations of E. coli LPS and METs were quantified
by quantifying extracellular DNA in the supernatant (Figure 2-7 B). Immunofluorescent imaging
of CB MKs co-incubated with live pHrodo conjugated . coli demonstrated a unique, jelly-fish-
like live formation of METs, which we believe is the beginning phase of MET formation (Figure
130
2-7 C). The positive Hoechst staining indicates that, although a MET is being formed, the cell
still has a viable nucleus; this is consistent with a recent paper which discovered that NET
formation is not always a terminal event. (Yipp BG, 2017) In order to differentiate between MET
formation and proplatelet budding, calcein stain was used to demonstrate the lack of cell
membrane around the extracellular DNA, as compared to platelet budding, where the platelet
buds stained positive for calcein and negative for DNA (Figure 2-7 D). Some extracellular traps
were visualized in the negative controls, usually around or on the hydrophobic pen marking.; this
may be due to the contact with the hydrophobic barrier on the slide. (Sperling C, 2017) MET
formation was subjectively less in with the cells co-incubated with the killed bacteria as
compared to the live bacteria, which may be due to the lack of bacterial toxins, motility, or
receptor-specific interactions. METs were also evaluated with immunofluorescent imaging to
confirm the presence of histones and myeloperoxidase along with the extracellular DNA (Figure
2-8). Electron micrograph imaging of Meg-01 cells co-incubated with live bacteria confirmed the
formation of extracellular traps with bacteria entangled within the extracellular DNA and various
organelles, which included extracellular mitochondria, granules, and nucleosomes (Figure 2-7 E-
F). Other cell morphology changes included swollen nuclei, breakdown of the nuclear
membrane, condensed chromatin, and re-localization of the cytoplasmic organelles and
mitochondria. (Pilsczek FH, 2010; Ueki S, 2013) Meg-01 cells expressing GFP-H2B were
imaged forming METs; which confirmed the perinuclear rearrangement of organelles (notably,
mitochondria) during MET formation (Figure 2-7 G-H).
2.4.4 Identification of circulating megakaryocytes using automated analyzers
Control samples were first analyzed to validate identification and quantification methods for
MKs in the peripheral circulation (Figure 2-1). Pure CB MKs were positively identified by the
automated CBC analyzer and, interestingly, were categorized as an unknown type of white blood
cells (WBCs) with an error notification. When spiked whole blood samples were analyzed, the
automated analyzer identified a corresponding increase in the WBC and, more specifically, the
neutrophil count, and did not display an error message (Figure 2-1 D). Meg-01 cells were unable
to be counted or analyzed accurately by the automated analyzer, both as a pure population and as
spiked whole blood. We suspect that this may be due to the differences in morphology between
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these two populations; while CB MKs are 10-30 tm and resemble small, granular lymphocytes
on light microscopy, Meg-Ol cells range from 15-75 pm and are often found in large clusters.
2.4.5 CD61*CD41*Draq5' cells are increased in the peripheral circulation of patients with
sepsis
Patient samples were then analyzed using imaging flow cytometry (Figure 2-9 A). Circulating
MKs were defined as CD61CD41Draq5+ cells. These cells were about 10 pim in size and
ranged from having one large nucleus to having paler DNA staining, which could represent
apoptotic cells. Interestingly, whereas both Meg-01 cells and CB MKs are usually CD162k, the
circulating CD6l*CD41Draq5+ cells identified in the patient samples were CD162~, which may
indicate that adult megakaryocytes are different in phenotype than neonatal megakaryocytes,
which are CD162' (Figure 2-3). The number of CD61CD4lIDraq5+ cells were identified to be
significantly higher in peripheral circulation in patients with sepsis as compared to controls (p
0.05; 9565 1 1675 vs 3502 + 741, respectively) (Figure 2-9 Bi). Surprisingly, the number of
MKs were also significantly increased in patients with 'complicated' versus 'uncomplicated'
sepsis (p = 0.01; 11077 + 6256 MK/mL vs 3587 + 1219 MK/mL, respectively), as defined by the
development of acute kidney injury (AKI) or acute respiratory distress syndrome (ARDS) based
on medical records (Figure 2-9 Bii). When further subdividing the sepsis patient population into
the source of the infection, gram negative bacterial infections had significantly higher MKs than
the gram positive or mixed infections (15070 + 5158 MK/mL, 5140 + 2082 MK/mL, 10146
7675 MK/mL, respectively) (Figure 2-9 Biii). We analyzed data of three patients at 2 time-points
and observed a decrease in circulating MKs in the patient that was recovered and discharged
from the hospital as compared to the two patients that remained in the hospital for multiple
weeks and developed AKI (Figure 2-9 Biv). Platelet count did not significantly differ in sepsis
versus control patients (p = 0.98; 251.1 207.6 plt x 106/mL and 253.6 + 34.5 plt x 106/mL,
respectively), whereas there was a significant difference between sepsis and control patients with
reference to total white blood cell counts (p = 0.0 15; 14.7 9.6 WBC x 10^6/mL and 5.2 + 1.1
WBC x 106/mL, respectively). There was no correlation between circulating MKs and platelet or
white blood cell count (Figure 2-10). Although the sample size is quite small and no definitive
conclusions can be drawn from these observation, it does suggest circulating MKs should be
further explored in the context of sepsis-related complications.
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2.4.6 CD61* cells are increased in the lungs and overall CD61' staining is increased in the
glomeruli of patients with sepsis
CD61V cells were increased in the peripheral organs of patients with sepsis. There was a
significantly increased number of large CD61 cells (MKs) in the alveoli of septic patients as
compared to controls per 40x field of view (FOV) (p = 0.013: 0.4 + 0.1 MK/FOV vs 1.5 + 0.2
MK/FOV, respectively) (Figure 2-11 A-B). As seen in the H&E images, as compared to the
companion CD61 IHC image, while MKs could generally be identified on H&E by their large,
darkly-stained nucleus, this was not always the case and demonstrates the utility of utilizing IHC
for accurate cell-type assessment (Figure 2-11 A). There was one 'control' patient that was
removed from pulmonary MK analysis because, although the cause of death was cardiac failure,
a patchy bronchopneumonia was diagnosed at autopsy; this patient also had an increased number
of MKs in the lungs (5.4 + 3.5 MK/FOV), suggesting that MKs may be increased within the
pulmonary parenchyma during localized as well as systemic infections. One patient that died
from sepsis complicated by DIC was noted to have severe pulmonary inflammation and
hemorrhage, as well as a micro-abscess, as defined by an increased number of neutrophils and
macrophages, in the lung pathology section (Figure 2-12). Gram staining and CD61 IHC was
positive for intracellular gram positive cocci, along with multiple large, homogeneously stained,
CD61I cells concentrated in the center of the abscess. This may indicate that these MKs actively
migrated out of the intravascular space and into the center of the abscess in response to
inflammatory signals or response to the bacteria.
Renal glomeruli from septic patients also had a significantly increased amount of CD61+
positive staining than the controls (p = 0.018; 0.16 + 0.08% CD61/Glomerulus vs 1.07 + 0.23%
CD61/Glomerulus, respectively) (Figure 2-11 C-D). As seen from the paired H&E and CD61
IHC glomeruli images, it was not possible to differentiate with any certainty whether large
CD6 1+ areas had associated MKs or whether they were platelet-rich fibrin thrombi (Figure 2-11
C). One patient, which had substantial microvascular thrombosis within the kidney and was
diagnosed with disseminated intravascular coagulation (DIC), had significantly elevated CD61
staining (2.29 + 3.0 % CD61/Glomerulus), consistent with the presence of platelet-rich micro
thrombi within the glomerular capillaries (Figure 2-11 D).
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2.5 Discussion
Megakaryocytes (MKs) have long been thought to have one primary role - the production of
platelets (plts). (Machlus KR, 2013) Plts are small, circulating anucleate cells which have been
reported to be one of the 'first responders' to pathogens and inflammatory insults, resulting in the
recruitment and subsequent activation of white blood cells and even directly trapping pathogens
themselves. (Semple JW, 2011; Morrell CN, 2014; de Stoppelaar SF, 2014) Because plts derive
their cellular components and functionality from their parent MK cell, it is logical to deduce that
the MK cell also harnesses immune cell capabilities. In this study, we explore the role of the MK
as an innate immune cell, and we demonstrate its ability to perform immune cell functions,
including: phagocytosis, chemotaxis, and extracellular trap formation. We then explore its
potential role in the peripheral circulation and end-organs of adult patients with sepsis. To our
knowledge, this is the first study exploring the dynamic role of the megakaryocyte as an innate
immune cell.
Two essential roles of innate immune cells include their ability to sense and chemotax towards a
pathogen and to interact and phagocytose the pathogen. Megakaryocytes have been documented
to internalize a number of pathogens, both in vitro and in vivo, including dengue virus, human
immunodeficiency virus, and aspergillus. (Zucker-Franklin S, 1989; Ferry JA, 1991; Clark KB,
2016; Clark KB, 2012) In this study, we utilize both electron microscopy and pHrodo conjugated
bacteria to demonstrate that, not only do MKs internalize bacteria, but they also localize the
bacteria to lysosomal-type granules, which is indicative of an active killing process. (Prosser A,
2013; Naqvi AR, 2015) Additionally, cord blood-derived hematopoietic stem cells (HSCs) were
observed to have phagocytic capabilities starting at day 3 of megakaryocyte differentiation; this
is consistent with previous literature which demonstrates that primitive HSCs are quiescent, and
as they differentiate into monocytes they develop progressive phagocytic capabilities (starting at
day 3). (Kolb-Maurer A, 2002) Chemotactic ability was also explored in MKs. In this study, we
demonstrated that Meg-0 1 cells undergo active chemotaxis towards pathogenic stimuli. MKs are
able to migrate through a < 6 pm channels/pores, which is within the range of a small capillary
vessel or intercellular pore, indicating that these cells may not merely get 'trapped' in
microcirculatory beds, but may be able to move through them and even potentially diapedese
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into surrounding tissues. (Alamo IG, 2017; Zuchtriegel G, 2016; Haemerle M, 2016; Lisman T,
2010; Singer G, 2006; Croner RS, 2006) Additionally, the budding of platelets into the channels,
acting as a sort of 'loaded gun', as well as the obstruction of the channels by the cells and
platelets may indicate a mechanism for the formation of microthombi within small capillary
vessels and potentially provide another mechanism for platelet extravasation. (Yadav H, 2015; de
Stoppelaar SF, 2014; Stokes KY, 2012; Wells S, 1984; Aabo K, 1978; Fuchs TA, 2007)
MKs were also demonstrated to be able to form megakaryocyte extracellular traps (METs).
Extracellular trap (ET) formation, or ETosis, is a type of cell death which has been demonstrated
in a number of immune cells, including: neutrophils (NETs) and eosinophils (EETs). (Ueki S,
2013; Fuchs TA, 2007) NETs are thought to be an essential part of the immune and coagulation
system, both entrapping pathogens and signaling to nearby inflammatory cells and the
coagulation system that there is an intruder in the system, while EETs have recently been shown
to play an important role in the lungs in chronic obstructive pulmonary disease (COPD) and
allergic airway conditions. (Dworksi R, 2011; Dworski R, 2011; Echevarria LU, 2017)
Extracellular DNA and histones are considered danger-associated molecular patterns (DAMPs)
in the peripheral circulation have been associated with sepsis as well as a number of autoimmune
diseases, while increased extracellular DNA and histones has been associated with both ARDS
and acute kidney injury (AKI). (Narasaraju T, 2011; Lv X, 2017; Xu Z, 2015; Jansen MPB,
2017; Xu J, 2009) We have also demonstrated that extracellular mitochondria, which are
proinflammatory and released from platelets during activation, are also released during MET
formation, providing another DAMP. (Maeda A, 2014; Boudreau LH, 2014) Up until now, it has
been postulated that most extracellular DNA and histones originate from neutrophils or
eosinophils. Our results suggest that one potential source of these DAMPs may be MKs; such as
during ARDs, when there are increased numbers of MKs within the pulmonary parenchyma.
(Wells S, 1984; Sulkowski S, 1999; Kadas L, 1981)
In this study, we were also able to show that MKs are increased in both the peripheral circulation
and in peripheral organs during sepsis. It was necessary in this study to utilize special staining in
order to positively identify and quantify MKs within the body and automated hematology
analyzers were unable to positively identify the presence of these abnormal cells. (Sanford D,
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2013; Erber WN, 1987) These findings are consistent with previous studies, showing that there
are increased MK precursors in the peripheral circulation of neonates with sepsis, in the renal
glomeruli of adults with sepsis, and in the lungs of patients with sepsis and ARDS. (Brown RE,
2008; Broghamer WL, 1981) Our results demonstrate that the average circulating MK was
between 10-15 tm in diameter with a scant cytoplasm, indicating that either small MKs
(micromegakaryocytes) are being prematurely released into the circulation from locations of
hematopoiesis due to the sepsis syndrome (increased vascular permeability and vasodilation), or
that these cells have shed their cytoplasm in the lung space and have subsequently entered the
circulation as naked nuclei. (Scheinin TM, 1963; Pederson NT, 1978) Additionally, it was noted
that treatment with anti-CD162 antibodies was necessary for the detection of circulating large
CD61'CD41'Draq5' cells; based on previous work, we hypothesize that the possible cause for
this is that these cells are more likely to be in the circulation in the form of 'clusters' with other
peripheral blood cell types, such as neutrophils. (Frydman GH, 2017; Wang X, 2014;
Asaduzzaman M, 2009)
In conclusion, we have shown that that MKs have innate immune cell capabilities, including
phagocytosis, chemotaxis, and extracellular trap formation. We have also shown that MKs have
an increased presence in the peripheral circulation, lungs, and kidneys in adult patients with
sepsis, which show evidence of being correlated with both, prognosis and type of infection.
These findings suggest that there may be a link between the presence of MKs and the
pathogenesis of sepsis and its' related complications. The implications of having an increased
MK presence in the body is now more complex, as they are now no longer merely sources of
platelets, but may also serve as an innate immune cell and contribute to the proinflammatory
state present in sepsis.
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Figure 2-1: Quantification of MKs in peripheral blood using flow cytometry.
The positive identification and quantification of MKs in whole blood samples was evaluated. (A & B) A
flow cytometry protocol was optimized for the accurate quantification of the total white blood cell
population in whole blood. White blood cells were identified by being double positive for CD162 and
CD45. Both CD45 and CD162 hi and lo populations were present, representing different types of white
blood cells. The cells that were double negative for CD45 and CD 162 were either platelets or red blood
cells, and the large cells that were positive for CD41 and CD61 were Meg-01 cells, as shown in panel B.
Cells that were negative for all markers are erythrocytes. (C) The total white blood cells per mL
calculated by flow cytometry were then compared to the automated CBC WBC count and showed a
strong correlation with an r of 0.998, confirming this as an accurate method of cell quantification based
on cell surface markers. (D & E) Meg-0 1 cells were spiked into whole blood and quantified using the
flow cytometry protocol. The MK manual count spiked correlated well with the flow cytometry
quantified MK count with an r value of 0.980.
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Figure 2-2: Flow cytometry analysis of cell phenotype
Imaging flow cytometry was used to characterize cord blood (CB)-derived MKs and Meg-0 I cells by
various cell surface markers, including: CD41 (i-ii), CD34 (i), CD162 (ii), HLA-DR (iii), vWF (iii).
HLA-ABC (iv), CD61 (iv), and CD62P (v). Scatter plots of CB MKs at days 0, 3, 7, 10, and 14 of
differentiation are shown in panel A-E and scatter plots of Meg-O 1 cells are shown in panel F. Images of
representative cells for various days of differentiation are shown in panel G-I. *vWF was not evaluated in
Meg-01 cells, therefore the scatter plot is of CD41 vs HLA-DR (E-iv).
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Figure 2-3: Megakaryocytes are capable of phagocytosis of pathogens.
Megakaryocytes were tested for their ability to phagocytose a number of pathogens. (A) Meg-O 1 cells
were co-incubated with various bacteria. Light microscopy with diff-quick staining shows that bacteria
appear to be associated with the cytoplasm and cell membrane of the cells. (B) Transmission electron
microscopy of both Meg-O 1 and CB MKs exhibiting bacterial association with the cell membrane as well
as internalization into vacuoles within the cytoplasm. Panel i is a control Meg-O 1 cell, while panel ii is a
Meg-Ol cell that was co-incubated with live S. aureus. Panel ii shows a CB MK with multiple bacteria
within a large cytoplasmic vacuole from a contaminated cell culture. Panel iii is from a CB MK culture
co-incubated with live S. pyogenes showing association of the bacteria with a platelet cell membrane. (C)
CB MKs were co-incubated with live pHrodo-conjugated bacteria. This is a representative image of a
control cell along with a cell co-incubated with E. coli. (D) Meg-01 cells were co-incubated with pHrodo-
conjugated live E coli and then imaged. Bacteria, red arrow; pseudopods, yellow arrow.
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Figure 2-4: Megakaryocytes are capable of phagocytosis throughout differentiation.
CB MKs are functional phagocytes starting at day 3 of differentiation. (A) CB MKs were co-incubated
with live pHrodo-conjugated bacteria on days 0, 3, 7, 10, and 14 of differentiation and were noted to be
capable of phagocytosis starting on day 3 of differentiation. Scale bars are 20 tm. (B) Meg-Ol cells were
co-incubated with zymosan particles overnight and then imaged. The red zymosan particles appear
fluorescent red within the cytoplasm of the Meg-0 1 cell when phagocytosed. Zymosan particles, green
arrow.
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Figure 2-5: Meg-01 cells are capable of chemotaxis to pathogenic stimulus.
Meg-01 cells were tested for their ability to chemotax towards LPS and zymosan particles. (A) A
microfluidic device was used for part of the chemotaxis experiments. In this device, the main channel is
connected to a circular reservoir by four 6um channels and a larger 8 um connecting channel in a comb-
like arrangement. The device is first primed with the condition (panel i) and the main channel is then
flushed with media in order to create a concentration gradient from the 'lollipops' into the main channel
(panel ii). (B) The MKs are stained with Hoechst for positive identification and then manually tracked.
The behavior of the MK was divided into 3 categories: cells attempting to enter the channel (yellow
arrowhead), cells inside the channel (white arrow), and cells through the channel and inside the reservoir
(green arrowhead). Zymosan particles are marked with a green asterisk. (C) Time lapse image of MKs
migrating into the lollipops which are primed with LPS (360 pg/mL) and zymosan particles. (D) Close-up
of time-lapse image were MKs are observed to attempt to enter the channel, extend an 'arm' into the side
channel (yellow arrowhead), and then bud off small platelet-like particles (red arrowhead). (E) Bar graph
representing MK chemotaxis within the microfluidic device. (F) Bar graph representing MK chemotaxis
within a transwell device, confirming the same observation as within the microfluidic device. LPS low, 22
pg/mL; LPS med, 220 pg/mL; LPS high, 2.2 ng/mL; Zym, zymosan particles; Zym+LPS, zymosan
particles with 220 pg/mL LPS. Bar graphs are the mean with standard error bars.
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Figure 2-6: Statistical summary of Meg-01 chemotaxis within a microfluidic device
One-way ANOVA was performed for each condition shown in Figure 2-5 E. Alpha = 0.05. LPS lo, 22
pg/mL; LPS med, 220 pg/mL; LPS hi, 2.2 ng/mL; Z, zymosan particles; positive, 220 ng/mL SDF la;
negative, media only; Z, zymosan particles; Z+L, zymosan with 220 pg/mL LPS.
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Figure 2-7: Megakaryocyte form extracellular traps (METs).
MKs were observed to form METs in response to pathogenic stimulus. (A) Meg-0 I cells co-incubated
with live E. coli and developed an ET-like morphology on light microscopy with diff-quick stain. This
morphology consists of an open cell membrane with cytoplasm outside of the cell and a swollen nucleus.
Green arrow, bacteria; red arrow, extracellular cytoplasm. (B) Meg-0 1 cells were co-incubated with
various concentrations of LPS and free ds DNA was quantified using a PicoGreen assay. The amount of
free dsDNA positively correlates with the increasing concentration of LPS. (C) CB MKs were co-
incubated with live pHrodo-conjugated E. coli and were observed to have extracellular DNA. Live cells
are stained blue with Hoechst, while extracellular DNA and dead cells are stained orange with SYTOX.
(D) Meg-0I cells were incubated with just media or with LPS. Cells in the negative control were noted to
have calcein staining (which indicates cell membrane) in the extracellular space, consistent with
proplatelet budding; whereas cells incubated with LPS were noted to have calcein scant calcein stain and
an abundance of extracellular DNA staining (red arrow). (E) Meg-0I cells were incubated with a variety
of live bacteria. Light microscopy of these cells demonstrated swollen nuclei, broken nuclear membranes,
extracellular DNA and granules, as well as bacteria associated with intra- and extracellular contents.
Panel i is the control, and panel ii and ii are co-incubated with E. coli and S. aureus, respectively. (E)
Transmission electron microscopy (TEM) of Meg-01 cells co-incubated with live bacteria. Panel I depicts
a control cell with an intact nuclear membrane (right top panel) and limited extracellular content. Panel ii
depicts multiple cells with swollen nuclei (N), broken nuclear membranes (bottom right panel),
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extracellular cytoplasmic contents (including granules and mitochondria, purple arrow), and an
abundance of bacteria primarily associated with cellular content. (G) TEM image of a Meg-01 cell co-
incubated with live . coli exhibiting a swollen nucleus and a rearrangement of mitochondria surrounding
the nucleus. (H) Meg-01 cells transfected with Bacmam H2b-GFP were seen to form METs that were
both positive for DNA (Hoechst) and histone 2B. Mitochondrial staining with MitoSox red shows active
mitochondria in a perinuclear arrangement, confirming the TEM findings from panel G.
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Figure 2-8: Megakaryocyte extracellular traps (METs) immunofluorescent staining.
Immunofluorescence was used to evaluate the extracellular traps made by Meg-01 cells. HL60 cells were
used as a positive control for the immuno-stains. In these cells, DAPI (DNA stain) and Histone 3
(phospho Ser28) staining were both localized to the nucleus of the cells, while myeloperoxidase (MPO)
was localized to the cytoplasm. In the Meg-Ol cells, the METs stained positive for DAPI, Histone 3, and
MPO.
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Figure 2-9: Megakaryocytes are present in increased amounts in the circulation during
sepsis.
Samples from patients diagnosed with sepsis were evaluated for the presence of possible MKs. In order to
positively identify MKs in the peripheral circulation, an MK was defined as CD41+CD61+ and
DRAQ5+. (A) Imaging flow cytometry was used to identify and quantify circulating
CD41+CD61+Draq5+ cells in the peripheral circulation. CD45 and CD162 were used as white blood cell
markers. The top 4 panels show examples of MKs, while the bottom two panels have a white blood cell
(bottom panel has an MK-WBC complex). (B) Circulating MKs were significantly higher in the
peripheral circulation in patients with sepsis (i). The amount of MKs was correlated with sepsis-related
complications, including ARDS and AKI, with 'complicated' sepsis having significantly higher MKs than
'uncomplicated' sepsis (ii). MKs were also noted to be higher in gram negative and mixed infections, as
compared to gram positive only infections (iii). Sequential blood samples on day I and 3 of sepsis
hospitalization suggested that there also may be a correlation with recovery and the development of sepsis
complications, such as AKI (iv). Significance is calculated via student t-test with significance being
defined as p < 0.05 (*).
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Figure 2-10: Correlation between CBC and Circulating megakaryocytes
Platelet and white blood cell (WBC; leukocyte) counts were compared to circulating MKs in patients. (A-
B) Patients with sepsis had significantly increased WBC counts as compared to controls but there was no
significant difference in platelet count. (C-D) There was no correlation between WBC or platelet count
and circulating MK count (r2 =0.0 15 and 0.004, respectively).
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Figure 2-11: Megakaryocytes are present in the peripheral organs during sepsis.
Autopsy pathology samples from patients that died from sepsis were evaluated for MKs. (A) MKs in the
lungs were defined as being large cells with dark, homogenous CD6I+ staining (brown). An example of a
lung image from a patient that died from heart disease as a negative control is shown in panel ia
(hematoxylin and eosin, H&E) and ib (CD6 1). In these images there are no MKs observed. A
representative image of two lung images from a patient that died from sepsis are shown in panel iia/iiia
(H&E) and iib/iiib (CD61), showing multiple MKs (green asterisks). Platelet staining is also noted (red
asterisks). While in some cases, a large dark staining basophilic nucleus can be seen in the H&E in the
area of the CD61 staining, this is not always the case and may be due to sectioning through the sample
and imaging different planes. This also suggests that CD61 may be more accurate when counting MKs
than H&E. A sample of bone marrow from a sepsis patient is shown in panel iva (H&E) and ivb (CD61)
as an example of a megakaryocyte with CD61 staining as a positive control (red box). (B) Glomeruli were
also evaluated for the presence of increased CD61 staining. Individual MKs could not be reliable counted
within the MKs, therefore percent of CD61 stain/glomeruli was evaluated. A glomerulus from a control
patient is shown in panel ia (CD61) and ib (H&E), with minimal CD61 staining. This is in contrast to a
glomerulus from a patient with sepsis and disseminated intravascular coagulation (DIC), which has much
higher amounts of CD6I staining along with microvascular thrombi within the glomerular capillaries
(green asterisk). Upon evaluation, there was significantly higher circulating MKs (C) and glomerular
CD61 staining (D) in the sepsis patients as compared to control. Significance is calculated via student t-
test with significance being defined as p < 0.05 (*). Scale bars are: Ai-ii, 100 pm, Aiii-iv and C, 50 ptm.
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Figure 2-12: Pulmonary micro abscess in a septic patient
Histopathological evaluation of a pulmonary abscess in a patient that died from sepsis. Hematoxylin and
Eosin (H&E) images of the abscess at l0x (ia) and 100X (iia) shows red blood cells, neutrophils,
macrophages, and intracellular cocci (green arrow). Gram stain at l0x (iia) and lO0x (iib) showing extra-
and intracellular gram positive cocci (green arrow). CD6 1 staining at l0x (iiia) and 10O0x (iiib) showing
multiple small CD6 1+ platelets (red arrow) and larger, dark-staining CD6 1+ cells suspected to be MKs
(purple arrow). Scale bar top row, 100 pim (lOX). Scale bar bottom row, 10 pim (bO0X).
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Figure 2-13: Proposed mechanism of megakaryocytes as immune cells
The megakaryocyte cell (left) is capable of chemotaxis towards pathogens (red stars). Upon contact with
pathogenic stimulus, the megakaryocyte can perform phagocytosis (top left) or form an extracellular trap
(bottom left) (DNA, purple; green, histones). These activated megakaryocytes and METs can then
propagate intravascular thrombosis. This intravascular thrombosis can result in end organ damage if
lodged within the lungs, resulting in acute respiratory distress syndrome, or the kidneys, resulting in acute
kidney injury.
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Tables:
Table 2-1: Patient descriptive statistics for circulating megakaryocytes
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Table 2-2: Patient descriptive statistics for histopathology analysis
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Path, Cause of death determined by pathologist;
Kidney and Lung, histopathology findings as determined by pathologist.
157
Videos:
Video 2-1: Zymosan particles co-incubated with Meg-01 cells.
Meg-01 cells were co-incubated with zymosan particles overnight. In this video z-stack image,
the particles appear to possible be associated with the cell membrane, but no internalization is
observed. Zymosan, red; Nuclear stain (Hoechst), blue; Membrane stain, calcein, green.
Video 2-2: Zymosan particles are internalized by Meg-01 cells.
Meg-01 cells were co-incubated with zymosan particles overnight. In this z-stack image video,
one of the cells is observed to have internalized the red zymosan particles. Zymosan, red;
Nuclear stain (Hoechst), blue; Membrane stain, calcein, green.
Video 2-3: Chemotaxis of Meg-01 cells.
Meg-01 cells chemotaxing from the main channel into the side comb and side channel into the
circular well containing LPS and zymosan particles. Zymosan, red; Nuclear stain (Hoechst),
blue.
Video 2-4: Platelet-like particle budding within a well after chemotaxis.
Meg-01 cell that has entered a circular well primed with SDFIa is observed undergoing
apoptosis and budding platelet-like particles within the well. Interestingly, some of the platelet-
like particles remain Hoechst-positive, indicating that there is DNA within some of the particles.
NOTE: This video was created on a different chemotaxis chamber design, where there is no
comb and only one side-channel leading into the well.
Video 2-5: Cytoskeletal rearrangement during chemotaxis.
Continuation of Video 2. Large Meg-01 cell undergoes active cytoskeletal rearrangement with
Hoechst-positive granules proximal to the nucleus, The cell is chemotaxing into a circular well
that has SDF Ia and platelet-like particles from a Meg-0I cell that had undergone apoptosis and
budded particles. This large cell fills up the entire length of the side channel and then appears to
get stuck and stops moving. NOTE: This video was created on a different chemotaxis chamber
design, where there is no comb and only one side-channel leading into the well.
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Video 2-6: Meg-01 cell carrying zymosan particle during chemotaxis.
Meg-01 cells are observed to chemotax towards wells primed with zymosan particles. One
zymosan particle is noted to be within the comb and is carried into the circular well by a cell as it
moves into the well. Zymosan, red; Nuclear stain (Hoechst), blue.
Video 2-7: Meg-01 cell budding platelet-like particles in the presence of zymosan and LPS.
Meg-0 1 cell is observed to migrate into a well primed with zymosan and LPS and then proceeds
to form connecting platelet-like particles. Zymosan, red; Nuclear stain (Hoechst), blue.
Video 2-8: Meg-01 cell budding platelets in the presence of SDFla.
A meg-01 cells is observed to migrate within the side channel, towards a well primed with
SDF I a. Right before it enters the circular well, the cell stops migration and starts to undergo
cytoskeletal rearrangement and buds what appears to be platelet-like particles. The cell does not
migrate further once the cytoskeletal changes occurs and appears 'stuck' within the channel.
Nuclear stain (Hoechst), blue.
Video 2-9: Meg-01 cell chemotaxis negative control.
Meg-0I cells are not observed to migrate to the negative control (RPMI + 10% FBS) within the
microfluidic device.
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Chapter 3
Megakaryocytes and Platelets Contain Extranuclear Histones
3.1 Abstract
Histones can be very dangerous when they are located in the extracellular compartment, promoting
inflammation and coagulation in various disease states. Patients with sepsis are known to have
increased extracellular histones, and these histones have been shown to correlate with prognosis
and the development of sepsis-related sequelae, such as end organ damage. Until now, the primary
source of extracellular histones during sepsis has been neutrophils. In this paper, we perform a set
of in vitro experiments demonstrating that megakaryocytes commonly contain extranuclear
histones; additionally, they appear to transmit these histones to their platelet progeny. We also
performed imaging flow cytometry on isolated platelets from patients with sepsis and
demonstrated that these patients do have increased platelet-associated histones as well as an
activated platelet phenotype. Taken together, these results suggest that the megakaryocyte and
platelet may be a source of extracellular histones during sepsis and should be further explored.
3.2 Introduction
Traditionally, histones have been recognized as a functional 'glue' for genetic material, wherein
core histones (H2A, H2B, H3, and H4) form octamers and linker histones (HI and H5) hold
DNA together in specific conformations. Specific histone post-translational modifications
(PTSMs) also directs site-specific activation or silencing of transcription. (Venkatesh S, 2015)
While histones are typically located within the nucleus of the cell, they can also be located
within the cytoplasm, the cell membrane, or can even be extracellular. (Chen R, 2014) When
histones are located outside of the cell they can change roles and serve as damage-associated
molecular patterns (DAMPs) and be dangerously proinflammatory and cytotoxic. (Chen R, 2014;
Parseghian MH, 2006) Extracellular histones have been shown to be associated with life-
threatening inflammatory conditions, such as sepsis and its' secondary complications, including
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acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI). (Xu Z, 2015; Miki
T, 2015; Li Y, 2009; Jansen MPB, 2017; Kalbitz M, 2015)
One of the primary sources of extracellular histones during sepsis is thought to be neutrophils,
via the formation of neutrophil extracellular traps (NETs). (Xu Z, 2015; Chaput C, 2009) NETs
are essentially a type of cell death where a neutrophil releases intracellular material - namely
DNA and associated histones. Extracellular DNA and histones have been shown to be both
proinflammatory and thrombogenic. (Fuchs TA, 2007) Circulating histones can result in
activation of nearby platelets and leukocytes, can activate thrombin to exacerbate intravascular
clot formation, and can initiate endothelial and epithelial cell death via Toll-like receptor-2 and -
4 (TLR2 and TLR4) signaling. (Xu Z, 2015; Chaput C, 2009; Gould TJ, 2015; Varju 1, 2015)
In Chapter 2, 'Megakaryocytes as Functional Immune Cells', we showed that megakaryocytes,
the precursors to platelets, are capable of forming megakaryocyte extracellular traps (METs) in
response to pathogenic stimuli. We have also shown that megakaryocytes appear to be increased
both in the peripheral circulation as well as in the peripheral organs (kidney and lungs) during
sepsis. In this set of experiments, we explore whether megakaryocytes can be a source of
extracellular histones, not only through MET formation, but also through the development of
histone-rich platelets. We also show that platelets from patients with sepsis have significantly
higher levels of platelet-associated histones and may themselves be a source of extracellular
histones during severe infection and inflammation.
3.3 Methods and Materials
3.3.1 Cell culture
Cord blood CD34' stem cells were purchased and cultured in StemSpanII media with the
megakaryocyte supplemental cytokines, according to the culture and differentiation protocols
from Stemcell Technologies (Stemcell Technologies Inc. Cambridge, MA). A megakaryoblastic
cell line (Meg-0 1) was purchased and cultured in RPMI with 10% FBS, according to the
standard cultures protocols from ATCC (American Type Culture Collection, Manassas, VA).
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3.3.2 Platelet and white blood cell isolation
Platelets and platelet-rich plasma was collected for most of these experiments. Neutrophils were
isolated as a positive control for histone staining. Platelets were prepared from blood collected
into 2.9 ml trisodium citrate Vacutainer tubes (Sarstedt, N*umbrecht, Germany). Platelet-rich
plasma (PRP) was first prepared by centrifugation of the whole blood at 210 g, 22'C, for 20 min.
The PRP supernatant was gently pipetted into a new tube with 20% volume ACD solution
(Boston Bioproducts, Ashland, MA, USA) and then centrifuged at 1900 g, 22'C, for 10 min. The
platelet-poor plasma (PPP) was removed, leaving a platelet pellet. Neutrophils were isolated
from whole blood collected in ACD BD Vacutainer tubes (Becton Dickinson, Franklin Lakes,
NJ, USA) using a negative-selection protocol. In brief, neutrophils were isolated using a density
gradient with HetaSep (Stemcell Technologies, Vancouver, BC, Canada) and then purified with
EasySep Human Neutrophil Kit (Stemcell Technologies), following the manufacturer's protocol.
3.3.3 Immunofluorescence Imaging
Both Meg-01 and cord-blood derived MKs (CB MKs) were fixed and stained for the evaluation
of cellular histone localization using immunofluorescence staining. Meg-01 cells were co-
incubated with various concentrations of E. coli lipopolysaccharide (LPS) (0111 :B4; Sigma
Aldrich, St Louis, MO), for 60 minutes at 370 C on poly-lysine coated slides (Sigma Aldrich, St
Louis, MO, USA) and then fixed with 4% paraformaldehyde (Santa Cruz Biotechnology, Dallas,
TX, USA). Platelet pellets were prepared as described in the 'Blood cell sample preparation'
section above. CB MKs, at day 14 of differentiation, and platelet pellets were fixed with 4%
paraformaldehyde for 30 minutes and then concentrated onto a poly-lysine coated slide using the
Cytospin 4 cytocentrifuge (Thermo Fisher Scientific), for 5 minutes at 1250 rpm, rinsed once
with di-water and stored at -80'C until staining and evaluation. For staining, the slides were
thawed at room temperature and blocked with 5% donkey serum (Jackson Immunoresearch) for
2 hours. The slides were rinsed three times with PBS and then treated with various combinations
of the following primary antibodies for two hours: rat anti-Histone H3 (phospho S28) antibody
(HTA28; Abcam, Cambridge, MA, USA) at 1:500, rabbit anti-Histone H4 (39270; Active Motif,
Carlsbad, Ca, USA), rabbit anti-Histone H2A.X (Active Motif), rabbit anti-Histone 3 (ab 1791;
Abcam, Cambridge, MA, USA), and mouse anti-Histone 3 (96C 10; Cell Signaling Technology,
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Danvers, MA, USA). The slides were then rinsed three times with PBS and incubated with
various combinations of the following secondary antibodies: mouse anti-human CD41 (GPIIb)
488 or 647 (Biolegend, San Diego, Ca, USA) at 1:250, donkey anti-rabbit 488, donkey anti-rat
647, and donkey anti-mouse 568 (Life Technologies) at 1:500 for 30 minutes. Slides were then
rinsed three times with PBS and then covered with Vectashield antifade mounting medium with
DAPI (Vector Labs, Burlingame, Ca, USA). The cells were then imaged with one of two
fluorescent microscopes: Life Technologies EVOS FL (Thermo Fisher Scientific) or Nikon
Eclipse 90i microscope (Nikon Instruments Inc., Melville, NY).
3.3.4 Histone-2B BacMam transfection of Meg-01 cells
Meg-01 cells were transfected with GFP-Histone 2B (H2B) for localization of cellular histone.
Meg-Ol cells were transfected with CellLight Histone 2B-GFP (BacMam 2.0, ThermoFisher
Scientific) at 30 uL/mL for 48-72 hours. Cell were then labeled with MitoSox Red mitochondrial
superoxide indicator (ThermoFisher Scientific) at 1:1000 Hoechst at 1:2000 for 30 minutes.
Cells were then pelleted at 1,900 x g for 10 minutes and rinsed twice with PBS. Cells were then
concentrated onto a poly-lysine coated slide using the Cytospin 4 cytocentrifuge (Thermo Fisher
Scientific), for 5 minutes at 1250 rpm. Slides were then rinsed with DI water, cover slipped, and
imaged on an EVOS fluorescent microscope.
3.3.5 Histone purification
Histones were extracted from both platelet pellets and Meg-01 cells for histone quantification.
For sample preparation, venous whole blood collected in acid citrate dextrose tubes (Research
Blood Components LLC, Boston, MA, USA). Platelet pellets were isolated as described in the
section above, 'Blood cell sample preparation'. Meg-01 cells were pelleted down at 1900 x g for
10 minutes. For histone purification the Active Motif Histone Purification Mini Kit (Active
Motif) was utilized per the manufacturer's instructions. Briefly, platelet and cell pellets were
washed twice with hepes-tyrode buffer and 20% acid citrate dextrose buffer (Boston
BioProducts, Boston, MA, USA). Pellets were then re-suspended in ice-cold Extraction Buffer.
Samples were homogenized in the Extraction Buffer using for 30 minutes and then left overnight
at 4'C. The samples were then spun at maximum speed (18,000 x g) in a microfuge for 5 minutes
at 40C. The supernatant, containing the crude histones, was then transferred to a new tube and
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neutralized with 5X Neutralization Buffer to a pH of 8. One aliquot of crude histones was saved
for downstream analysis. Spin columns provided by the kit were then equilibrated and the crude
histones along with the Elution Buffer were run through the columns at 500 x g for 3 minutes.
One aliquot of the eluted histones was saved for downstream analysis. Histones were then
precipitated with perchloric acid. Briefly, histones were precipitated overnight at 40C with 4%
perchloric acid. The histones were then spun down at maximum speed for 1 hour at 4C. The
pellet was washed with 1 mL cold 4% perchloric acid, then twice in ice cold acetone with 0.2%
HCl, and then twice in ice cold acetone. The resulting pellet was air dried for 10 minutes and
then re-suspended in sterile water. All histones and aliquots were stored at -80 0C until the
samples were analyzed.
3.3.6 Histone quantification
Histone quantification was performed using two methods: absorbance measurements and
ELISAs. For the absorbance measurements, both total protein and histone-specific absorbances
were performed as follows using the DS-1 1 Spectrophotometer (DeNovix Inc., Wilmington, DE,
USA): 230 nm for total protein, 280 nm for histone quantification with the following molecular
weight extinction coefficients, as recommended by Active Motif (Table 3-1). Histones purified
from calf thymus (Sigma-Aldrich, St. Louis, MO, USA) were used as a positive control at 2
mg/mL. For histone quantification using ELISAs the Luminex Histone H3 PTM Multiplex
Assay (Active Motif) was used according to the manufacturer's protocol. For sample
preparation, serial dilutions of Meg-01 and platelet pellet purified histones were prepared. For
the positive control, the purified histone 3 protein that was provided with the kit was used in this
assay. Both total Histone 3 (H3) and H3 post-translational modifications (PTSMs) were
evaluated for each sample (Table 3-2). Briefly, the samples were co-incubated with multiple
magnetic beads, were conjugated to antibodies targeted to specific H3 PTSM, on a shaker plate
for 2 hours. The beads were then washed 3 times and incubated with biotinylated anti-H3
antibodies on a shaker plate for 30 minutes. The beads were then washed 3 times and then
incubated with streptavidin-phycoerythrin for 30 minutes, followed by the final
washes. Samples were read by using a Flexmap 3D (Luminex). The standard curve was
generated by using 5-parametric-curve fitting with platform-specific software (xPONENT
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Software Solutions, Luminex, Austin, TX). Samples were run in duplicate on each plate for
quality control.
3.3.7 Flow cytometry
Flow cytometry was performed in order to evaluate cells and platelets for histone expression.
Meg-01 cells, platelet, and whole blood were fixed with 4% paraformaldehyde with or without
0.1 % TritonTM X- 100 detergent (Sigma-Aldrich) for permeabilization for a total of 10 minutes.
Samples were then pelleted down at 1,900 x g for 10 minutes and re-suspended in PBS. Cells
were first incubated with primary, unconjugated antibodies, rabbit anti-Histone 3 (ab 1791;
Abcam) or rat anti-Histone H3 (phosphoS28) antibody (HTA28; Abcam) at 1:400 for 20 minutes
and were then washed twice with PBS. Cells were then stained with a combination of conjugated
primary antibodies and secondary antibodies for 15 minutes, including: mouse anti-human CD41
PacBlue, mouse anti-human CD45 594, mouse anti-human CD162P PE, mouse anti-human
CD62P PE, mouse anti-human CD61 FITC (Biolegend, San Diego, Ca), and goat anti-rabbit 488
or donkey anti-rat 647 (Thermo Fisher Scientific, Waltham, MA) at 1:200 for 15 minutes, with
the exception of CD41 which was at 1:100. Cells were then stained with Draq5 (Thermo Fisher
Scientific, Waltham, MA) at a concentration of 1:10000 for 5 minutes. Data was obtained
through the Amnis ImageStreamX Mark II imaging flow cytometer and INSPIRE Software
(EMD Millipore, Billerica, MA). The accompanying IDEAS Software was used to perform data
analysis. Data is reported as the percent of the total cell population that stained positive for the
specific marker.
3.3.8 Transmission electron microscopy and immune-gold labeling
For transmission electron microscopy, cells were fixed in 2.5% gluteraldehyde, 3%
paraformaldehyde with 5% sucrose in 0.1M sodium cacodylate buffer (pH 7.4), scraped, pelleted
in a small eppendorf tube. Wash with 0.1 M sodium cacodylate buffer 3x, post fixed in 1% OsO4
in veronal-acetate buffer 1 hour. The pellet was stained overnight with 0.5% uranyl acetate in
veronal-acetate buffer, dehydrated and embedded in Embed 812 resin. Sections were cut on a Leica
Ultracut UCT microtome with a Diatome diamond knife at a thickness setting of 50 nm, stained
with uranyl acetate, and lead citrate. The sections were examined using a FEI Tecnai spirit at
80KV.
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For the immunogold labeling protocol, the protocol was as follows. (Tokuyasu KT, 1980) The
cells were fix mildly Using PLP (paraformaldehyde / lysine / sodium periodate) fixative for 4
hours. Cells were pelleted and trimmed into small (<lmmsq) blocks. Infused with a cryo-
protectant for at least one hour (PVP/ sucrose). Blocks were mounted onto cryo-pins, and snap
frozen in liquid nitrogen. Ultrathin sections were cut at -110 degrees C with a Leica UC7
equipped with a FC7 cryo-stage using a glass knife, and immunolabeled, stained and embedded
using the Tokuyasu technique. For the immmunolabeling, rabbit anti-histone 4 antibody (39270;
Active Motif) was used. The material was examined using a FEI techni Spirit biotwin.
3.3.9 Patient sample collection
Venous blood from patients diagnosed with sepsis was collected and evaluated for histone-
associated platelets (IRB protocol numbers, MGH No: 2014P002087; MIT No:150100681R001).
A patient was categorized as sepsis when one of the diagnoses for the patient was 'sepsis' and
when there was a confirmed infection. Twenty-one samples were evaluated with 16 sepsis
samples (age 36-85 yrs., 4 females, 12 males) collected from MGH and 5 healthy control
samples purchased from Research Blood Components (Research Blood Components, LLC,
Boston, MA) (Table 3-3). Platelet pellets were isolated as described in the 'Histone purification'
section from venous blood collected in vacutainer EDTA tubes and then frozen at -800C until
analyzed. Flow cytometry was performed as described above, in the 'Flow cytometry' section. In
order to assess for the effect of platelet activation in the expression of histone as well as to
account for the effects of freeze-thawing of the patient platelet pellets, one set of control samples
and one sepsis sample was pre-treated with the following conditions: paraformaldehyde fixation,
fixation with 0.1% TritonTM X- 100 permeabilization, activation with 1 pig/mL a-thrombin
(coagulation Factor Ila; Haematologic Technologies, Essex Junction, VT, USA), 0.2 mM CaCI2,
and vortexing for 10 seconds, freeze at -800C followed by thaw in 4% paraformaldehyde (how
the sepsis samples were treated), and free at -800 C followed by thaw in 4% paraformaldehyde
with 0.1% TritonTM X-100. Samples were evaluated as described in the section above, 'Flow
cytometry'.
3.3.10 Statistical analysis
Platelet were evaluated both as 'singles' and as 'clusters' in order to parse between the more
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activated platelets that are more likely to be present as clusters and individual platelets in
circulation. Statistics were performed using both Excel (Microsoft, Redmond, WA, USA) and
GraphPad Prism Software (GraphPad Software, Inc.). Either one-way ANOVA or student t-tests
were performed to compare between conditions. Pearson's correlation was used to determine
whether there was a correlation present between platelet phenotype and platelet count or white
blood cell count. A p-value of <0.05 was considered significant.
3.4 Results
3.4.1 Megakaryocytes contains extranuclear histones
Immunofluorescent imaging used to localize histones within megakaryocytes showed that
extranuclear histones are common in both Meg-Ol cells and in cord blood-derived (CB) MKs
(Figure 3-1). Histone 3 phosphorylated at position serine 28 (PhosphoH3; Ser28; H3s28ph) was
used as a histone marker. Ser28 increases in response to activation of the MAPK pathway and is
increased during mitosis. (Dunn KL, 2005. Light granular staining was seen diffusely throughout
the Meg-Ol cell membrane and cytoplasm, with an increase in staining at the nucleus of cells
with mitotic figures (Figure 3-1 A). CB MKs were also positive for Ser28, with small, round
quiescent cells having mainly cell membrane and cytoplasmic staining, while more activated
cells appeared to have positive staining within cellular extensions at, what appears to be, the
uropod of the cell (Figure 3-1 B). Upon stimulation with E. coli LPS, CB MKs were observed to
form MET-like structures, as previously described in Chapter 2, with extracellular histones and
DNA; Meg-01 cells displayed histone staining within what appeared to be proplatelet buds
(Figure 3-1 C).
BacMam technology was used to transfect Meg-OI cells with GFP-Histone 2B (H2B) in order to
allow for a non-antibody-dependent method of confirming the presence of extracellular histones
within megakaryocytes. In the majority of the cells, H2B appeared to be primarily located to the
nucleus. Rarely, extranuclear histone was visualized within the cytoplasm of the cell or within
platelet-like particles within the cell culture (Figure 3-2). The visualization of GFP-H2B is less
likely to be artifact or background, as compared to antibody-dependent methods, such as
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immunofluorescent staining, because the GFP-H2B must be synthesized by the cell itself. It was
observed that the cells that appeared to have cytoplasmic GFP-H2B also had very strong GFP
signal within the nucleus, which may either indicate that the cell is overexpressing the histone or
the cell is polyploidy and approaching its apoptotic stage, where histones are likely to end up
within the cytoplasm of the cell. (Chen R, 2014; Gabler C, 2004; Zhao B, 2016) These results
strongly suggest that both Meg-01 cells and CB MKs appear to have extranuclear histones,
although perhaps H2B is not the most prominent extranuclear histone in these cells.
3.4.2 Platelet contain histones
Immunofluorescent imaging was used to probe whether peripheral blood platelets are positive for
histones. Isolated neutrophils were used as a positive control for the Ser28 staining and
confirmed the nuclear localization of this stain (Figure 3-3 A). Buffy coats were then stained
with Ser28 and showed that platelets did appear to stain positive for histones; where Ser28
appeared to be primarily around the platelet membrane, while CD41 positively identified the
platelet and had diffuse staining (Figure 3-3 B). White blood cells noted on the slide were used
as an internal positive control. Platelets were then probed with a generic Histone 3 (H3) and
Histone (4) antibody to further confirm the presence of platelet histones (Figure 3-3 C & D).
Imaging flow cytometry was then used to further test for the presence of platelet-associated
histones in both permeabilized and non-permeabilized cells. Interestingly, staining with the
generic H3 antibody was positive in the non-permeabilized cells, and appeared to be localized to
the platelet membrane; whereas the permeabilized cells stained the entire platelet (Figure 3-4 A).
Ser28, on the other hand, did not stain the non-permeabilized platelets, but did appear to stain the
permeabilized platelets (Figure 3-4 B). These results suggest that there are Ser28, H3, and H4
platelets-associated histones.
Transmission electron microscopy (TEM) immuno-gold imaging was then used to attempt to
determine the cellular localization of histones within platelets. Platelets stained positive for H4
(Figure 3-5). Interestingly, the labeling appeared to be fairly diffuse throughout the cytoplasm of
the cell. There were pockets of more concentrated labeling, which tended to be either on the
platelet membrane or on electron-dense areas of the TEM image. There was little-to-no immuno-
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gold labeling within the platelets granules or mitochondria. These findings suggest histones are
present diffusely within the platelets and are not packaged within platelet granules.
3.4.3 Histone quantification
Platelet histone quantification was attempted utilizing a combination of methods, including:
absorbance and bead-based ELISA assays. The absorbance method for total protein and histone
quantification results are shown in Table 3-1. The total protein was calculated with the following
equation (Eq. 1):
Eq. 1: (OD 0.42) / (1 mg/mL) = (measured OD at 230 nm)/ (X mg/mL)
X = total protein concentration
Calf thymus histones were used as a positive control for this methodology and showed a
relatively good agreement between the expected total protein concentration (10 mg/mL) and the
measured total protein concentration (10.35 mg/mL). The Meg-01 histones were calculated to be
at a concentration or 7.07 mg/mL and the two platelet extracts that were tested were calculated to
be 0.18 mg/mL and 0.15 mg/mL. The samples were then evaluated for individual histone
concentrations using their expected molecular weights and extinction coefficients. The total
histone concentration (H2A, H2B, H3, and H4) of the calf thymus, Meg-Ol cells, and both
platelet extracts were 9.75 mg/mL, 6.28 mg/mL, 1.51 mg/mL, and 1.17 mg/mL, respectively.
Although the histone concentrations are close to the total protein concentrations for the calf
thymus and the Meg-Ol cells, they were about ten times higher than the protein concentrations
for the platelet extracts. The lower detection limit of the absorbance reader was 0.04 mg/mL;
therefore, we do believe that the concentration should be within the detectable range for the
reader.
Next we used a bead-based ELISA assay for the quantitation of histone 3 and a few specific
histone 3 post-translational modifications. (Table 3-2). Sequential dilutions of the Meg-01
purified histones were performed in order to verify the assay protocol as well as derive the
histone concentration in the platelet extract sample (Figure 3-6 A & Table 3-4). The dilution
curve for the Meg-OI cells fit a logarithmic line (Eq. 2) with an R-squared value of 0.99.
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Eq. 2: Y = 614.9 ln(X) + 462.9
Y = MFJ, mean fluorescent intensity; X = histone concentration (ng/uL)
Using eq. 2, the MFI for the platelet histones was used to back-calculate the total histone
concentration in the sample. This concentration was then used to calculate the total amount of H3
per platelet (Eq. 3), using an estimated input platelet count of 300 x 106 platelets.
Eq. 3: Y = X/A
Y = ng /platelet; X = total His3 concentration (ng); A = platelet count (x 106)
According to Eq. 3, the estimated His3 concentration in platelets was 0.42-0.46 ng / 106 platelets.
This protein concentration is within the range of other protein concentrations, as calculated by
Peterson JE, et al (2010). (Peterson JE, 2010) Total estimated concentration for each of the His3
modifications measured with the bead-based assay are listed in Table 3-5. Although we were
able to calculate the best-fit line for total H3, this was not able to be done for the H3 PTSMs
tested because we did not know the initial input of each of these PTSMs; therefore, these specific
histones are expressed in terms of percent of total H3 expressed. As seen in Table 3-6, H3kme4
and H3k27me3 were the PTSMs expressed in the highest abundance in the Meg-01 cells, as
compared to H3k56ac and H3sIOph. In the platelet extracts, the histone PTSM expression
appeared to follow a similar trend as the Meg-01 cells, with both H3k56ac and H3s1Oph
appearing to be below the limit of detection (Figure 3-6 B). Here we have demonstrated that, in
addition to total H3, we can also detect specific PTSMs within platelets. At this point in time, we
cannot draw any conclusions as to what these specific PTSM patterns signify, as the histones
tested were 'total' histone extracts and were not specific for any gene sequence.
3.4.4 Sepsis results in increased platelet-associated histones
In order to evaluate whether platelet-associated histones were increased in patients with sepsis,
we performed imaging flow cytometry on isolated platelet pellets. The markers that were
evaluated included: CD34, which can either be increased if budding off of immature
megakaryoblasts or can be decreased if platelets are activated, Draq5' which may be present in
some platelets if platelet-formation results in DNA-containing platelets, as seen in Chapter 2
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(Video 2-4), His3, which we hypothesize to be increase in patients with sepsis, and Draq5'His3'
cells, which may indicate that His3 and DNA are bound together within the platelet. Platelets
were positively identified by gating for small CD41' (GPIIb) cells. Platelet analysis was also
further subdivided into 'single' platelets and 'clustered or aggregated' platelets. The reasoning
for this classification is because it is much more likely for platelets that are in aggregates to
express higher levels of activation markers, and possible different amounts of DNA or His3.
To account for the sample storage and preparation conditions of the patient platelets, which
included platelet isolation followed by storage at -800C, we first evaluated the effect of these
conditions on control platelets from healthy patients (Figure 3-7). When comparing the fresh
platelets to the freeze-thawed platelets, there were changes in cell surface marker expression, for
both single and clustered platelets, including: an increase in His3' platelets (plts) (1.8 0.6 and
28.9 1 1.7 % His3' plts vs. and 7.0 + 1.6 and 52.9 + 5.5 % His3+ plts, respectively), an increase
in CD34+ plts (2.0 + 1.8 and 28.9 + 1.7 % CD34+ plts vs. and 9.4 + 1.9 and 52.9 + 5.5 %
CD34+ plts, respectively), a decrease in Draq5+ plts (4.9 6.0 and 47.4 + 17.7 % Draq5' plts vs.
and 0.05 + 0.02 and 14.3 + 1.4 % Draq5' plts, respectively) and Draq5+His3+ plts (0.5 + 0.9 and
25.3 + 4.6 % Draq5+His3+ plts vs. and 0.02 + 0.01 and 13.9 + 1.3 % Draq5+His3+ plts,
respectively. There was also decrease in the percent of platelets that are within clusters or
aggregates (51.1 1 17.8 vs. 24.1 + 3.7 % Clusters, respectively). The same changes were seen in
the single and clustered groups, although to a greater extent in the clustered, likely due to
increased activation. At this point in time, we are not sure why CD34+ increased with freeze
thawing, as it has previously been shown to decrease with platelet activation; this may be due to
rupture of the platelet membrane upon thawing and increased exposure of internal CD34
resulting in increased CD34+ cells. Due to the differences in platelet phenotype with freeze-
thawing, we treated all controls to freeze-thawing and used those values as the negative control
to the sepsis patients; this would allow us to compare relative changes between groups.
As expected, patients with sepsis did have a different platelet phenotype than the control patients
(Figure 3-8). There were significantly more His3' plts in the sepsis group as compared to the
control group for both the single plts (27.1 20.6 and 7.0 + 1.6 % His3+ plts, respectively),
whereas there were significantly less His3+ plts the clustered platelets (27.3 13.4 and 52.9 + 5.5
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% His3' pits, respectively). There was no significant difference in Draq5' platelets in the sepsis
group as compared to the control group, for both single and clustered platelets (4.2 + 4.7 and
0.05 + 0.02 % Draq5' pits vs. 33.5 1 21.7 and 14.3 + 1.4 % Draq5+ pits, respectively).
CD34' platelets were significantly decreased in patients with sepsis as compared to controls, for
both single and clustered platelets (2.6 3.6 and 9.4 + 1.8 % CD34+ pits vs. 24.4 1 12.3 and 80.1
+ 2.4 % His3+ pits, respectively). Draq5+His3+ platelets were significantly increased in the single
platelets (0.8 + 0.8 and 0.02 + 0.01 % Draq5+His3 plts, respectively), but not in the clustered
platelets (14.2 + 8.2 and 13.9 + 1.3 % Draq5+His3+ pits). Notably, there was no significant
difference in the number of platelet clusters between control and sepsis patients (21.1 + 11.5 and
24.1 + 3.7 % Clustered pits, respectively), further supporting that the changes in the platelet
phenotype are not simply due to increase platelet activation and aggregation. There was no
correlation between platelet phenotype and platelet count or total white blood cell count.
Interestingly, His3+ platelets in sepsis patients also appeared to have two different populations, a
His3lo and a His3hi population; these two populations were not seen in the control groups (Figure
3-8 E). His3+ cells also appeared to be at higher levels in patients diagnosed with Gram positive
bacterial infections, as compared to gram - infections (Figure 3-8 F).
Changes in platelet phenotype were also explored over time in patients with sepsis (Figure 3-9).
Nine patients were followed on sequential days during hospitalization and it was noted that His3'
platelets were significantly higher during early sepsis than on subsequent days in six of the
patients (Fig 9A). There were two patients that did not follow this trend: patient 2, which was
diagnosed with sepsis but by the time the blood sample was collected, the urine culture was
negative (who was subsequently not included in analysis), and patients 11 and 12, which were
both diagnosed with chronic sepsis, were under 'palliative care', had been in and out of the
hospital for weeks-months prior to sample collection, and did not recover from this event. The
platelet phenotype was also different for both Gram positive and mixed infections, with a mixed
infection being defined as at least 2 or more of the following: Gram negative bacteria, Gram
positive bacteria, fungal organism, viral organism (Fig 9B-F). Cumulatively, these results
suggest that, in addition to increased platelet activation, as noted by decreases in CD34'
platelets, there was an increased number of platelets that had associated DNA (Draq5) and His3.
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3.5 Discussion
Histones are an essential building block for nuclear material, helping form chromatin and acting
as control switches for the transcription of DNA. In addition to their essential role in
transcriptional regulation, histones also have important roles outside of the nucleus, including
serving as damage-associated molecular patterns (DAMPs). (Xu Z, 2015; Miki T, 2015) When
histones are outside of the cell, they bind to a number of different receptors on white blood cells
and platelets, such as toll-like receptor 2 and 4 (TLR2 and TLR4). (Chaput C, 2009; Silk E,
2017; Russell RT, 2017; Semeraro F, 2011) Extracellular histones are typically degraded by a
variety of enzymes, such as histone deacetylases (HDACs); but when they are significantly
increased they can bind and activate the surrounding cells and may result in white blood cell
activation, platelet activation, and endothelial cell damage. (Eckaney ML, 2014) Extracellular
histones can be significantly increased during sepsis and are thought to play an integral role in
the pathophysiology of severe systemic inflammation and immunothrombosis. (Li Y, 2009;
Eckaney ML, 2014; Garcia-Gimenez JL, 2017; Kim JE, 2015; Kimball AS, 2016) Experimental
treatment with TLR4 receptor inhibitors and HDACs in animal models of sepsis have helped
support this mechanistic hypothesis. (Savva A, 2013; Fenhammer J, 2014; Ciarlo E, 2013;
Takebe M, 2014; Li Y, 2015; Li Y, 2014) Up until now, platelets have been shown to bind
extracellular histones through TLR2 and TLR4 receptors and also liberate histones from bound
DNA through the release of highly positively charged platelet factor 4 (PF4), but platelets have
not been explored as a potential source of extracellular histones themselves. (Semeraro F, 2011;
Gollomp K, 2015) In this paper, we demonstrated that megakaryocytes (MKs) commonly
contain extranuclear histones, and that that the 'parent' MKs may transmit these histones to their
'daughter' platelets, resulting in an additional source of extracellular histones during severe
inflammation and platelet activation, such as in sepsis. We also demonstrated that patients with
sepsis appear to have increased platelet-associated histones.
Although histones are most commonly located within the nucleus of a cell, extranuclear histones
have been demonstrated in a variety of cells and in a number of conditions. The role histones
outside of the nucleus is not completely clear, but they have been shown to be extremely
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proinflammatory and even prothrombotic. (Chen R, 2014; Parseghian MH, 2015; Xu Z, 2015;
Miki T, 2015) There are a number of mechanisms by which histones can be found outside of the
nucleus, including extracellular trap formation, apoptosis, via escape or leakage through nuclear
membrane pores, and as a functional protein within the mitochondrial membrane. (Chen R, 2014;
Fuchs TA, 2007; Gabler C, 2004; Zhao B, 2016) As hematopoietic stem cells (HSCs)
differentiate into MKs and mature into platelet-producing cells, they typically undergo controlled
apoptosis (Discussed in more detail in Section 1.2, 'Platelet production'). (Kile BT, 2014;
Joseffson EC, 2011; Li J, 2001; Kozuma Y, 2009; Clarke MCH, 2003; De Bottom S, 2002)
During this, typically, caspase-mediated apoptosis, it is not surprising that MKs likely develop
nuclear membrane pores, where intranuclear material, such as histones, can leak out into the
cytoplasm. (Gabler C, 2004; Zhao B, 2016; Gabler C, 2003) In this paper, we have demonstrated
that MKs do in fact commonly contain histones in both their cytoplasm and along their cell
membrane. The exact role of the histones in these compartments of cells is not currently
understood.
Platelets are organized buds composed of MK cell membrane and cytoplasmic material;
therefore, it is not out of the question for extranuclear histones within the cell membrane and
cytoplasm of the MK to be a part of the resultant platelet (Figure 3-10). Platelets have been
shown to bind to extracellular histones via TLR receptors, potentially playing a role in the
proinflammatory and prothrombotic nature of extracellular histones during sepsis and its' related
complications. (Xu Z, 2015; Semeraro F, 2011; Semple JW, 2011) Up until now, platelets have
not been explored as potential sources of histones themselves. One paper by Stewart D.I.H., et al.
(1983), did show that protein isolation of platelet pellets contained small concentrations of
histone proteins, but at the time this was attributed to likely contamination of the platelet pellet
with nucleated white blood cells and was disregarded. (Stewart DIH, 1983) Although we were
able to confirm these findings through histone purification and quantitation, there is always the
possibility that there were contaminating nucleated cells within our platelet pellets as well. More
suggestive proof of platelet-associated histones was demonstrated by showing that platelets stain
positive for H4 in both the cytoplasm as well as the cell membrane on electron microscopy.
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We next explored whether there was an association between the presence of platelet-associated
histones and sepsis. Our results demonstrated that there was an increase in His3' platelets, as
well as an increase in Draq5' platelets and Draq5'/His3' platelets. Although this is suggestive
that there may be an increase in platelet-associated histone and DNA content during sepsis, we
cannot rule out that the histones and platelets were not just bound to the platelet membrane from
the circulation, as plasma histones and DNA are known to be increased during sepsis. (Xu Z,
2015; Gould TJ, 2015) There was also a significant decrease in CD34' platelets, which is
suggestive of platelet activation, although platelet clusters, another sign of platelet activation,
was not increased in sepsis patients. (Lewandoaska K, 2003) Interestingly, this unique phenotype
lacking platelet aggregation but having an increase in platelet activation is consistent with
previous research demonstrating that platelets from patients with sepsis are more likely to
spontaneously activate but are less likely to aggregate in response to various platelet agonists.
(Hurley SM, 2016; Layois N, 2017; Woth G, 2011; Davies GR, 2014) This unique platelet
phenotype was also observed to revert to 'normal' over time as a patient was treated for sepsis,
suggesting that this may also be an early indicator of sepsis. The increase in platelet-associated
histones may also be another mechanism by which platelets form platelet-leukocyte aggregates
(PLAs) and are increasingly cleared or sequestered, leading to peripheral thrombocytopenia; both
of which are known consequences of sepsis. (Gabler C, 2003; Grozovsky R, 2010; Ma R, 2017;
Rondina MT, 2015; Tejera P, 2017)
In conclusion, this set of experiments has demonstrated that platelets may contain extranuclear
histones, and that platelet-associated histones are increased in patients with sepsis. Due to the
small concentration of platelet histones that we identified, we do not think that platelets are a
primary source of plasma histones during sepsis; although, when platelets are activated, whether
the histones are released or whether they are brought to the plasma membrane, these may be
stimulatory enough to propagate intravascular inflammation and thrombosis (Figure 3-11).
Future studies to further explore this potential source of extracellular histones during sepsis
includes testing platelets for histone release upon activation and testing the platelet-associated
histones for their proinflammatory and prothrombotic properties. Additionally, because platelets
appear to have various H3 PTSMs, testing whether these are bound to DNA or whether the
175
different histone PTSMs have specific interactions with the immune and coagulation system, as
seen with CitH3, would also potentially be very valuable.
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Figure 3-1: Megakaryocytes have extranuclear histones.
Immunofluorescent images of megakaryocytes demonstrating extranuclear localization of PhosphoH3
(Ser28) histones. (A) Meg-0l cells are observed to have histone staining throughout the cell, including the
cell membrane and cytoplasm. Perneabilized Meg-01 cells (iia-c) demonstrate strong nuclear staining,
specifically in cells with mitotic figures, such as those shown in the bottom left panel (iii). (B) CB MKs at
day 10 of differentiation were fixed, permeabilized prior to staining and imaging. Cells on the bottom left
panel (ii) appear to be quiescent and round, while the cell on the bottom right panel (iii) has much
stronger histone staining and what appears to be pseudopods or proplatelet buds that stain positive for
histones. (C) CB MKs (i) and Meg-Ol cells (ii) were co-incubated for 1 hour with 3 pg/mL and 30 pg/mL
E. coli LPS, respectively. The cells were then fixed, permeabilized, stained and imaged. The top right
panel (ii) is representative of cells that were observed to have a break in the cell membrane and release
extracellular DNA and histones, likely forming extracellular traps. The bottom right panel appears to be a
cell extending histone-positive proplatelet buds (iii).
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Figure 3-2: GFP-H2B expressing Meg-01 cells have extranuclear histones.
Meg-01 cells were transfected with GFP-Histone 2B (H2B) BacMam to explore the cellular localization
of H2B in megakaryocytes. (A) H2B was mostly observed to be restricted to the nucleus within Meg-O I
cells (i); although, occasionally cells were noted to have some extranuclear histones, such as the cells in
the panel on the right (ii). (B) Cells were co-incubated with MitoSox red in order to show the cytoplasmic
location of metabolically active mitochondria. While H2B was normally within the nucleus and within the
boundaries of the cell membrane, isolated platelet-like particles with H2B expression were noted as well
(ii).
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Figure 3-3: Immunofluorescent images of platelet-associated histones.
Immunofluorescent images of white blood cells and platelets confirm the presence of platelet-associated
histones. (A) Isolated human neutrophils were used as a positive control to demonstrate the specificity of
the PhosphoH3 (Ser28) antibody to the nucleus of the cell. A close-up of this image is seen on the right
(ii). (B) Platelet-rich plasma was fixed, permeabilized, and probed for the presence of Ser28 and showed
positive staining both within white blood cells (ii) and platelets (iii). Notably, it appeared that the CD41
platelet staining was towards the center of the platelets, while the Ser28 staining was concentrated around
the periphery. (C) Platelet pellets were further probed with anti-Histone 3 (i) and anti-Histone 4 (ii)
antibodies, which both stained positive for white blood cells and platelets, as seen in the close up of the
anti-Histone 4 composite image on the lower right panel (iii). White blood cell, white arrowhead;
Platelets, yellow arrowhead.
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Figure 3-4: Imaging flow cytometry shows platelet-associated histones.
Flow cytometry was used to probe for histones in platelets. (A) Histone 3 appeared to be present around
the platelet membrane in the non-permeabilized cells (i) and throughout the cell in the permeabilized cells
(ii). A white blood cell used as an internal control has histone 3 nuclear staining (iii). (B) Phospho3
(Ser28) did not stain the non-permeabilized cells (i), but did stain the permeabilized cells (ii). A white
blood cell did stain positive for nuclear Phospho3 (Ser28) (iii). Yellow box is around the histone-stain
channel.
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Figure 3-5: Transmission electron microscopy and immuno-gold labeling of platelet
histones.
Cells were immuno-gold labeled with anti-histone 4 antibodies and then imaged with transmission
electron microscopy. (A-B) Platelets are shown to label positive for histone 4 in their cytoplasm as well as
on their cell membrane. Magnified images are shown in the bottom panels (Aii and Bii). (C) HT-29 cells
were also immuno-labeled and imaged as a positive control and showed nuclear labeling of histone 4.
Magnification of the nuclear envelope with labeling is shown on the bottom panel (Cii). Red arrows point
towards immuno-gold particles (6nm).
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Figure 3-6: Histone quantification using bead-based ELISA assays.
Histones extracted and purified from Meg-Ol cells and platelet pellets were quantified. (A) Meg-01 cell
histone-extract serial dilutions were run on the ELISA assay. His3 concentration based on absorbance
measurements were used to extrapolate the histone concentration input (ng/uL) in each dilution. These
concentrations were then plotted against the mean fluorescence intensity (MFI) reading from the ELISA
assay. The points were then fit with a logarithmic best-fit line, which has an R value of >0.99. (B) The
Meg-01 and platelet histone extracts were also assessed for various H3 PTSMs. These are expressed in
terms of % of total H3 based on MFI readings. MI, Meg-Ol at a 1:250 dilution; M2, Meg-01 at a 1:500
dilution; M3, Meg-OI at a 1:1000 dilution; M4, Meg-Ol at a 1:2000 dilution; P1, Platelet at a 1:25
dilution; P2, Platelet at a 1:50 dilution.
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Figure 3-7: Flow cytometry comparison of fresh versus freeze-thawed platelets.
Flow cytometry was performed on both fresh and freeze-thawed platelets, in order to control for the
effects of storage conditions on the patient platelet analysis. (A-F) Representative scatter plots of flow
cytometry results comparing fresh platelets (i) and freeze-thawed platelets (ii). (G-K) Scatter plots with
mean and standard error bars comparing fresh compared to freeze-thawed platelets for both single
platelets (i) and clustered platelets (ii). Student unpaired t-test was performed, with significance defined
as p < 0.05 according to a paired student t-test for all samples. d, Draq5; h, His3.
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Figure 3-8: Flow cytometry analysis of platelets from patients diagnosed with sepsis.
Flow cytometry was performed in order to explore the platelet phenotype of (A-F) Representative scatter
plots of flow cytometry results comparing control patients (i) and sepsis patients (ii). A magnified
example of single platelet-associated His3 signal is represented for both the control patient (Eiii) and the
sepsis patient (Eiv) (G-K) Scatter plots with mean and standard error bars comparing fresh compared to
freeze-thawed platelets for both single platelets (i) and clustered platelets (ii). Student unpaired t-test was
performed, with significance defined as p <0.05 according to a paired student t-test for all samples. d,
Draq5; h, His3.
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Figure 3- 9: Platelet phenotype is associated with type of infection.
Flow cytometry was performed to evaluate platelet phenotype from patients diagnosed with sepsis. (A)
Platelet were evaluated on multiple days of hospitalization. His3' platelets appeared to be highest in
patients with acute sepsis and on day 1 of evaluation and decreased as the patient was treated
(P1,2,3,6,7,8,9). Patients with chronic sepsis that had been in the hospital for a prolonged period did not
have the same changes in His3' platelets and these patients did not recover. (B-F) Platelet phenotype was
also compared for patients with different types of infection: Gram positive, Gram negative, or Mixed.
Single platelets (i) and clustered platelets (ii) were evaluated. One-way ANOVA testing was performed
comparing the type of infection to the control group, with significance being defined as p < 0.05 (*).
Statistics were not performed on the Gram - group as there was only one patient in this group.
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Figure 3-10: Megakaryocytes contain extranuclear histones, which are passed on to
platelets.
The proposed mechanism for the development of platelet-associated histones. A mononuclear
hematopoietic stem cell (HSC) differentiates into a megakaryoblast and undergoes endomitoses to form
multiple nuclei. The nuclei (purple) contain various intranuclear histones (green circles). Once
differentiation is complete and a mature megakaryocyte is made, the cell begins undergoing a controlled
apoptosis, where the nuclear membrane develops pores and histones begin to leak into the cytoplasmic
compartment. Upon the formation of proplatelet buds, the cytoplasmic and cell membrane-associated
histones are also packed into the resultant platelets. The histones can be present in histones either
primarily bound to the cell membrane (1), primarily within the cytoplasm (2), or a combination of the 1
and 2, where platelet activation results in the increased expression of histones on the cell membrane and
possible release into the environment accompanied by degranulation.
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Figure 3-11: Potential sequela of platelet-associated histones
Platelet-associated histones can affect the inflammation and coagulation system via various mechanisms.
Platelets (light blue polygons) can either release extracellular histones (green circles) upon stimulation or
express them on their cell membranes. The release of extracellular histones (top left) can result in direct
cytotoxicity of endothelial and epithelial cells (dark blue rectangles), resulting in both, increased vascular
permeability, and a prothrombotic surface. The binding of both platelet-associated histones and
extracellular histones to leukocytes (orange circle) (top middle) can result in the development of platelet-
leukocyte aggregates (PLAs), as well as stimulate the cell to increase production and release
proinflammatory cytokines (purple stars). These PLAs can then either diapedese across the endothelium
or escape through the increase endothelial permeability into extravascular tissue (bottom middle) and
further propagate inflammation. Thrombosis can be initiated and propagated through various mechanisms
(right), where platelet-associated histones can bind to each other through TLR receptors (top right) which
results in subsequent activation and an increase in thrombin generation and release (purple circles).
Extracellular histones are also themselves, prothrombotic and anti-fibrinolytic, promoting thrombosis.
Tables:
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Table 3-1: Histone protein measurement.
Histone MW (kDa) E/1000
Histone 2A 13.960 4.05
Histone 2B 13.774 6.07
Histone 3 15.273 4.04
Histone 4 11.236 5.40
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Table 3-2: Histone post-translational modifications
Histone Modification Residue Modification Functions
H3k4me3 Lys4 Tri-methylation Euchromatin,
transcriptional
activation
H3k56ac Lys56 Acetylation DNA damage repair,
chromatin assembly
H3s1Oph SerlO Phosphorlyation Mitosis, immediate
early gene activation
H3k27me3 Lys27 Tri-methylation Transcriptional silencing
H3s28ph Ser28 Phosphorylation T Mitosis
Cit H3 N/A Citrullination Catalyzed by PAD4
H2A.X N/A N/A DNA damage repair,
response to double
strand DNA breaks
192
Table 3-3: Patient descriptive statistics
Patient Signalment Infectious Agent Source of Bacterial
ID (sex/age) Infection Classification
1 F/82 - idesiella pneumoniae 
-Urine Mixed
- Influenza
2 M/36 - Pseudomonas aeruginosa 
- Urine Gram negative
3 M/67 - Enterococcus faecalls 
- Lungs Mixed
- Staphylococcus aureus 
- Lungs
- Streptococcus pneumonlae - Lungs
- Yeast 
- Lungs
4 M/73 - Pseudomonas aeruginosa 
- Lungs and Mixed
- Enterococcusfaecium Urine
- Yeast -Lungs
- Lungs
5 M/85 - Enterococcusfaecfum 
- Wound Mixed
- Coagulase-negative Staphylococcus - Lungs
- Candida albicans - Wound
- Yeast 
-Lungs
6 M/49 - P-hemolytic Streptococcus A - Lungs Mixed
- Staphylococcus aureus - Lungs
- Enterococcus faecium 
- Lungs
- Aspergillusfumigatus 
- Lungs
- Yeast
7 M/61 - Streptococcus pneumoniae 
- Lungs Mixed
- Multi-drug resistant Staphylococcus aureus - Lungs
- influenza
8 M/71 - Enterococcusfaecalis 
- Blood Mixed
- Enterobacter aerogenes 
- Lungs
- Corynebacterium 
- Lungs
9 M/62 - Multi-drug resistant Staphylococcus aureus - Blood Mixed
- Enterobacter aerogenes - Blood
10 M/61 
- Staphylococcus aureus - Lungs Gram positive
11 M/77 -Streptococcus Intbriedlus 
- Pleural fluid Gram negative
12 M/59 - Klebsiella pneumoniae - Blood and Mixed
- Proteus mirabilis Lungs
- Enterococcus - Blood
- Blood
13 F/76 - Metapneumovirus - N/A Mixed
- No positive bacterial cultures
14 F/73 - Escherichia coll 
- Blood and Mixed
- Staphylococcus epidermidis Urine
- Blood
15 F/67 - Escherlchia cofl 
- Blood and Mixed
- Staphylococcus epidermidis Urine
- Blood
16 M/81 - Enterococcusfaecalis 
- Blood Gram positive
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Table 3-4: Histone protein quantification
Sample Total Protein Total Protein' H2A2  H2B3  H34  H45
(OD)1  (mg/mL) (mg/mL) (mg/mL) (mg/mL) (mg/mi)
Calf thymus 0.577 10.356 2.81 1.8 3.3 1.84
Meg-01 cells 2.977 7.07 1.76 1.4 2 1.12
Platelet 1 0.074 0.18 0.27 0.62 0.44 0.18
Platelet 2 0.064 0.15 0.36 0.18 0.34 0.29
1.
2.
3.
4.
5.
6.
7.
230 nm
280 nm; MW (kDa), 13.960; E/1000, 4.05
280 nm; MW (kDa), 13.774; E/1000, 6.07
280 nm; MW (kDa), 15.273; E/1000, 4.04
280 nm; MW (kDa), 11.236; E/1000, 5.40
Expected concentration is 10 mg/mL total histones
Sample diluted 1:10
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Table 3-5: Histone post-translational modification quantification
Sample Total H3 1  H3k4me31  H3k56acl H3slOphl H3k27me3I
Positive Contr612(1:25) 3278.5 3360 2006 2170 2196
Bla nk 18 9 13 14 10
Meg-Ol (1:250) 1760 401 185 296.5 598
Meg-Ol (1:500) 1354 175.5 66 108 315
Meg-01 (1:1000) 60.5 27
Meg-O4 (1:2000) 35 16 24 92
Platelet (1:25) 108 23.510 3516 15 28
Platelet (1:50) 62 15.5 14 12 21
1. All measurements are provided as MFI (mean fluorescent intensity), with the exception of the LOD row.
2. Positive control of HeLa cell extract, estimated to be 0.5 mg/mL total protein; information provided by Active
Motif.
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Table 3-6: Histone post-translational modification percentages
Sample Total H3 1  H3k4me32  H3k56ac2  H3s1Oph2  H3k27me3 2
Meg-Ol (1:250) 200.0 / 1970.9 22.5 9.9 16.2 33.8
Meg-Ol (1:500)
_______(1:500) 100.0 / 2046.7 12.5 4.0 7.0 22.8
Meg- (1 0 50.0 / 1995.8 5.8 1.6 3.3 15.9
Meg-Ol (1:2000)
25.0 / 1987.4 5.7 0.7 2.2 17.9
Platelet (1:25) 13.75 / 0.463 16.1 3.3 1.1 20.0
Platelet (1:50) 12.75 / 0.423 14.8 2.3 
-4.5 25.0
LOD4
2 30 7.8 8 3
1. Total input per well in ng / Concentration in units of ng/uL of stock protein
2. % of total H3 based on MFI
3. LOD, Limit of detection. Based on purified histones input. Total ng input.
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Chapter 4
Development of Microfluidic Device for the In Vitro
Exploration of the Platelet-Neutrophil Interaction at a Single-
Cell Level
As published in:
Frydman GH, Anna Le, Ellet F, Jorgensen J, Fox JG, Tompkins RG, Irimia D. Technical
Advance: Changes in neutrophil migration patterns upon contact with platelets in a
microfluidic device. J Leukoc Biol, 2017; 101(3):797-806.
4.1 Abstract
Neutrophils are traditionally regarded as the "first responders" of the immune system. However,
recent observations revealed that platelets often respond earlier to recruit and activate neutrophils
within sites of injury and inflammation. Currently, platelet-neutrophil interactions are studied by
intravital microscopy. Although such studies provide exceptional, physiologic in vivo data, they
are also laborious and have low throughput. To accelerate platelet-neutrophil interaction studies,
we have developed and optimized an ex vivo microfluidic platform with which the interactions
between platelets and moving neutrophils are measured at single-cell level in precise conditions
and with high throughput. With the use of this new assay, we have evaluated changes in neutrophil
motility upon direct contact with platelets. Motility changes include longer distances traveled,
frequent changes in direction, and faster neutrophil velocities compared with a standard motility
response to chemoattractant fMLP. We also found that the neutrophil- platelet direct interactions
are transient and mediated by CD62P-CD 162 interactions, localized predominantly at the uropod
of moving neutrophils. This "crawling," oscillatory neutrophil behavior upon platelet contact is
consistent with previous in vivo studies and validates the use of this new test for the exploration
of this interactive relationship.
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4.2 Introduction
Activation of the acute innate immune response is complex, consisting of both cellular and soluble
components. In tissue injury and infection, neutrophils were long thought to be the first and most
robust responders, being recruited by both the pathogenic stimulus and the tissue resident cells.
(Kim ND, 2015; Kumar V, 2010) Platelets are increasingly recognized as key players in the innate
immune responses, being activated by tissue injury and several infections before neutrophils and
subsequently, recruiting and activating them. (Engelman B, 2013; Semple JW, 2010;
Sreeramkumar V, 2014) Platelets can be activated in hundreds of milliseconds, faster than
neutrophils activate. (Frojmovic MM, 1999) Platelet adhesion to pathogens or injured vessel walls
results in platelet activation and has been described to facilitate binding to neutrophils, the release
of neutrophil chemotactic substances, and the formation of neutrophil extracellular traps.
(Engelman B, 2013; Ghasemzadeh M, 2013; Hurley SM, 2015; Kim KH, 2013)
In this study, we optimized and validated a microfluidic platform that enabled us to examine
platelet-neutrophil interactions ex vivo with single-cell resolution. We found that upon contact
with PRPt, neutrophils migrate spontaneously in the absence of chemoattractant gradients.
Neutrophils appear to associate and dissociate frequently from platelets during migration, and the
interactions are mediated by CD62P. In straight channels, neutrophils move in an oscillatory
pattern between platelets, similar to the crawling behavior described in vivo. (Sreerkumar V, 2014)
4.3 Materials and Methods
4.3.1 Platelet preparation
Blood was collected from healthy volunteers in accordance with Institutional Review Board
protocols (2009-P-000295). Platelets were prepared from blood collected into 2.9 ml trisodium
citrate Vacutainer tubes (Sarstedt, N*umbrecht, Germany). PRPt was prepared by centrifugation
of the whole blood at 210 g, 22'C, for 20 min. The PRPt supernatant was gently pipetted into 2
tubes. In 1 tube, 20% vol ACD solution (Boston Bioproducts, Ashland, MA, USA) was added, and
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the PRPt was incubated at 370C until the start of the experiment. The second tube was centrifuged
at 1900 g, 22'C, for 10 min. The PPP was removed, leaving a platelet pellet. IMDM buffer with
20% FBS was used to resuspend the platelet pellet, and ACD was added to the PPP and the platelet
suspension. Platelet cell membrane was stained with 1:1000 calcein green (Thermo Fisher
Scientific, Waltham, MA, USA). Total platelet count was performed on all samples, with
acceptable purity defined as ,2% WBC or RBC contaminant. PPP acellularity (,2%) was also
verified using a hemocytometer. The PRP platelet count ranged from 25 to 45 3 109 platelets/ml,
whereas the WP count ranged from 15 to 25 3 109 platelets/ml; decreased platelet count in WP
was most likely a result of platelet loss during the washing step. All plasma preparations were kept
at 370 C until the start of the experiment.
4.3.2 Neutrophil isolation
Blood was collected in ACD BD Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ, USA).
Neutrophils were isolated from whole blood using a negative-selection protocol, as previously
described [10]. In brief, neutrophils were isolated using a density gradient with HetaSep (Stemcell
Technologies, Vancouver, BC, Canada) and then purified with EasySep Human Neutrophil Kit
(Stemcell Technologies), following the manufacturer's protocol. Neutrophil purity was assessed
to be .98%, and cell count was performed using a hemocytometer. Neutrophils were subsequently
resuspended in IMDM with 20% FBS (Thermo Fisher Scientific) for a total neutrophil
concentration of 5-6 3 106 cells/ml. The cellular nucleic acid was stained with 1:2000 Hoechst
Dye 33342 (Thermo Fisher Scientific) for 20 min, followed by I wash step. For experiments that
evaluated the effect of blocking CD162, neutrophils were also stained with 1:200 mouse
antihuman CD162 (clone KPL1; BioLegend, San Diego, CA, USA) for 20 min, followed by 1
wash step. Samples were processed within 1 h of blood draw and were maintained at 370 C.
4.3.3 Design and fabrication of the microfluidic devices
The microfluidic devices were manufactured using standard microfabrication techniques. In brief,
a 2-layer photoresist design (SU-8; MicroChem, Newton, MA, USA), with a first and second layer
(3 and 50 mm thick, respectively), was patterned on 1 silicon wafer via sequentially aligned
photolithography masks and processing cycles, according to the manufacturer's protocols. The
resulting patterned wafer was then used as a mold to produce PDMS (Thermo Fisher Scientific)
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devices, which were subsequently, irreversibly bonded to glass slides (1 3 3 in.; Thermo Fisher
Scientific). Gradients were generated between an array of orthogonal side channels (6 mm width,
800 mm height), primed with the chemoattractant and serving as the source (of chemoattractant),
and a central channel (500 mm width, 50 mm height), serving as the sink (Figure 4-1 A).
4.3.4 Priming and loading the microfluidic devices
The microfluidic devices were loaded with various solutions uniformly or used to generate
chemical gradients, as previously described. (Jones CN, 2014; Butler KL, 2010) To generate
gradients, a 2-step process was involved. The microfluidic devices were primed with various
solutions: media (negative control), fMLP (100 nM, positive control), PRPt, PPP, or WP. Because
the side channels are closed at the distal end, when the main channel is washed with media, a linear
gradient is formed along the length of the side channel (Figure 4-1 B). To load a device, a 1 ml
syringe filled with solution was connected to 1 port of the device and the solution pushed through
the main channel, and then the outlet port was clamped off. With the application of steady pressure
to the syringe, the solution was infused into the device, displacing the air into the PDMS. Once the
solution was infused, the neutrophils were loaded into the main channel of the device and allowed
to settle by clamping off both ports of the device.
4.3.5 Neutrophil motility analysis
Neutrophil migration was recorded, starting within 15 min of neutrophil loading, using time-lapse
imaging on a fully automated Nikon Ti-E microscope with the biochamber at 37'C and 80%
humidity and in the presence of 5% carbon dioxide gas. Images of the neutrophils were acquired
automatically, every 2.5-3.5 min for up to 2 h, from at least 5 distinct locations on each of 4
microfluidic devices run in parallel in the same experiment. ImageJ manual tracking software (U.S.
National Institutes of Health, Bethesda, MD, USA) was used for the analysis of neutrophil
migration and behavior. Previous reports showed that when neutrophils are mechanically confined
to the smaller side channels during migration, the cell trajectories and velocities can be measured
more easily and with higher precision than any of the current assays. (Jones CN, 2014)
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4.3.6 Platelet-neutrophil interactions
Platelet-neutrophil interactions were analyzed using multiple parameters. For each side channel
in which there was neutrophil migration, the total number of platelets within the channel was
counted; this included platelets that were attached to neutrophils as they entered from the main
channel. Neutrophils traveling in channels containing no platelets were not included in statistical
analyses for platelet interactions. Neutrophil-platelet interactions were categorized as "arrested"
or "carrying." Arrested contact involved a migrating neutrophil stopping at the position of the
platelet, in contact with the platelet, for one time-frame (i.e., at least 2.5 min; Figure 4-2A). Platelet
carrying occurred when neutrophils and platelets moved together through the channel for at least
one time-frame (Figure 4-2 B). The platelet-neutrophil interaction was further categorized by the
number of times that a neutrophil carried a platelet, the total distance it carried the platelet, and the
duration of time a platelet was carried. The mean and SD of each of these conditions were
calculated for all groups that had contact with platelets, and Student's 2-tailed t-tests were carried
out to compare the behavior of the PRPc with the PRPn.
4.3.7 Flow cytometry
Phlebotomy was performed with a 24-gauge butterfly needle, and blood was collected into an 8.5
ml ACD BD Vacutainer tube (Becton Dickinson). Isolated neutrophils were stained with 1:200
mouse anti-human CD162 antibodies (clone KPL1; BioLegend) and incubated with PRP. For the
negative control, neutrophils were neither stained with anti-CD162 nor incubated with PRP. For
the positive control, neutrophils were not stained with anti-CD 162 and were incubated with PRP.
All samples were stained with 1:200 mouse anti-human CD66b (clone G1OF5; BD Biosciences,
San Jose, CA, USA) and 1:200 mouse anti-human CD41 (clone HIP8; BioLegend) markers. Data
were obtained through the Amnis ImageStreamX Mark II imaging flow cytometer and INSPIRE
software (EMD Millipore, Billerica, MA, USA). The accompanying IDEAS software (EMD
Millipore) was used to perform data analysis.
4.3.8 Statistical analysis
For determination of the neutrophil phenotype upon interaction with platelets, all cells in each
condition (fMLP, PRPt, PPP, and WP) were manually tracked, and the total distance traveled, time
spent in a side channel, and average velocity were calculated for each individual neutrophil.
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Histograms were prepared for all conditions and the skewness, intermediate quartile range, and
95% Cl were reported. The number of directional changes a neutrophil made within a channel
described neutrophil oscillatory behavior. A change in directionality was defined as when a
neutrophil traveled for a minimum of 50 mm in one direction after a turn. Changes in direction
were calculated for each neutrophil in all conditions. Arrested contact with a platelet was defined
as a neutrophil stopping and interacting with a platelet for one time frame (2-3.5 min) and traveling
a distance of ,50 mm in any direction. The mean and SD for each condition was calculated and
compared across conditions (fMLP, PRPt, PRPc, PRPn, PPP, and WP) using Student's 2tailed t
tests, with P < 0.05 considered significant. The experiment was performed for a total of 5 biologic
replicates for interdonor comparison. Four intradonor samples were compared and were not found
to be significantly different. The same analysis was performed on the samples that were blocked
with anti-CD162 antibody, and this was performed on 3 biologic replicates. Statistical analysis
was performed using Excel (Microsoft, Redmond, WA, USA).
The flow cytometry experiments to determine the effectiveness of the antiCD162 antibody were
conducted on 3 biologic replicates. Each neutrophil that had a platelet attached was defined as a
PLA. The percentage of PLAs in each was calculated, and the number of neutrophils that were
determined to be PLAs was compared between experimental conditions. The percent of "PLA
inhibition" was determined by calculating the difference in the percent of PLAs formed with and
without anti-CD 162 antibody. Statistical analysis was performed using Excel (Microsoft)
4.4 Results
4.4.1 Spontaneous migration of neutrophils in the absence of chemoattractant
Spontaneous neutrophil migration into the side channels occurred in the absence of a
chemoattractant. Surprisingly, neutrophils migrated into the side channels for both the PRPt and
PPP (231 and 182 total neutrophils, respectively), equivalent to the migration of neutrophils
when exposed to fMLP (201 total neutrophils). Neutrophil migration in the WP was rare (18 total
neutrophils). Interestingly, the average velocity of the migrating neutrophils in the PRPt and PPP
was, 28.4 + 5.8 lim/min and 29.5 5.8 pm/min respectively, as compared to the fMLP, 19.5 +
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9.1 ptm/min (Table 4-1). Evaluating the representative histogram curves of average velocity for
all conditions, the neutrophils in fMLP were clustered on the left, while the neutrophils in PRPt
and PPP were clustered towards the right (Figure 4-3 and Table 4-2). This implies that PRPt and
PPP stimulation of neutrophils results in neutrophils moving at higher velocities than those
stimulated by fMLP. This phenomenon is not seen with platelets without the plasma component
(WP). This is notable, as fMLP is one of the most potent neutrophil chemoattractants currently
known (12).
This data suggests that there are factors within the plasma that result in spontaneous neutrophil
migration. These soluble factors may include: exosomes; microparticles; members of the
coagulation and fibrinolysis cascade; complement, or the leukotriene family. (Boneschansker L,
2014; Nakagawa H, 1993; Patrick RA, 1980; Paegelow I, 2002; Schuliga M, 2015) The
discovery and analysis of plasma factors that may stimulate neutrophils is beyond the scope of
this paper, but is important and should be pursued in future studies. Additionally, although there
are minimal platelets in PPP, and spontaneous chemotaxis is seen in the PRPt without direct
contact with platelets, there may be platelet activation during both processing of the plasma, as
well as the plasma loading into the microfluidic device. This may result in a number of factors
being released by the platelets, including microparticles and exosomes; many of which have been
shown to result in neutrophil activation. (Yanez-Mo M, 2015) The lack of spontaneous migration
observed in the WP group provides a useful negative control for presence of ACD, and suggests
that if platelet activation is responsible for neutrophil migration, additional plasma-derived
components must also be required to stimulate this activity.
4.4.2 Frequent directional changes by neutrophils after interaction with platelets
Neutrophils in PRPt changed directions in the side channels more frequently than those in PPP or
in fMLP (Figure 4-4). Plotting of representative neutrophil velocities versus time showed a clear
phenotypic difference between PRPt, PPP, and tMLP (Figure 4-4 B-D). Additionally,
neutrophils that came into contact with a platelet often displayed an oscillatory behavior,
switching directions within the side channel at a higher rate than those without platelet contact
(Figure 4-5 A, Table 4-1). The majority neutrophils in fMLP and WP changed directions only
once (68.7% and 76.5%, respectively) and usually at the end of the channels, as reported
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previously (14) (Figure 4-5 A, Table 4-1, and Video 4-1). By comparison, a large proportion of
neutrophils in PRPt and PPP changed in direction 3 or more times (34.6% and 25.3%,
respectively) (Figure 4-5 A, Table 1, and Video 4-2). The difference in proportions of
neutrophils changing directions 3 or more times was statistically significant between fMLP and
PRPt (p-value <0.01) (Table 4-3). This data shows that there is a unique oscillatory phenotype
present in neutrophils when exposed to PRP and PPP, as opposed to WP and fMLP. The PRPc
neutrophils made significantly more directional changes in the side channel than the PRPn
neutrophils (50.6% and 25.7% respectively, p-value <0.01), and this was in the absence of any
exogenous chemoattractant (Table 4-1 and 4-2). This oscillatory behavior seen in neutrophils
exposed to plasma, and exacerbated by direct contact with platelets, is similar to the 'crawling'
behavior observed in vivo (5).
4.4.3 Time and distance traveled by neutrophils after interactions with platelets
The time spent in the channel by neutrophils also revealed differences between neutrophil
migration patterns in each condition. Neutrophils exposed to PRPt, PPP, and fMLP spent an
average of 61.4 + 29.8 min, 53.0 _ 30.4 min, and 64.0 _ 36.2 min in the side channels,
respectively (Figure 4-5 Bi and Table 4-1). The distributions for fMLP and washed platelets
demonstrated bimodality, indicating that the behavior of these neutrophils is bimodal (Figure 4-3
and Supp. Table 4-1). Conversely, the distributions for PRPt and PPP followed a normal
distribution curve. The distance traveled in the side channels is also influenced by both PRP and
the interaction with platelets. The average total distance traveled in the PRPt and PPP was,
1695.7 + 811.0 [tm and 1470.3 + 736.8 [tm respectively, as compared to the fMLP, 1047.7 +
460.3 tm. (Figure 4-5 Bii and Table 4-1). Statistical comparisons between all conditions is
summarized in Table 4-3. Overall, the neutrophil phenotype of fMLP was similar to that of WP,
while the phenotype of PRPn was similar to that of PPP, with the exception of the velocity of the
neutrophil. When comparing PRPc to PRPn, it is apparent that, with the exception of the velocity
of the neutrophil, contact with platelets does significantly change the migration behavior of the
neutrophil.
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4.4.4 Neutrophils migrate faster after direct, physical interaction with platelets
Direct platelet-neutrophil interactions resulted in either the arrest of neutrophil motility after
contact with a platelet (20.1 % of interactions), or in the neutrophil carrying the platelet (67.3%
of interactions) (Table 4-1). The duration of time that a neutrophil carried a platelet along the
side channel was indicative of the transient nature of the platelet-neutrophil interactions, with
most neutrophils carrying platelets for less than 4 minutes over a distance of approximately 120
prm. Surprisingly, some neutrophils carried platelets for up to one hour and for more than 2100
ptm (Figure 4-2 C). Occasionally, neutrophils were noted to carry a platelet from the main
channel into a side channel; these neutrophils exhibited a similar phenotype to the neutrophils
that came into contact with a platelet within the side channel. Initial contact with the platelet
mostly involved the leading edge of the neutrophil due to the spatial constraints within the side
channels of the device. Interestingly however, the neutrophils that did attach to and carry
platelets along the channels appeared to bind at the uropod (the trailing edge). This is consistent
with previously published literature establishing that two of the main receptors involved in the
platelet-neutrophil interaction are CD62P on the surface of the activated platelets and CD162 on
the uropod of the activated neutrophil (5, 15, 16). Further experiments to validate the binding of
the platelet to the neutrophil uropod are described later, in the section concerning neutrophil
phenotypes following blockage of CD 162.
Direct contact with platelets had an effect on the time spent in the side channel, the total distance
traveled, and the velocity, with neutrophils in the PRPc group having faster velocities and
spending longer time in the channels than the PRPn group, 71.5 + 28.0 and 55.7 29.4 min,
2029.7 + 812.9 and 1508.4 749.8 [im, and 29.1 + 5.7 and 28.0 + 5.9 tm/min, respectively
(Figure 4-5 4Bi-iii and Table 4-1). Histograms of these behaviors were also plotted (Figure 4-3
and Table 4-2). The difference between PRPc and PRPn was statistically significant for both the
total time spent in the channel (p-value <0.01) and the total distance traveled (p-value <0.01)
(Table 4-3). These observations indicate that interactions between neutrophils and platelets result
in an altered neutrophil phenotype, making them significantly more mobile than neutrophils that
simply migrate into the channels.
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4.4.4 The platelet-neutrophil interaction is mediated by CD62P-CD162 interactions
To further verify the utility of this assay and validate the importance of the CD62P-CD 162
interaction in the platelet-neutrophil interaction, CD 162 was blocked. Blocking of CD 162 on
neutrophils resulted in a decrease in the amount of PLA formation ex vivo (Figure 4-6). Flow
cytometry experiments showed that co-incubation of isolated neutrophils with PRP resulted in an
increase in PLA formation (1.3 + 0.9% compared to 39.4 + 17.4%); however, when neutrophils
were treated with anti-CD 162 antibody prior to co-incubation with PRP, formation of PLAs
decreased (39.4 + 17.4% compared to 14.1 1.8%) (Figure 4-6 B and C). We also compared the
amount of PLA formation before and after neutrophil isolation (4.0 0.8% as compared to 1.3 +
0.9%) to show that there was minimal PLA formation with the blood collection technique, and
that neutrophils resulting from the negative isolation technique used were primarily not bound to
platelets (Figure 4-6 B and C).
The microfluidic assay was then run using CD 162-blocked neutrophils, to determine whether a
change in platelet-neutrophil interaction would be observed. Activation and polarization of
CD162 at the uropod of the neutrophil was clearly visualized in both the main channel and the
side channel of the microfluidic device (Figure 4-7 A). There was no significant difference in
migration behaviors for the neutrophils with and without CD162 blocked upon exposure to
fMLP (Figure 4-7 and Tables 4-4 and 4-5). There was a significant difference in migration
behavior between neutrophils in PRP with and without blocking of CD 162, for both the total
distance traveled (p < 0.01) and the average velocity (p < 0.01) (Table 4-5). As expected, there
was also a significant decrease in the amount of neutrophils that bound to and carried platelets
when CD162 was blocked in PRP (Table 4-6). There was no significant different in neutrophil
migration behavior for neutrophils that did not come into contact with a platelet (PRPn and
PRPn+anti-CD162), although there were significant differences in behavior with the neutrophils
that came into contact with platelets (PRPc and PRPc+anti-CD162) (Figure 4-7 B-E and Tables
4-4 and 4-5). These findings demonstrate that blocking CD 162 on neutrophils does significantly
inhibit initial platelet-neutrophil binding, although if a platelet was bound, neutrophils displayed
a phenotype consistent with platelet interaction.
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4.5 Discussion
Neutrophil-platelet interactions and their role in the initiation of innate immune responses are
under intense scrutiny. (Sreeramkumar V, 2014) However, previous studies were limited by the
techniques available. While intravital microscopy has contributed a great deal of knowledge
regarding this relationship, it has its limitations as well; including the use of live animals, highly
technical equipment, and microsurgical training. (Xu N, 2011) Additionally, although the
utilization of in vivo experiments has an essential role in exploring physiology, complex
mechanistic studies can sometimes be better teased apart under highly controlled conditions,
restricting the number of variables. The ex vivo assay we have developed for the study of the
platelet-neutrophil interaction utilizing microfluidic devices fills this void, enabling precise
control of soluble and cellular inputs and analysis at the single-cell level. Using this assay, we
studied the effect of various platelet containing solutions on neutrophil motility, and the changes
of neutrophil motility after direct, physical interactions with platelets.
Using this new microfluidic technique, we observed spontaneous migration of neutrophils to
both PRPt and PPP, although the average velocity of neutrophils in PRPt was almost double of
that in fMLP. This suggests that either soluble components or microparticles within the plasma
result in spontaneous neutrophil migration. Additionally, there were significant differences in the
number of neutrophil directional changes, velocity, and total time spent in the side channels,
dependent on whether the neutrophils made direct contact with platelets. This spontaneous
migration and oscillatory phenotype has been reported before in the context of sepsis after bum
injuries. (Jones CN, 2014) This is the first time that this behavior has been recapitulated in an ex
vivo system. Platelets can play both pro- and anti-inflammatory roles. For instance, CD62P-
CD 162 interactions can instigate the activation and 'crawling' of neutrophils, and neutrophils
can utilize platelet arachidonic acid for the biosynthesis of leukotrienes; these events can take
place in both the circulatory system as well as in peripheral organs. (Sureerkumar V, 2014;
Antoine C, 1992) A better understanding of neutrophil-platelet interactions could help advance
our understanding of neutrophil dysfunction and mechanisms leading to sepsis. (Gawaz M, 1997;
Opal SM, 2003; Russwurm S, 2002)
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Our observations of the interactions between platelets and moving neutrophils, in conditions of
mechanical confinement, are suggestive of a mechanism by which neutrophils may transport
platelets inside tissues. This biological property is likely relevant to certain disease states, when
platelets do not always remain within the circulatory system. On many occasions, platelets have
been noted to be present in extravascular spaces, suggesting a mechanism for platelet diapedesis.
Platelets and neutrophils have been observed in the skin of rats after intradermal injection of
platelet activating factor and in the sinusoidal and perisinusoidal Disse spaces in the liver of mice
and rats after injection of lipopolysaccharide. (Endo Y, 1993; Endo Y, 1992; Nakamura M, 1998;
Pons F, 1993; Pirotzky E, 1984) The recent study by Zuchtriegel G., et al. (Zuchtriegel G, 2016),
investigating the binding of CD 162 by CD62P showed that this interaction leads to ERK 1/2
MAPK-dependent conformational changes of leukocyte integrins, promoting the successive
extravasation of neutrophils and monocytes. Importantly, this study also revealed that platelet-
directed, spatiotemporally organized crosstalk between platelets and leukocytes are essential in
the trafficking of neutrophils towards sites of inflammation. One hypothesis emerging from this
literature suggests that neutrophils mediate transport of platelets, and that the role of this
behavior in disease should be studied in more detail. These interactions may also serve a
protective function during inflammation and injury, as suggested by the biosynthesis of
inflammation resolution mediators such as Maresin 1. (Abdulnour RE, 2014) In our study, some
neutrophils in the PRPt were noted to migrate from the main channel into the side channel with a
platelet already adhered, demonstrating that this ex vivo technique could potentially provide a
platform for the study of platelet extravasation secondary to neutrophil diapedesis.
The development of microfluidic techniques for the study of platelet-neutrophil interactions at a
single-cell level can provide new insights into innate immune cell behavior. In this study,
phenotypic changes of the neutrophil upon platelet binding are identified and described in detail.
Future applications of the assay presented here can be broadened to explore the effect of drugs,
molecules and various disease states on the neutrophil-platelet interaction.
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Figure 4-1: Microfluidic device work-flow.
Ai) Photomicrograph of the microfluidic device prior to priming and loading. The main channel (red star)
of the device is loaded with fluorescein (ii). One end of the main channel is clamped off and fluorescein is
pushed into the side channels (white arrowhead), displacing the air and filling them with dye (iii). The
main channel is opened and is flushed with buffer, creating a fluorescein concentration gradient within the
device (iv). B) Schematic of neutrophil migration protocol. Blood is collected (1) and aliquoted into two
samples, one for neutrophil isolation and one for platelet isolation. Experimental conditions, PRP, PPP,
and WP are prepared via differential centrifugation and stained with Calcein (2a) and neutrophils are
collected via negative isolation and stained with Hoechst dye (2b). The microfluidic device is primed
using the plasma preparation (3a) and then the neutrophils are loaded into the main channel (3b). Image
analysis is then performed on time-lapse fluorescence microscopy of the neutrophils in the different
experimental conditions (4). fMLP is used as a positive control that triggers persistent neutrophil
migration.
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Figure 4-2: Definition of platelet-neutrophil interactions.
A) Montage of time-lapse fluorescent imaging of the platelet-neutrophil interaction. A neutrophil
(Hoechst, blue) in PRP is shown to stop in place and interacting with a platelet (Calcein, green) for 10.35
minutes. B) A neutrophil is shown migrating down a side-channel towards a platelet, then attaching and
carrying the platelet on its uropod (red arrow) as it changes directions. Direction towards the blind end of
the side channel is indicated by the green arrow. C) Graphs of the total amount of neutrophils migrating
as a function of duration of time that a platelet was carried by a neutrophil (i) and the total distance that a
platelet was carried by a neutrophil (ii).
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Figure 4-3: Distribution curves.
Distribution curves for average speed (um/min), total time spent in the side channel (min), and total
distance traveled (um) for all four conditions (fMLP, PRPt, PPP, WP).
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Figure 4-4: Neutrophil directionality.
Neutrophil behavior was evaluated in microfluidic devices, with individual velocities recorded and
analyzed. A) A montage of time-lapse (207 seconds) fluorescent imaging shows a representative
neutrophil (Hoechst, blue) in PRPt (Calcein, green), migrating and interacting in a side channel. B) The
velocity of this individual neutrophil towards the end of the channel was tracked and displayed on a graph
over time. The migratory behavior of a representative neutrophil is also displayed for fMLP (C) and PPP
(D).
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Figure 4-5: Neutrophil phenotype in various conditions.
Neutrophil phenotype was evaluated in all four conditions (PRPc, PRPn, PPP, WP, and fMLP). A) Bar
graph represents the percent of neutrophils that displayed a certain number of directional changes (orange,
0; blue, 1; green, 2; red, 3+). B) Box scatter plots showing the 95% confidence intervals are shown for
time spent in the side channel (i), the distance traveled within the side channel (ii), and the velocity (iii).
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Figure 4-6: Inhibition of platelet-neutrophil complexes with anti-CD162 antibody.
Various of preparations of blood were treated with anti-CD 162 antibodies. (A) Imaging flow cytometry
was used to confirm dissociation of PLA. (B&C) % of PLA formation was observed to be significantly
decreased in the PMN+PRP condition treated with anti-CD 162 antibodies.
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Figure 4-7: Neutrophil phenotype after treatment with anti-CD162 antibody.
A) Neutrophils in the microfluidic device, stained with both Hoechst (blue) and anti-CD162 antibody
(red). The top 4 photos show the neutrophil within the main channel. Activation of the neutrophil is
characterized by the polarization of the uropod and the localization of the anti-CD 162 staining (green
arrow). Neutrophils that are not activated are not polarized and display CD 162 staining diffusely
throughout their cell membrane (white arrow). B) Bar graph represents the percent of neutrophils that
displayed a certain number of directional changes (orange, 0; blue, 1; green, 2; red, 3+). Neutrophil
phenotype was evaluated in all four conditions (fMLP, fMLP + anti-CD162, PRPc, PRPc + anti-CD162,
PRPn, PRPn + anti-CD 162). Box scatter plots showing the 95% confidence interval are shown for
velocity (C), time spent in the side channel (D), and the distance traveled within the side channel (E).
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Table 4-1: Comparison of neutrophil migration and interaction with platelets
Total
Number of directional changes1  Total Time distance Time
Number of dst__ ______y spn___nNeutrophil Neutrophil
Conditio neutrphil - distance Velocity spent In ars ercryn platelet plateletCondItIon neutrophils traveled m/min channel ar near carrying carried carried
mIgrating 0 1 2 3+ (Ma)2  (min) (pm) (min)2
fMLP 201 24.9% 68.7% 4.5% 2.0% NA NA NA NAt460.3 9.1 36.2 NAA NA A
1695.7 28.4 61.4 468.3 16.1PRPt 231 14.7% 48.5% 2.2% 34.6% 20.1% 67.3%811.0 5.8 29.8 507.1 16.4
PRPc 83 7.2% 37.4% 4.8% 50.6% 2029.7 29.1 71.5 67.3% 468.3 16.1
+812.9 +5.7 +28.0 507.1 16.4
PRPn 148 18.9% 54.7% 0.7% 25.7% 1508.4 28.0 55.7 NAA NA A
+749.8 +5.9 +29.4 NA N A N
182
17
20.9%
23.5%
51.7%
76.5%
2.2%
0.0%
25.3%
5.9%
1470.3
736.8
1155.5510.1
29.5
5.8
27.0
7.6
53.0
30.4
44.6
22.9
0.0%
0.0%
1.1% 475.3517.3
17.4
19.7
0.0% NA NA
'Percent of neutrophils moving in a given number of directions within two hours.
2Mean ( SD)
3cent of neutrophils in channels which arrested at the position of a platelet for more than one time frame.
4Percent of neutrophils in channels which grabbed and carried a platelet once or more for at least one time
frame.
219
ppP
WP
Table 4-2: Data from histogram curves
Average
velocity
(stm/min)
Time spent
in the side
channel
(min)
Count
Mean
Median
Variance
SD
SEM
Skewness
IQR
95% CI b
95% Club
Mean
Median
Variance
SD
SEM
Skewness
IQR
95% Cl lb
95% Club
fMLP
199
19.5
20.2
81.8
9.0
0.6
0.1
15.4
18.3
20.8
64.0
55.7
1312.5
36.2
2.6
0.3
55.2
59.0
69.1
PRPt
231
28.4
28.1
33.7
5.8
0.4
-0.2
8.2
27.6
29.1
61.4
55.7
888.3
29.8
2.0
0.3
41.8
57.5
65.2
PRPc
83
29.1
29.5
32.4
5.7
0.6
-0.5
8.1
27.9
30.3
71.5
69.0
785.0
28.0
3.1
0.1
44.7
65.5
77.5
PRPn
148
28.0
27.6
34.2
5.9
0.5
-0.0
8.3
27.0
28.9
55.7
51.0
861.6
29.4
2.4
0.4
39.9
51.0
60.4
ppP
181
29.5
29.5
33.0
5.7
0.4
0.1
6.8
28.7
30.4
53.0
51.0
923.5
30.4
2.3
0.4
40.7
48.6
57.4
Wp
20
28.0
28.3
39.5
6.3
1.4
-0.5
9.6
25.1
31.0
45.6
45.3
552.4
23.5
5.3
0.0
17.4
34.6
56.6
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Table 4-3: Comparison of neutrophil behavior in different conditions
Condition
fMLPv. PRPt
# of directional
changes
<0.01
F Distance tra'eled
<0.01
Velocity
<0.01
Time spent In channel
0.40
fMLP v. PRPn <0.01 <0.01 <0.01 0.02
fMLPv. PRPa <0.01 <0.01 <0.01 0.09
fMLP v. PPP <0.01 <0.01 <0.01 I_<0.01
fMALPv.WP 0.30 0.21 <0.01 0.03
PRPt v. PPP 0.02 <0.01 0.05 0.01
PRPn v. PPP 0.97 0.64 0.02 0A2
PRPcv. PPP <0.01 <0.01 0.59 <0.01
PRPt v. WP 0.01 0.01 0.79 0.02
PRPn v.WP 0.12 0.06 0.98 0.14
PRPc v. WP <0.01 <0.01 0.46 <0.01
PPP v. WP 0.11 0.09 0.28 0.29
PRPc v. PRPn <0.01 <0.01 0.16 <0.01
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Table 4-4: Comparison of neutrophil migration and interaction with platelets in the presence
of anti-CD162 antibody
Total
Number of directional Changes 1  Total Tim, distance rime
Number r distance velocity spent In Neutrophil Neutrophil
traveled (pm/min) channel arrest near carrying carried carried
migrating 0 1 2 3+ (pfm)2  (mm) platlet pla
fMLP 189 27.0% 63.0% 8.0% 11.0% 991.9 17.8 60.6 NA NA NA NA600.2 1.4 33.4
an + 153 27.5% 67.3% 4.0% 4.0% NA NA NA NA
antl-CD162 ____ ___ _ ____ 553.0 7.2 33.5 ____
1700.1 23.8 73.5 491 16.0PRPt 207 10.6% 19.3% 12.1% 58.0% 8.3% 17.4% 0 5
PRPe 32 3.1% 9.4% 12.5% 75% 8.3% 17.4% 4 1
1+781.7 +1.8 20.7 1 531.0 16.5
1664.8 19.3 86.4 240PRPn 173 12.1% 21.4% 11.6% 54.9% NA NA NA NA
+586.4 +.710.4.
228 16.2% 19.7% 10.5% 53.5% 6.25% 7.6%
aPtim 20 5.0% 20.0% 5.0% 70% 1647.3 23.9 71.2 6.25% 7.6% 202.9 9.3
PRPn + 1502.5 22.0 7293
anti-16 208 17.3% 19.7% 11.1% 51.9% +650.3 + NA NA NA NA
'Percent of neutrophils moving in a given number of directions within two hours.
2Mean ( SD)
3cent of neutrophils in channels which arrested at the position of a platelet for more than one time frame.
4Percent of neutrophils in channels which grabbed and carried a platelet once or more for at least one time
frame.
222
Table 4-5: Comparison of neutrophil behavior in different conditions in the presence of anti-
CD162 antibodies
Condition # of directional Distance traveled Valocity Tim. spent In channel
changesII
fMLPv. 0.21 0.19 0.89 0.24
fMLP+anti-CD162
fMLP v. PRPt <0.01 <0.01 <0.01 <0.01
fMLPv. <0.01 <0.01 <0.01 <0.01
PRPt+anti-CD162
fMLP+antI-CD162v. <0.01 <0.01 <0.01 <0.01
PRPt
fMLP+anti-CD162v. <0.01 <0.01 <0.01 <0.01
PRPt+anti-CD162
PRPt v. 0.74 <0.01 <0.01 0.99
PRPt+anti-CD1U
PRPcv. 0.89 0.25 0.07 0.66
[PRPeftnt[cD1U_ _ _ _
PRPev. 0.09 <0.01 0.36 0.05
PRPn+antt-CD162
PRPn v. 0.54 0.03 <0.01 0.73
PRPn+anti.CD162
PRPn v. 0.04 0.91 <0.01 0.02
PRPc+ant-:D162
PRPn v. PRPc 0.02 0.05 <0.01 <0.01
PRPn+antI-CD162v.
Rc+antICD62
0.13 0.28 0.03 0.06
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Table 4-6: Comparison of neutrophil migration and platelet interaction in the presence of
anti-CD162 antibodies
Distance plateletwas carried (sm)
PRPce
449.1+113.2
PRPc+ anti-CD1621 P-value'
214.0+64.2 0.19
Time duration platelet was carried (min) 16.0+3.5 10.4+_2.9 0.32
17.4
8.3
% Neutrophils carrying platelets
% Neutrophils in arrested near platelets
Time duration of arrested platelet contact (min) 4.9+2.3
0.01
0.47
0.94
7.6
6.3
5+2.8
'Mean ( SD)
2Two-tailed student t-test between the PRP and PRP+PSGL1 group
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Videos:
Video 4-1: Neutrophil motility in the presence of PRP.
Neutrophils (Hoechst, blue) migrate into the side channel and interact with platelets (green) in
PRP.
Video 4-2: Neutrophil chemotaxis towards fMLP.
Positive control. Neutrophils (Hoechst, blue) undergo 1 or 2 direction changes.
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Chapter 5
Conclusions and Future Work
Megakaryocytes (MKs) have traditionally played a primary role in hemostasis as precursors to
platelets. Recently, platelets have been shown to play a key role in the immune system, often
playing the role of 'first responder.' Once activated by an inflammatory or pathogenic stimulus,
platelets can both directly stimulate neighboring white blood cells as well as release signals into
the surrounding area, which can propagate inflammation and thrombosis formation. (Semple JW
2011) While platelets are studied for their various roles in inflammation, the role of MKs within
the innate immune system has, until now, gone unexplored. Taking into consideration that
'daughter' platelets derive their form, function, and intracellular content from their 'parent' MK,
we hypothesized that the MK also harbors innate immune cell functions. The overall objectives
of this project were thus to explore the role of the MK as a functional innate immune cell, to
delineate the role that platelets have in inflammation at the origin of the 'parent' MK, and to
demonstrate how this may tie into the pathophysiology of sepsis.
In a series of comprehensive in vitro experiments, we have demonstrated that both cord blood-
derived MKs (CB MKs) and MKs from a megakaryoblastic lineage (Meg-01) have innate
immune cell functions, including phagocytosis, formation of extracellular traps, and chemotaxis
towards pathogenic stimuli (Chapter 2). Samples from patients diagnosed with sepsis were
evaluated and demonstrated both an increase in CD61PCD41 cells in the venous blood as well as
an increase in total CD61+ staining within renal glomeruli and the lungs. The amount of MKs
also appeared to correlate with both type of infection, with Gram negative bacteria proving the
most significant, as well as the development of complications, such as acute respiratory distress
syndrome (ARDS) and acute kidney injury (AKI). In addition to a primary role as immune cells,
MKs were also shown to contain extranuclear histones, which the MKs appear to release within
budding platelets into the peripheral circulation (Chapter 3). We then evaluated platelets from
patients with sepsis and demonstrated that platelet-associated histones are significantly increased
in patients with sepsis; this is also correlated with the type of infection and prognosis. Platelets
from patients with sepsis also appeared to have a specific phenotype, including increased
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activation and increased DNA and histone staining.
We also developed new tools in order to evaluate the interaction between platelet and leukocytes
in an in vitro system (Frydman GH 2017). By creating a microfluidic chip for the single-cell
evaluation of platelet-neutrophil interactions, we were able to characterize the change in
neutrophil migration behavior upon contact and bonding with platelets (Chapter 4). We then
performed preliminary in vitro experiments (Appendix) exploring the effect of endotoxin on
megakaryocyte differentiation in order to help elucidate the origin of platelet phenotype changes
during sepsis. These preliminary results demonstrate that if MKs are exposed to endotoxin
during differentiation, they can develop an alternate phenotype that may have downstream
effects on the resultant platelets.
In summary, the studies comprising this thesis explore a newly recognized role of the MK as a
functional innate immune cell and demonstrate that MKs, both directly and indirectly, through
their platelets, may have a significant role in the pathophysiology of sepsis and its related
complications. These findings have many implications for the pathophysiological mechanisms
underlying sepsis and end organ dysfunction, as well as for the potential future discoveries for
the early diagnosis and treatment of this complex and deadly syndrome. While the inflammation
and coagulation system are.intimately intertwined, it is only recently that scientists have
elucidated that inflammatory cells play a major role in coagulation and that cells originally
thought to only be important in coagulation, play an essential role in inflammation. By
understanding that the different conversation that cells have with each other may have
downstream effects on cellular phenotype and behavior, we will allow ourselves to be open-
minded enough to discover the complexity of systemic inflammation and infections.
One example of the effect of this cross-talk and cell phenotype change occurs during a post-
sepsis complication termed compensatory anti-inflammatory response syndrome (CARS).
Patients fortunate enough to survive sepsis are at an increased risk for having CARS, which
results in chronic immune-suppression and a number of other complications which sometimes
permanently effects quality of life. (Adib-Conquy M 2009) Studies have shown that sepsis and
bacterial infections can cause permanent changes to leukocytes starting at the bone marrow level
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through mechanisms such as modification of histone post-translational modifications (PTSMs),
which, in turn, results in endotoxin tolerance (Hamon MA 2008; Weiterer S 2015). As
demonstrated in this thesis, megakaryocytes may play an important role in the immune and
coagulation systems during sepsis; therefore, it is also plausible that during sepsis they may
undergo similary phenotypic changes that have both immediate and long-term effects on patient
prognosis and health. Because MKs are the source of platelets in the body, any change in the
molecular signaling and phenotype of the MK may also change the downstream platelets. This
thesis presents just one example of how one cell that has been traditionally overlooked, the
megakaryocyte, can potentially be a key to the pathophysiology of some of the most dangerous
inflammatory conditions, such as hemorrhagic fevers, autoimmune diseases, and sepsis.
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Figure 5-1: Proposed mechanisms and sequelae of megakaryocytes as immune cells
Presented above is a summary of the proposed mechanisms of the MK and the platelet within the immune
and coagulation system. On the top panel is a summary of Figure 2-13 and the bottom panel is a summary
of Figure 3-10 and 3-11.
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Figure 5-2: Proposed role of the megakaryocyte and platelet in sepsis
Here we propose one example of how megakaryocytes and platelets play a role in the pathophysiology of
sepsis and end organ damage. An injury incites cytokine and complement/coagulation activation; these
soluble signals and DAMPs travel through the circulation, where they reach sites of HSCs and MKs, such
as the bone marrow and the lungs; here the MKs can be activate and function as primary innate immune
cells, and their progeny platelets and microparticles can also play a role in inflammation and coagulation,
such as being a source of extracellular histones. The MK and platelet activation can result in increased
MET formation, circulating clusters of histones, DNA, and various cell types, white blood cell activation,
microthrombi formation, and endothelial cell apoptosis or necrosis. Depending on the physiological
localization of these events, end organ damage can occur and result in severe injury and increased
morbidity and mortality.
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Appendix
The Effect of Lipopolysaccharide on Megakaryocyte
Differentiation
1. Abstract
Lipopolysaccharide (LPS) is a recognized mitogen and stimulant of leukocytes. One situation in
which a person's bone marrow may be exposed to LPS is during Gram negative sepsis. Patients
with sepsis often have abnormal platelet indices, including changes in mean platelet volume,
reticulated platelets, and cell surface markers. Although alterations in platelet phenotype during
sepsis have been superficially explored, very little research has looked at their 'parent'
megakaryocytes. In this paper, we perform a preliminary set of in vitro experiments in order to
determine if hematopoietic stem cell exposure to Escherichia coli (F. coli) LPS during
megakaryocyte differentiation would result in an altered megakaryocyte phenotype. The results
of these studies are suggestive of an altered phenotype, including changes in cell number, cell
size, nuclear content, cell surface markers, and ultrastructure. Although this study merely grazing
the surface, it is highly suggestive that LPS exposure may result in aberrant megakaryo- and
thrombopoiesis, potentially producing abnormal platelet phenotypes, such as those identified in
patients with sepsis.
2. Introduction
Megakaryocytes have been shown to pass on their form and function to platelets during
thrombopoiesis. Perturbations during megakaryo- or thrombopoiesis can result in changes in the
circulating platelet phenotype. Sepsis is a syndrome where changes in platelet indices have been
shown to be important indicators of condition and prognosis. (Gao Y, 2014; Ramesh Bhat Y,
2017; Enz Hubert RM, 2015) Changes in megakaryocytes during sepsis have also started to be
explored. (Brown RE, 2008; Freishtat RJ, 2009) In depth studies into the morphological,
transcriptional, and translational effects of sepsis on the development of the MK cell and its'
progeny platelets have yet to be explored.
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Previous literature demonstrates that different types of stimulus can result in both transcriptional
and translational changes in megakaryocytes, resulting in changes in the platelet cargo and
function. The platelet transcriptome during certain disease states, such as lupus and sickle cell,
has revealed variations from normal platelets. (Lood C, 2011; Raghavachari N, 2007; Healy AM,
2006) Sepsis-associated changes in MK and platelet mRNA have been identified. In mice, septic
megakaryocytes and platelets were found to have increased expression of granzyme-B mRNA,
and these platelets exhibited increased in vitro lymphotoxicity. (Freishtat RJ 2009) Both platelets
from septic patients and normal platelets stimulating with endotoxin contained splicing of tissue
factor pre-mRNA and accelerated plasma clotting, suggesting that this may be a marker to an
altered platelet phenotype and function in sepsis. (Rondina MT, 2011) A thorough evaluation of
the megakaryocyte and platelet axis has not yet been evaluated in sepsis.
In this study, we perform a set of preliminary in vitro experiments investigating the effect of
lipopolysaccharide (LPS) on the differentiation and maturation of the MK. Here we show that
there are changes in cell count, cellular ultrastructural morphology, and even cell surface marker
expression.
3. Materials and Methods
3.1 Cell culture
Cord blood CD34' hematopoietic stem cells and Meg-01 cells were cultured and differentiated
into megakaryocytes (CB MKs). Cord blood CD34' hematopoietic stem cells were purchased
and cultured in StemSpanIl media with the megakaryocyte supplemental cytokines, according to
the culture and differentiation protocols from Stemcell Technologies (Stemcell Technologies Inc.
Cambridge, MA). Cell cultures were co-incubated with E. coli lipopolysaccharide at 360 pg/mL
starting at day 7 of differentiation (0111: B4, y-irradiated for cell culture; Sigma Aldrich, St.
Louis, MO, USA) (Figure A1-1).
3.2 Cell morphology analysis
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Cell cultures were analyzed for total cell numbers as well as cell size. Manual cell counts were
performed using hemacytometers (INCYTO C-Chip Disposable Hemacytometers; Fisher
Scientific, Pittsburgh, PA, USA) on each culture at day 1 and day 14 of differentiation.
Brightfield pictures of the cells were taken on day 14 of differentiation with one of two
fluorescent microscopes: Life Technologies EVOS FL (Thermo Fisher Scientific) or Nikon
Eclipse 90i microscope (Nikon Instruments Inc., Melville, NY). Cell size was measured using
Fiji software (NIH). (Shindelin J, 2012)
3.3 Flow cytometry
Flow cytometry was performed in order to verify appropriate cellular differentiation and for the
evaluation of cell surface markers. Briefly, cells were stained with antibodies at a concentration
of 1:200 for 15 minutes, with the exception of CD4 1, which was at a concentration of 1:100.
Cells were then stained with Draq5 (Thermo Fisher Scientific, Waltham, MA) at a concentration
of 1:10000 for 5 minutes. Antibodies included: anti-human HLA-ABC (MHC class I), HLA-DR
(MHC class II), CD162 (p-glycoprotein-1; SELPG), CD41 (GPIIb), CD34 (Biolegend, San
Diego, Ca), and CD62P (P-selectin) (BD Biosciences, San Jose, CA). Data was obtained through
the Amnis ImageStreamX Mark 1I imaging flow cytometer and INSPIRE Software (EMD
Millipore, Billerica, MA). The accompanying IDEAS Software was used to perform data
analysis. Data is reported as the percent of the total cell population that stained positive for the
specific marker.
3.4 Transmission electron microscopy (TEM)
Cord blood-derived MKs were cultured until day 14 of differentiation, with or without E. coli
LPS. The cells were then pelleted down at 1900 g for 10 minutes. Immediately after removal of
the culture medium, KII fixative (2.5% glutaraldehyde, 2.0% paraformaldehyde, 0.025 %
Calcium Chloride in a 0. 1M Sodium Cacodylate buffer, pH 7.4) was added to the cell pellet,
mixed, and allowed to fix for 20 minutes. A rubber tipped cell scraper was then used to gently
remove the fixed monolayer from the plastic substrate. The samples were centrifuged, the
fixative removed, replaced with buffer, and stored at 4'C until further processing. To make a cell
block, the material was centrifuged again and resuspended in warm 2% agar in a warm water
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bath to keep the agar fluid. The material was then centrifuged again and the agar allowed to gel
in an ice water bath. The tissue containing tip of the centrifuge tube was cut off resulting in an
agar block with the material embedded within it. This agar block was then processed routinely
for electron microscopy in a Leica LynxTM automatic tissue processor. Subsequent processing
was done using a Lieca LynxTM automatic tissue processor. Briefly, they were post-fixed in
osmium tetroxide, stained En Bloc with uranyl acetate, dehydrated in graded ethanol solutions,
infiltrated with propylene oxide/Epon mixtures, embedded in pure Epon, and polymerized
overnight at 60'C. One micron sections were cut, stained with toluidine blue, and examined by
light microscopy. Representative areas were chosen for electron microscopic study and the Epon
blocks were trimmed accordingly. Thin sections were cut with an LKB 8801 ultramicrotome and
diamond knife, stained with lead citrate, and examined in a FEI Morgagni transmission electron
microscope. Images were captured with an AMT (Advanced Microscopy Techniques) 2K digital
camera.
3.5 Ultrastructural Image Analysis
TEM images were analyzed using Fiji software. Image thresholding and quantification was
performed in order to calculate the percent of white space, which would represent either vacuoles
or open canalicular spaces, as a percent of the total cell area imaged. (Eckly A, 2009)
3.6 Statistical Analysis
Statistics were performed using both Microsoft Excel and GraphPad Prism Software (GraphPad
Software, Inc.). Paired student t-tests were performed to compare between conditions for each
experiment, with the exception of an un-paired student t-test for the EM thresholding analysis.
Each parameter evaluated in this study had at least 3 experimental groups evaluated. A p-value
of <0.05 was considered significant.
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4. Results
4.1 LPS treatment results in decreased cell count and cell size
Cord blood-derived (CB) MKs appeared to have a change in gross cell morphology upon
treatment with E. coli LPS during differentiation (Figure A 1-2). Upon microscopic evaluation,
the cells appeared to be subjectively smaller in size and were frequently found in clusters (Figure
A 1-2 A). Cells counts were evaluated by calculating the average number of MKs in culture per
each input hematopoietic stem cell (HSC) (Eq 1&2).
Eq. 1: (# CB MKs on day 14) / (# input HSC on day 1) = # CB MKs/HSC
Eq. 2: ((LPS # CB MKs/HSC) / (Control # CB MKs/HSC) * 100) - 100 = % change LPS CB
MKs/HSC
The number of CB MKs/HSC was significantly higher in the LPS-treated group as compared to
the control group, as shown by the total percent change between groups (14-59%) (Figure Al-2
B). When cell size was evaluated, the cells were significantly decreased in the LPS-treated group
as compared to the control group (11.3 + 0.5 pm vs. 12.7 1 0.8 pm, respectively). Cells in the
LPS-treated group were also frequently found in clusters and with, subjectively less platelet
buds, than the control group (Figure A1-2 C).
4.2 LPS treatment results in changes in nuclear content and cell surface markers
Imaging flow cytometry was performed on the CB MKs in order to evaluate any changes in their
cell surface marker or nuclear content phenotype. Cells were divided into 'nucleated' or
'pyknotic' cells, based on their nuclear content, as estimated by Draq5 staining intensity, and by
their accompanying image (Figure A 1-3 A). The mean Draq5 DNA staining intensity for
nucleated cells were then compared between LPS-treated and control cells, and showed that there
was a statistically significant decrease in Draq5 staining in the LPS-treated group (7.8-71.7%
decrease in Draq5 staining intensity) (Figure A1-3 B). This decrease in staining intensity can be
due to a number of causes, including being associated with decreased cell size, or having a
decrease in endomitosis, resulting in a decrease in nuclear content.
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Cell surface markers were also evaluated for each LPS and control groups, for both nuclear and
pyknotic cells. There was a significant increase in the percent of CD62P'CD34' and a significant
decrease in the percent of CD62P-CD34~ cells, nucleated and pyknotic (p = 0.020 and p = 0.004
vs. p = 0.006 and 0.014). There was no significant difference in the percent of CD162' cells.
Statistics were not performed on HLA-ABC, HLA-DR, and von Willebrand factor (vWF)
because they were only evaluated in two experimental groups; while there did not appear to be a
difference between the two groups for both MHC-receptors, there did appear to be a decrease in
the average vWF staining intensity in the LPS-treated group. There was a significant increase in
the amount of CD34' pyknotic cells in the LPS group as compared to the control group (p =
0.011), but no significant difference in nucleated CD34' cells between groups (p = 0.073). This
phenotype change indicates an increase in immature apoptotic cells within the LPS-treated
group.
4.3 LPS treatment results in ultrastructural changes
Transmission electron microscopy (TEM) images of the CB MKs demonstrated some subtle
differences in the ultrastructural morphology of the LPS and control groups. One of the more
significant difference noted was the change in the amount of 'empty' spaces within the cell
(Figure A1-4 A); these spaces were either vacuoles or were part of the open canalicular network
system. To quantify the 'empty' space within the cells, we used imaging software to threshold
the white space and then quantify the % of the cell that was taken up by this white space (Figure
A1-4 B). This approach demonstrated that there was a significantly increased amount of 'empty'
space within each cell in the LPS-treated groups, as compared to the control group (33.3 + 7.9 %
white space vs. 21.8 + 13.5% white space, respectively; p <0.001). This increase in 'empty'
space is consistent with a number of hereditary MK disorders, which are associated with a
subsequent abnormality in platelet formation and platelet granule content. Another unique
finding was the presence of small intracytoplasmic inclusion bodies (Figure A1-4 C). At this
point in time, we are not sure of the significance of this finding, as it was not seen in all samples,
but the inclusions appear to resemble 'D6hle bodies', which are abnormal cytoskeletal inclusions
due to defect in Nonmuscle Myosin Heavy Chain IIA. The potential significance of these
ultrastructural changes will be explored further in the 'Discussion' (section 1.5).
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5. Discussion
Exposure to E. coli lipopolysaccharide (LPS) is known to have mitogenic effects on multiple cell
types. (Skidmore BJ 1975; Goodman GW 1979) In order to explore the effects of E. coli LPS on
the differentiation and maturation of the MK cell, we performed some a set of preliminary
experiments and exposed cord blood-derived MKs to LPS starting at day 7 of differentiation and
compared their phenotype at day 14 to the control cells. Early results demonstrate that their does
appear to be a phenotypic change in MK cells upon exposure to LPS during differentiation,
including changes in cell count, cell size, ultrastructural morphology, as well as cell surface
markers.
MKs are one of the only cell types in the body to undergo endomitosis; the replication of
chromosomes in the absence of cell or nuclear division, which, in MKs, results in polyploid
cells. Exposure to LPS starting at day 7 of differentiation resulted in an increase in cell count and
a decrease in cell size and nuclear content. LPS is a known mitogen, resulting in an increase in
cell division; therefore, it is no surprise that exposure to LPS resulted in an increase in MK cell
count. The decrease in nuclear content could be a result of either an increase in complete mitosis,
or it may simply be related to the decrease in cell size. Previous literature has confirmed these
findings in mice, demonstrating that exposure to LPS resulted in an increase in CFU-MK
(colony-forming unit MKs) and an increase CD41' expression, however, LPS was also found to
increase MK polyploidization in this study. (Wu D 2015) These differences in the effects of LPS
can be a result of species difference in the origin of the cells or can be a result of the difference
between adult and neonatal megakaryocytes, which are known to have differences in both cell
morphology, nuclear ploidy, and cell surface marker expression. (Mattia G, 2002)
Cell surface markers were also observed to change with LPS-treatment, resulting in an increase
in CD34' pyknotic cells. MKs undergo a controlled apoptosis when fully differentiated and when
undergoing thrombopoiesis (see section 1.2.2, 'Thrombopoiesis'). One of the explanations for
this increase in CD34' pyknotic cells could be that the MKs are prematurely undergoing
thrombopoiesis. This finding could potentially explain one of the mechanisms by which patients
that are exposed to LPS, such as in the case of sepsis, have increased circulating reticulated
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platelets, which represent an immature platelet fraction. (Enz Hubert RM, 2015) The likelihood
of the LPS being cytotoxic after 7 days of culture is not likely, but if some cells bound more LPS
than others, then this is still a possibility.
The ultrastructural changes identified in the MKs exposed to LPS may explain the changes in
platelet morphology and function seen in patients with sepsis. Platelet indices have been shown
to be correlated with sepsis and prognosis, with reticulated platelets and mean platelet volume
(MPV) being increase in septic patients. (Gao Y, 2014; Ramesh Bat, 2017; Enz Hubert RM
2015) Stimulation of toll-like receptor 4 (TLR4) has been suggested to play a role in MK
thrombopoiesis. (Beaulieu LM, 2010) Platelet function has also been noted to be altered, with
septic patients having platelets that spontaneously activate but have a defect in agonist-dependent
aggregation. (Hurley SM, 2016; Yaguchi A, 2004; Woth G, 2011; Alt E, 2004) The increase in
MK 'empty' space identified in the LPS-treated cells could result in large, hypogranular,
abnormally functioning platelets; such as those seen in other MK abnormalities, including Grays
Platelet Syndrome and May Hegglin Anomaly. (Eckly A, 2009; Kahr WHA, 2013) The
occasional cytoskeletal inclusion bodies noted in the MKs appear to be morphologically similar
to d6hle bodies. Ddhle bodies are inclusion bodies, most commonly described to be due to
abnormalities in MYH9, resulting in myosin aggregates within the cytoplasm of the cell.
Interestingly, d6hle bodies are present during both hereditary abnornalities, such as May
Hegglin anomaly, as well as during sepsis. (Oski FA, 1962; Easton JA, 1966; Botero JP, 2016;
Lazarchick J, 2010; Labert JL, 2016) During sepsis, one of the classic changes seen in
leukocytes, specifically neutrophils, is toxic change consisting of: foamy basophilic cytoplasm,
hyper segmented nuclei, and d6hle body inclusions; interestingly, the ultrastructural evaluation
of neutrophil d6hle bodies in toxic neutrophils are described as being rough endoplasmic
reticulum (RER) aggregates and not cytoskeletal inclusions. (McCall CE, 1969) It is also
important to note that patients with May Hegglin anomaly also usually also have a
macrothrombocytopenia, which is also seen during sepsis. (Oski FA, 1962; Ruhoy SM, 2016)
The mechanism by which d6hle bodies appear in neutrophils during sepsis is not currently
known; perhaps the finding of ddhle bodies in MKs as a result of LPS exposure is an indication
towards a mechanism.
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Together, these preliminary results demonstrate that LPS exposure during MK differentiation
may result in abnormal MK differentiation and maturation. Although these are not conclusive,
this approach may help to understand the etiology of the abnormal circulating platelet during
sepsis, and may help elucidate novel mechanisms of cellular dysfunction in the face of
endotoxemia.
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Figure A1-1: Experimental Design.
Cord blood-derived CD34+ cells were cultured and differentiated into mature megakaryocytes over 14
days. E. coli LPS was added at a concentration of 360 pg/mL at day 7 of differentiation. Cells were then
harvested at day 14 for subsequent analysis. MK, megakaryocyte; HSC, hematopoietic stem cell, CD34
cell; CFU-MK, colony-forming unit MK.
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Figure A1-2: Megakaryocyte morphology after exposure to LPS.
MK cell count and cell size was evaluated and compared between LPS-treated and control groups. (A)
Cell counts were significantly increase in the three LPS-treated groups evaluated (p = 0.03). (B) Cells size
was significantly decreased in the LPS-treated cells as compared to the control cells (p < 0.00). (C)
Images of the control (i) and LPS (ii) group showed morphology changes, including smaller cell size,
increase cell clustering, and decreased proplatelet buds. Cell clustering and proplatelet bloods were not
quantified. Scale bar is approximately 50 ptm.
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Figure Al- 3: Evaluation of nuclear content.
Imaging flow cytometry was performed in order to evaluate the total DNA content (nuclear content) of
the cells in culture. Cells were first identified as MKs (CD41 cells). These cells were then further
subdivided into cells that were nucleated (meaning cells with identifiable nuclei) and cells that were
pyknotic (small, segmented nuclear staining). This is shown in the images on the top two panels (A & B).
The nuclei were stained with Draq5, which stains DNA. The histogram visualization of the mean intensity
of the Draq5 staining enabled the segregation of the nucleated and pyknotic cells (C). The Ideas Software
also allowed for the analysis of the Draq5 staining intensity for both groups, including, but not limited to:
cell count, mean, standard deviation, minimum and maximum Draq5 staining intensity (D).
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Figure A1-4: Evaluation of cellular 'empty' space.
Transmission electron microscopy (TEM) was performed on the LPS-treated and control MKs. (A) TEM
images demonstrated that the control cells (i) subjectively had decreased 'empty' space (red arrow) within
the cytoplasm as compared to the LPS-treated group (ii). (B) Image analysis software was used to
quantify the percent of the cell that was occupied by this 'empty' space and confirmed that the LPS-
treated cells had significantly more 'empty' space than the control cells (p < 0.01). Data is shown as a bar
graph with standard error bars. Scale bar is approximately 2 pm.
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Figure A1-5: Megakaryocyte inclusion bodies
TEM imaging of MKs showed that there were occasional inclusion bodies within the cytoplasm of the
cell. (A & B) These inclusion bodies appeared to have a sharp, linear, electron-dense morphology.
Magnification of these inclusions are shown in panel Aii and Bii. Patients with May-Hegglin anomaly
have a somewhat similar sharp, electron-dense inclusion body within neutrophils, termed d~hle bodies.
(C) A light micrograph of a neutrophil with a ddhle body (red arrow) next to a giant platelet (green arrow)
is shown (i) alongside the companion TEM of a neutrophil (ii) with a d~hle body (yellow arrow). Scale
bar is approximately 2 pm. Images for panel C are from: Botero JP, Patnaik MM. Delayed diagnosis of
MYH9-related disorder and the role of light microscopy in congenital macrothrombocytopenias. Blood,
2016;127:1940.
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